


**CUMULATIVE
SUPPLEMENT 4
APRIL 2017**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

37th EDITION

Department of Health and Human Services

**Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy**

2017

Prepared By
Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

37th EDITION

**Cumulative Supplement 4
April 2017**

CONTENTS

	<i>PAGE</i>
1.0 INTRODUCTION.....	v
1.1 How to use the Cumulative Supplement.....	v
1.2 Cumulative Supplement Content	vi
1.3 Applicant Name Changes	vii
1.4 Levothyroxine Sodium.....	vii
1.5 Availability of the Edition	viii
1.6 Report of Counts for the Prescription Drug Product List.....	ix
1.7 Cumulative Supplement Legend.....	x
DRUG PRODUCT LISTS	
Prescription Drug Product List	1-1
OTC Drug Product List	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List.....	3-1
Orphan Product Designations and Approvals List	4-1
Drug Products Which Must Demonstrate in vivo Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution	5-1
PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms	B-1

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

37th EDITION

CUMULATIVE SUPPLEMENT 4
April 2017

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 37th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; drug products with approval under Section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) administered by the Center for Biologics Evaluation and Research; and approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, Discontinued Drug Product, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the

next Edition. The current Annual Edition Section 2.1, How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
 - Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).

- New Drug Application (NDA) approvals appear in the CS month they were approved.
- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at orangebook@fda.hhs.gov.

mail to: FDA/CDER Orange Book Staff
 Office of Generic Drugs
 7620 Standish Place
 Rockville, MD 20855-2773

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

<u>FORMER APPLICANT NAME</u> <u>(FORMER ABBREVIATED NAME)</u>	<u>NEW APPLICANT NAME</u> <u>(NEW ABBREVIATED NAME)</u>
JAI PHARMA LTD (JAI PHARMA LTD)	MYLAN LABORATORIES LTD (MYLAN LABS LTD)

1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 076187), Levoxyl (King Pharms NDA 021301), Synthroid (Abbvie NDA 021402), and Levo-T (Alara NDA 021342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets.

Levo-T (Alara NDA 021342), Levothyroxine Sodium (Mylan ANDA 076187), and Unithroid (Jerome Stevens NDA 021210) tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbvie NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Mylan ANDA 076187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 076187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levotheroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products in the active section of the Orange Book. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Strength	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	021210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	076187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	021301	001
SYNTHROID	ABBVIE	0.025MG	AB1	021402	001
LEVO-T	ALARA PHARM	0.025MG	AB1	021342	001
SYNTHROID	ABBVIE	0.025MG	AB2	021402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	076187	001
LEVO-T	ALARA PHARM	0.025MG	AB2	021342	001
UNITHROID	STEVENS J	0.025MG	AB2	021210	001
LEVOXYL	KING PHARMS	0.025MG	AB3	021301	001
LEVO-T	ALARA PHARM	0.025MG	AB3	021342	001
UNITHROID	STEVENS J	0.025MG	AB3	021210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	076187	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	076187	001

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <http://www.fda.gov/opacom/morechoices/fdaforms/default.html>.

The current listing of the Orphan Product Designations and Approvals is available at <http://www.fda.gov/orphan/designat/list.htm>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2016</u>	<u>MAR 2017</u>	<u>JUN 2017</u>	<u>SEP 2017</u>	<u>DEC 2017</u>
DRUG PRODUCTS LISTED SINGLE SOURCE	18130 2646 (14.6%)	18391 2688 (14.6%)			
MULTISOURCE	15484 (85.4%)	15703 (85.4%)			
THERAPEUTICALLY EQUIVALENT	15335 (84.7%)	15581 (84.7%)			
NOT THERAPEUTICALLY EQUIVALENT	129 (0.7%)	122 (0.7%)			
EXCEPTIONS ¹	73 (0.4%)	73 (0.4%)			
NEW MOLECULAR ENTITIES APPROVED	7	14			
NUMBER OF APPLICANTS	1051	1053			

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route of Administration and then by trade name (or established name of the active ingredient, if no trade name exists).

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, Reference Standard symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug

Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form, new route(s) of administration, new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >D>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN**	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CHRS	Change. Reference Standard.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

****Note:**

The Cumulative Supplement (CS) currently displays a condensed 20 character collapsed applicant holder firm name and the Electronic Orange Book (EOB) query may display up to a 240 character full applicant holder firm name. An applicant holder firm name change usually changes both the collapsed name and long name. On occasion, only the long name is changed resulting in the CS displaying only the collapsed name for the >D> and >A> action. The new firm long name will display in the EOB query.

ABACAVIR SULFATE; LAMIVUDINE

TABLET;ORAL

ABACAVIR SULFATE AND LAMIVUDINE

AB	AUROBINDO PHARMA LTD	EQ 600MG BASE;300MG	A206151	001	Mar 28, 2017	Mar	NEWA
AB	CIPLA LTD	EQ 600MG BASE;300MG	A091144	001	Mar 28, 2017	Mar	NEWA
AB	LUPIN LTD	EQ 600MG BASE;300MG	A204990	001	Mar 28, 2017	Mar	NEWA

>A> ABALOPARATIDE

>A> SOLUTION;SUBCUTANEOUS

>A> TYMLOS

>A>	+	RADIUS HEALTH INC	3.12MG/1.56ML (2MG/ML)	N208743	001	Apr 28, 2017	Apr	NEWA
-----	---	-------------------	------------------------	---------	-----	--------------	-----	------

ACETAMINOPHEN

SOLUTION;IV (INFUSION)

ACETAMINOPHEN

AP	CUSTOPHARM INC	1GM/100ML (10MG/ML)	A202605	001	Jun 13, 2016	Jan	CAHN
----	----------------	---------------------	---------	-----	--------------	-----	------

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

TABLET;ORAL

>A> BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

>A>	AA	ACTAVIS LABS UT INC	325MG;50MG;40MG	A088616	001	Nov 09, 1984	Apr	CTNA
-----	----	---------------------	-----------------	---------	-----	--------------	-----	------

AA	MALLINCKRODT INC	325MG;50MG;40MG	A087804	001	Jan 24, 1985	Mar	CAHN
----	------------------	-----------------	---------	-----	--------------	-----	------

>D> FIORICET

>D>	AA	ACTAVIS LABS UT INC	325MG;50MG;40MG	A088616	001	Nov 09, 1984	Apr	CTNA
-----	----	---------------------	-----------------	---------	-----	--------------	-----	------

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET;ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA	MALLINCKRODT INC	300MG;5MG	A206718	001	Mar 31, 2017	Mar	NEWA
----	------------------	-----------	---------	-----	--------------	-----	------

AA		300MG;7.5MG	A206718	002	Mar 31, 2017	Mar	NEWA
----	--	-------------	---------	-----	--------------	-----	------

AA		300MG;10MG	A206718	003	Mar 31, 2017	Mar	NEWA
----	--	------------	---------	-----	--------------	-----	------

>A>	AA	MIKART	300MG;7.5MG	A040658	002	Mar 24, 2006	Apr	CMS1
-----	----	--------	-------------	---------	-----	--------------	-----	------

>A>	AA		300MG;10MG	A040658	003	Jun 23, 2004	Apr	CMS1
-----	----	--	------------	---------	-----	--------------	-----	------

AA	UPSHER-SMITH LABS	325MG;5MG	A206484	001	Mar 24, 2017	Mar	NEWA
----	-------------------	-----------	---------	-----	--------------	-----	------

AA		325MG;7.5MG	A206484	002	Mar 24, 2017	Mar	NEWA
----	--	-------------	---------	-----	--------------	-----	------

AA		325MG;10MG	A206484	003	Mar 24, 2017	Mar	NEWA
----	--	------------	---------	-----	--------------	-----	------

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

TABLET;ORAL

OXYCODONE AND ACETAMINOPHEN

AA	ASCENT PHARMS INC	325MG;2.5MG	A207419	001	Mar 22, 2017	Mar	NEWA
----	-------------------	-------------	---------	-----	--------------	-----	------

AA		325MG;5MG	A207419	002	Mar 22, 2017	Mar	NEWA
----	--	-----------	---------	-----	--------------	-----	------

AA		325MG;7.5MG	A207419	003	Mar 22, 2017	Mar	NEWA
----	--	-------------	---------	-----	--------------	-----	------

AA		325MG;10MG	A207419	004	Mar 22, 2017	Mar	NEWA
----	--	------------	---------	-----	--------------	-----	------

AA	NOVEL LABS INC	325MG;2.5MG	A204407	001	Feb 24, 2017	Feb	NEWA
----	----------------	-------------	---------	-----	--------------	-----	------

AA		325MG;5MG	A204407	002	Feb 24, 2017	Feb	NEWA
----	--	-----------	---------	-----	--------------	-----	------

AA		325MG;7.5MG	A204407	003	Feb 24, 2017	Feb	NEWA
----	--	-------------	---------	-----	--------------	-----	------

AA		325MG;10MG	A204407	004	Feb 24, 2017	Feb	NEWA
----	--	------------	---------	-----	--------------	-----	------

PERCOCET

AA	!	VINTAGE PHARMS LLC	325MG;7.5MG	A040330	003	Nov 23, 2001	Jan	CMS1
----	---	--------------------	-------------	---------	-----	--------------	-----	------

AA	!		325MG;10MG	A040330	004	Nov 23, 2001	Jan	CMS1
----	---	--	------------	---------	-----	--------------	-----	------

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

TABLET;ORAL

TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN

AB	AUROBINDO PHARMA LTD	325MG;37.5MG	A207152	001	Mar 22, 2017	Mar	NEWA
----	----------------------	--------------	---------	-----	--------------	-----	------

>A>	AB	MACLEODS PHARMS LTD	325MG;37.5MG	A206885	001	May 02, 2017	Apr	NEWA
-----	----	---------------------	--------------	---------	-----	--------------	-----	------

ACETIC ACID, GLACIAL

SOLUTION;IRRIGATION, URETHRAL

ACETIC ACID 0.25% IN PLASTIC CONTAINER

AT	ICU MEDCL	250MG/100ML	N017656	001		Feb	CAHN
----	-----------	-------------	---------	-----	--	-----	------

ACYCLOVIR

CAPSULE;ORAL

ACYCLOVIR

@ CHARTWELL MOLECULES 200MG

ZOVIRAX

AB	+	MYLAN PHARMS INC	200MG	N018828	001	Jan 25, 1985	Jan	CAHN
----	---	------------------	-------	---------	-----	--------------	-----	------

SUSPENSION;ORAL							
ZOVIRAX							
AB	+	MYLAN PHARMS INC	200MG/5ML	N019909	001	Dec 22, 1989	Jan CAHN
TABLET;ORAL							
ACYCLOVIR							
	@	CHARTWELL MOLECULES	400MG	A074834	001	Apr 24, 1997	Jan CAHN
	@		800MG	A074834	002	Apr 24, 1997	Jan CAHN
>D>	@	HERITAGE PHARMS INC	400MG	A074891	001	Oct 31, 1997	Apr CMFD
>A>	AB		400MG	A074891	001	Oct 31, 1997	Apr CMFD
>D>	@		800MG	A074891	002	Oct 31, 1997	Apr CMFD
>A>	AB		800MG	A074891	002	Oct 31, 1997	Apr CMFD
AB		MYLAN PHARMS INC	400MG	A075211	001	Sep 28, 1998	Mar CAHN
AB			800MG	A075211	002	Sep 28, 1998	Mar CAHN
ZOVIRAX							
AB	+	MYLAN PHARMS INC	400MG	N020089	001	Apr 30, 1991	Jan CAHN
AB	+		800MG	N020089	002	Apr 30, 1991	Jan CAHN
<u>ACYCLOVIR SODIUM</u>							
INJECTABLE;INJECTION							
ACYCLOVIR SODIUM							
	@	ATHENEX INC	EQ 500MG BASE/VIAL	A074596	002	Apr 22, 1997	Mar CAHN
	@		EQ 1GM BASE/VIAL	A074596	001	Apr 22, 1997	Mar CAHN
AP	!	HIKMA PHARMS LLC	EQ 1GM BASE/VIAL	A205771	002	Feb 29, 2016	Mar CTEC
AP		MYLAN LABS LTD	EQ 500MG BASE/VIAL	A203927	001	Mar 29, 2017	Mar NEWA
AP			EQ 1GM BASE/VIAL	A203927	002	Mar 29, 2017	Mar NEWA
<u>ADENOSINE</u>							
INJECTABLE;INJECTION							
ADENOSINE							
AP		WEST-WARD PHARMS INT	3MG/ML	A076404	001	Jun 16, 2004	Jan CAHN
AP			3MG/ML	A076500	001	Jun 16, 2004	Jan CAHN
	@		3MG/ML	A076501	001	Jun 16, 2004	Jan CAHN
<u>ALBUTEROL SULFATE; IPRATROPIUM BROMIDE</u>							
SOLUTION;INHALATION							
ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE							
AN		WATSON LABS TEVA	EQ 0.083% BASE;0.017%	A077063	001	Dec 31, 2007	Feb CAHN
<u>ALPRAZOLAM</u>							
TABLET;ORAL							
ALPRAZOLAM							
>D>	AB	ACTAVIS ELIZABETH	0.25MG	A074342	001	Oct 31, 1993	Apr CAHN
>A>	AB		0.25MG	A074342	001	Oct 31, 1993	Apr CAHN
>D>	AB		0.5MG	A074342	002	Oct 31, 1993	Apr CAHN
>A>	AB		0.5MG	A074342	002	Oct 31, 1993	Apr CAHN
>D>	AB		1MG	A074342	003	Oct 31, 1993	Apr CAHN
>A>	AB		1MG	A074342	003	Oct 31, 1993	Apr CAHN
>D>	AB		2MG	A074342	004	Oct 31, 1993	Apr CAHN
>A>	AB		2MG	A074342	004	Oct 31, 1993	Apr CAHN
TABLET, EXTENDED RELEASE;ORAL							
ALPRAZOLAM							
AB		AUROBINDO PHARMA LTD	0.5MG	A090871	001	Jun 07, 2011	Jan CAHN
AB			1MG	A090871	002	Jun 07, 2011	Jan CAHN
AB			2MG	A090871	003	Jun 07, 2011	Jan CAHN
AB			3MG	A090871	004	Jun 07, 2011	Jan CAHN
	@	IMPAX LABS INC	0.5MG	A077996	001	Jan 31, 2007	Feb CAHN
	@		1MG	A077996	002	Jan 31, 2007	Feb CAHN
	@		2MG	A077996	003	Jan 31, 2007	Feb CAHN
	@		3MG	A077996	004	Jan 31, 2007	Feb CAHN
<u>ALPROSTADIL</u>							
SUPPOSITORY;URETHRAL							
MUSE							
	+	MYLAN SPECIALITY LP	0.125MG	N020700	001	Nov 19, 1996	Mar CAHN
	+		0.25MG	N020700	002	Nov 19, 1996	Mar CAHN
	+		0.5MG	N020700	003	Nov 19, 1996	Mar CAHN
	+		1MG	N020700	004	Nov 19, 1996	Mar CAHN

AMANTADINE HYDROCHLORIDE

SYRUP;ORAL

AMANTADINE HYDROCHLORIDE

>D>	AA	!	CAROLINA MEDCL	50MG/5ML	A075819	001	Sep 11, 2002	Apr	CAHN
>A>	AA	!	CMP PHARMA INC	50MG/5ML	A075819	001	Sep 11, 2002	Apr	CAHN
			SYMMETREL						
		+	@ ENDO PHARMS	50MG/5ML	N016023	002		Jan	CRLD
			TABLET;ORAL						
			AMANTADINE HYDROCHLORIDE						
AB			NEWGEN PHARMS LLC	100MG	A207571	001	Jan 31, 2017	Jan	NEWA

AMIFOSTINE

INJECTABLE;INJECTION

AMIFOSTINE

>D>	AP		SUN PHARMA GLOBAL	500MG/VIAL	A077126	001	Mar 14, 2008	Apr	CAHN
>A>	AP			500MG/VIAL	A077126	001	Mar 14, 2008	Apr	CAHN

AMINO ACIDS

INJECTABLE;INJECTION

AMINOSYN 10%

			ICU MEDCL	10% (10GM/100ML)	N017673	003		Feb	CAHN
			AMINOSYN 10% (PH6)						
			ICU MEDCL	10% (10GM/100ML)	N017673	008	Nov 18, 1985	Feb	CAHN
			AMINOSYN 3.5%						
			ICU MEDCL	3.5% (3.5GM/100ML)	N017789	004		Feb	CAHN
			AMINOSYN 5%						
			ICU MEDCL	5% (5GM/100ML)	N017673	001		Feb	CAHN
			AMINOSYN 7%						
			ICU MEDCL	7% (7GM/100ML)	N017673	002		Feb	CAHN
			AMINOSYN 7% (PH6)						
			ICU MEDCL	7% (7GM/100ML)	N017673	006	Nov 18, 1985	Feb	CAHN
			AMINOSYN 8.5%						
			ICU MEDCL	8.5% (8.5GM/100ML)	N017673	004		Feb	CAHN
			AMINOSYN 8.5% (PH6)						
			ICU MEDCL	8.5% (8.5GM/100ML)	N017673	007	Nov 18, 1985	Feb	CAHN
			AMINOSYN II 10%						
			ICU MEDCL	10% (10GM/100ML)	N019438	005	Apr 03, 1986	Feb	CAHN
			AMINOSYN II 10% IN PLASTIC CONTAINER						
			ICU MEDCL	10% (10GM/100ML)	N020015	001	Dec 19, 1991	Feb	CAHN
			AMINOSYN II 15% IN PLASTIC CONTAINER						
			ICU MEDCL	15% (15GM/100ML)	N020041	001	Dec 19, 1991	Feb	CAHN
			AMINOSYN II 3.5%						
			@ ICU MEDCL	3.5% (3.5GM/100ML)	N019438	001	Apr 03, 1986	Feb	CAHN
			AMINOSYN II 5%						
			@ ICU MEDCL	5% (5GM/100ML)	N019438	002	Apr 03, 1986	Feb	CAHN
			AMINOSYN II 7%						
			ICU MEDCL	7% (7GM/100ML)	N019438	003	Apr 03, 1986	Feb	CAHN
			AMINOSYN II 8.5%						
			ICU MEDCL	8.5% (8.5GM/100ML)	N019438	004	Apr 03, 1986	Feb	CAHN
			AMINOSYN-HBC 7%						
			ICU MEDCL	7% (7GM/100ML)	N019374	001	Jul 12, 1985	Feb	CAHN
			AMINOSYN-PF 10%						
			ICU MEDCL	10% (10GM/100ML)	N019492	002	Oct 17, 1986	Feb	CAHN
			AMINOSYN-PF 7%						
			ICU MEDCL	7% (7GM/100ML)	N019398	001	Sep 06, 1985	Feb	CAHN
			AMINOSYN-RF 5.2%						
>D>			HOSPIRA	5.2% (5.2GM/100ML)	N018429	001		Apr	CAHN
>A>			ICU MEDCL	5.2% (5.2GM/100ML)	N018429	001		Apr	CAHN

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

AMINOSYN 3.5% M

			ICU MEDCL	3.5%;21MG/100ML;40MG/100ML;128MG/100ML;234MG/100ML	N017789	003		Feb	CAHN
--	--	--	-----------	--	---------	-----	--	-----	------

AMINO ACIDS; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN 3.5% M

@ ICU MEDCL	3.5%;21MG/100ML;128MG/100ML;234MG/100ML	N017789	005			Feb	CAHN
-------------	---	---------	-----	--	--	-----	------

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN II 10% W/ ELECTROLYTES

>D>	HOSPIRA	10%;102MG/100ML;45MG/100ML;522MG/100ML;410MG/100ML	N019437	004	Apr 03, 1986	Apr	CAHN
>A>	ICU MEDCL	10%;102MG/100ML;45MG/100ML;522MG/100ML;410MG/100ML	N019437	004	Apr 03, 1986	Apr	CAHN

AMINOSYN II 7% W/ ELECTROLYTES

>D>	@ HOSPIRA	7%;102MG/100ML;45MG/100ML;522MG/100ML;410MG/100ML	N019437	006	Apr 03, 1986	Apr	CAHN
>A>	@ ICU MEDCL	7%;102MG/100ML;45MG/100ML;522MG/100ML;410MG/100ML	N019437	006	Apr 03, 1986	Apr	CAHN

AMINOSYN II 8.5% W/ ELECTROLYTES

>D>	HOSPIRA	8.5%;102MG/100ML;45MG/100ML;522MG/100ML;410MG/100ML	N019437	005	Apr 03, 1986	Apr	CAHN
>A>	ICU MEDCL	8.5%;102MG/100ML;45MG/100ML;522MG/100ML;410MG/100ML	N019437	005	Apr 03, 1986	Apr	CAHN

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE; INJECTION

AMINOSYN II 3.5% M

>D>	@ HOSPIRA	3.5%;30MG/100ML;97MG/100ML;120MG/100ML;49MG/100ML	N019437	007	Apr 03, 1986	Apr	CAHN
>A>	@ ICU MEDCL	3.5%;30MG/100ML;97MG/100ML;120MG/100ML;49MG/100ML	N019437	007	Apr 03, 1986	Apr	CAHN

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN 7% W/ ELECTROLYTES

ICU MEDCL	7%;102MG/100ML;522MG/100ML;410MG/100ML	N017789	002			Feb	CAHN
-----------	--	---------	-----	--	--	-----	------

AMINOSYN 8.5% W/ ELECTROLYTES

ICU MEDCL	8.5%;102MG/100ML;522MG/100ML;410MG/100ML	N017673	005			Feb	CAHN
-----------	--	---------	-----	--	--	-----	------

AMIODARONE HYDROCHLORIDE

TABLET; ORAL

AMIODARONE HYDROCHLORIDE

AB	MAYNE PHARMA INC	200MG	A075389	001	Jan 25, 2001	Jan	CAHN
	@ MYLAN	200MG	A075188	001	Feb 24, 1999	Mar	DISC
AB	! SANDOZ	200MG	A075315	001	Dec 23, 1998	Mar	CHRS
AB	TARO PHARM	100MG	A075424	002	Dec 18, 2002	Mar	CAHN
AB		200MG	A075424	001	Mar 30, 2001	Mar	CAHN
		300MG	A076362	002	Dec 02, 2003	Mar	CAHN
AB		400MG	A076362	001	Nov 29, 2002	Mar	CAHN
	CORDARONE						
	+ @ WYETH PHARMS INC	200MG	N018972	001	Dec 24, 1985	Jan	DISC

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

ELAVIL

+ @	ASTRAZENECA	10MG	N012703	001		Mar	CRLD
+ @		25MG	N012703	003		Mar	CRLD
+ @		50MG	N012703	004		Mar	CRLD
+ @		75MG	N012703	005		Mar	CRLD
+ @		100MG	N012703	006		Mar	CRLD
+ @		150MG	N012703	007		Mar	CRLD

AMLODIPINE BESYLATE

TABLET; ORAL

AMLODIPINE BESYLATE

AB	MYLAN PHARMS INC	EQ 2.5MG BASE	A076418	001	Oct 03, 2005	Mar	CAHN
AB		EQ 5MG BASE	A076418	002	Oct 03, 2005	Mar	CAHN
AB		EQ 10MG BASE	A076418	003	Oct 03, 2005	Mar	CAHN

AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL

TABLET; ORAL

AMLODIPINE AND OLMESARTAN MEDOXOMIL

>D>	AB	TORRENT PHARMS LLC	EQ 5MG BASE;20MG	A202933	001	Nov 25, 2016	Apr	CAHN
>D>	AB		EQ 5MG BASE;40MG	A202933	002	Nov 25, 2016	Apr	CAHN
>D>	AB		EQ 10MG BASE;20MG	A202933	003	Nov 25, 2016	Apr	CAHN
>D>	AB		EQ 10MG BASE;40MG	A202933	004	Nov 25, 2016	Apr	CAHN
>A>	AB	TORRENT PHARMS LTD	EQ 5MG BASE;20MG	A202933	001	Nov 25, 2016	Apr	CAHN
>A>	AB		EQ 5MG BASE;40MG	A202933	002	Nov 25, 2016	Apr	CAHN
>A>	AB		EQ 10MG BASE;20MG	A202933	003	Nov 25, 2016	Apr	CAHN
>A>	AB		EQ 10MG BASE;40MG	A202933	004	Nov 25, 2016	Apr	CAHN

AMMONIUM LACTATE

LOTION; TOPICAL

LAC-HYDRIN

+	@	RANBAXY	EQ 12% BASE	N019155	001	Apr 24, 1985	Jan	CRLD
---	---	---------	-------------	---------	-----	--------------	-----	------

AMOXAPINE

TABLET; ORAL

AMOXAPINE

@ WATSON PHARMS TEVA

25MG

A072418 001 May 11, 1989 Feb CAHN

@

50MG

A072419 001 May 11, 1989 Feb CAHN

@

100MG

A072420 001 May 11, 1989 Feb CAHN

@

150MG

A072421 001 May 11, 1989 Feb CAHN

AMOXICILLIN

FOR SUSPENSION; ORAL

AMOXIL

@ DR REDDYS LABS INC

200MG/5ML

N050760 001 Apr 15, 1999 Feb DISC

@

400MG/5ML

N050760 002 Apr 15, 1999 Feb DISC

TABLET; ORAL

AMOXIL

+ @ DR REDDYS LABS INC

500MG

N050754 002 Jul 10, 1998 Mar DISC

+ @

875MG

N050754 001 Jul 10, 1998 Mar DISC

TABLET, CHEWABLE; ORAL

AMOXICILLIN

TEVA

125MG

A064013 002 Sep 11, 1995 Feb CTEC

!

250MG

A064013 001 Dec 22, 1992 Feb CTEC

AMOXIL

+ @ DR REDDYS LABS INC

125MG

N050542 002 Feb DISC

+ @

250MG

N050542 001 Feb DISC

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION; ORAL

AUGMENTIN '200'

+ @ DR REDDYS LABS INC

200MG/5ML;EQ 28.5MG BASE/5ML

N050725 001 May 31, 1996 Feb DISC

AUGMENTIN '400'

+ @ DR REDDYS LABS INC

400MG/5ML;EQ 57MG BASE/5ML

N050725 002 May 31, 1996 Feb DISC

AUGMENTIN ES-600

+ @ DR REDDYS LABS INC

600MG/5ML;EQ 42.9MG BASE/5ML

N050755 001 Jun 22, 2001 Feb DISC

TABLET; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB ! SANDOZ

250MG;EQ 125MG BASE

A065189 001 Aug 23, 2005 Feb CHRS

AB ! SANDOZ INC

500MG;EQ 125MG BASE

A065117 001 Nov 27, 2002 Feb CHRS

AUGMENTIN '250'

+ @ DR REDDYS LABS INC

250MG;EQ 125MG BASE

N050564 001 Aug 06, 1984 Feb DISC

AUGMENTIN '500'

+ @ DR REDDYS LABS INC

500MG;EQ 125MG BASE

N050564 002 Aug 06, 1984 Feb DISC

TABLET, CHEWABLE; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

TEVA

200MG;EQ 28.5MG BASE

A065205 001 Feb 09, 2005 Feb CTEC

!

400MG;EQ 57MG BASE

A065205 002 Feb 09, 2005 Feb CTEC

AUGMENTIN '200'

+ @ DR REDDYS LABS INC

200MG;EQ 28.5MG BASE

N050726 001 May 31, 1996 Feb DISC

AUGMENTIN '400'

+ @ DR REDDYS LABS INC

400MG;EQ 57MG BASE

N050726 002 May 31, 1996 Feb DISC

AMPICILLIN SODIUMINJECTABLE; INJECTION
AMPICILLIN SODIUM

@	WEST-WARD PHARMS INT	EQ 125MG BASE/VIAL	A 062692	001	Jun 24, 1986	Jan CAHN
@		EQ 250MG BASE/VIAL	A 062692	002	Jun 24, 1986	Jan CAHN
@		EQ 500MG BASE/VIAL	A 062692	003	Jun 24, 1986	Jan CAHN
@		EQ 1GM BASE/VIAL	A 062692	004	Jun 24, 1986	Jan CAHN
@		EQ 2GM BASE/VIAL	A 062692	005	Jun 24, 1986	Jan CAHN
@		EQ 10GM BASE/VIAL	A 062692	006	Jun 24, 1986	Jan CAHN

AMPICILLIN SODIUM; SULBACTAM SODIUMINJECTABLE; INJECTION
AMPICILLIN AND SULBACTAM

AP	WEST-WARD PHARMS INT	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A 065074	001	Mar 19, 2002	Jan CAHN
AP		EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A 065074	002	Mar 19, 2002	Jan CAHN
AP		EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL	A 065076	001	Mar 19, 2002	Jan CAHN

ANAGRELIDE HYDROCHLORIDECAPSULE; ORAL
ANAGRELIDE HYDROCHLORIDE

AB	MYLAN PHARMS INC	EQ 0.5MG BASE	A 076811	001	Apr 18, 2005	Mar CAHN
AB		EQ 1MG BASE	A 076811	002	Apr 18, 2005	Mar CAHN

ARGATROBANINJECTABLE; INJECTION
ARGATROBAN

+!	HIKMA PHARM CO LTD	50MG/50ML (1MG/ML)	N 203049	002	Sep 30, 2016	Feb NEWA
----	--------------------	--------------------	----------	-----	--------------	----------

ASPIRIN; BUTALBITAL; CAFFEINETABLET; ORAL
FIORINAL

+	@ ALLERGAN SALES LLC	325MG;50MG;40MG	N 017534	003	Apr 16, 1986	Jan CRLD
---	----------------------	-----------------	----------	-----	--------------	----------

ASPIRIN; DIPYRIDAMOLECAPSULE, EXTENDED RELEASE; ORAL
ASPIRIN AND DIPYRIDAMOLE

AB	IMPAX LABS INC	25MG;200MG	A 206964	001	Jan 18, 2017	Jan NEWA
AB	PAR PHARM INC	25MG;200MG	A 207944	001	Jan 18, 2017	Jan NEWA
AB	SANDOZ INC	25MG;200MG	A 206739	001	Jan 18, 2017	Jan NEWA

ATORVASTATIN CALCIUMTABLET; ORAL
ATORVASTATIN CALCIUM

AB	TEVA PHARMS USA	EQ 10MG BASE	A 205300	001	Mar 27, 2017	Mar NEWA
AB		EQ 20MG BASE	A 205300	002	Mar 27, 2017	Mar NEWA
AB		EQ 40MG BASE	A 205300	003	Mar 27, 2017	Mar NEWA
AB		EQ 80MG BASE	A 205300	004	Mar 27, 2017	Mar NEWA

ATORVASTATIN CALCIUM; EZETIMIBETABLET; ORAL
EZETIMIBE AND ATORVASTATIN CALCIUM

>A>	WATSON LABS TEVA	EQ 10MG BASE;10MG	A 206084	001	Apr 26, 2017	Apr NEWA
>A>		EQ 20MG BASE;10MG	A 206084	002	Apr 26, 2017	Apr NEWA
>A>		EQ 40MG BASE;10MG	A 206084	003	Apr 26, 2017	Apr NEWA
>A>	!	EQ 80MG BASE;10MG	A 206084	004	Apr 26, 2017	Apr NEWA

ATOVAQUONESUSPENSION; ORAL
ATOVAQUONE

>A>	AB	PADDOCK LLC	750MG/5ML	A 207833	001	Apr 28, 2017	Apr NEWA
-----	----	-------------	-----------	----------	-----	--------------	----------

ATRACURIUM BESYLATEINJECTABLE; INJECTION
ATRACURIUM BESYLATE
@ WATSON PHARMS TEVA 10MG/ML
ATRACURIUM BESYLATE PRESERVATIVE FREE

AP	MYLAN LABS LTD	10MG/ML	A 206001	001	Apr 07, 2017	Mar NEWA	
>D>	@	HOSPIRA	10MG/ML	N 018831	002	Jun 20, 1985	Apr CMS1
>A>	+	@	10MG/ML	N 018831	002	Jun 20, 1985	Apr CMS1

INJECTABLE; INJECTION
TRACRIUM PRESERVATIVE FREE

>D>	@ HOSPIRA	10MG/ML	N018831	001	Nov 23, 1983	Apr CMS1
>A>	+ @	10MG/ML	N018831	001	Nov 23, 1983	Apr CMS1

AZACITIDINE

POWDER; IV (INFUSION), SUBCUTANEOUS
AZACITIDINE

AP	ACTAVIS LLC	100MG/VIAL	N208216	001	Apr 29, 2016	Mar CTEC
AP	DR REDDYS LABS LTD	100MG/VIAL	A201537	001	Sep 16, 2013	Mar CDFR
AP	MYLAN INSTITUTIONAL	100MG/VIAL	A204949	001	Apr 28, 2016	Mar CDFR
AP	SHILPA MEDICARE	100MG/VIAL	A207518	001	Sep 29, 2016	Mar CDFR
VIDAZA						
AP	+! CELGENE	100MG/VIAL	N050794	001	May 19, 2004	Mar CDFR

AZELASTINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
AZELASTINE HYDROCHLORIDE

AT	SANDOZ INC	0.05%	A202305	001	May 31, 2012	Feb CAHN
OPTIVAR						
AT	+! MYLAN SPECIALITY LP	0.05%	N021127	001	May 22, 2000	Mar CAHN
SPRAY, METERED; NASAL						
ASTEELIN						
AB	+! MYLAN SPECIALITY LP	EQ 0.125MG BASE/SPRAY	N020114	001	Nov 01, 1996	Mar CAHN
ASTEPRO						
AB	+! @ MYLAN SPECIALITY LP	EQ 0.125MG BASE/SPRAY	N022203	001	Oct 15, 2008	Mar CAHN
AB	+!	EQ 0.1876MG BASE/SPRAY	N022203	002	Aug 31, 2009	Mar CAHN
AZELASTINE HYDROCHLORIDE						
AB	BRECKENRIDGE PHARM	EQ 0.125MG BASE/SPRAY	A090176	001	Jul 28, 2015	Feb CAHN
AB	UPSHER-SMITH LABS	EQ 0.125MG BASE/SPRAY	A202609	001	Mar 17, 2017	Mar NEWA

AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE

SPRAY, METERED; NASAL

>A>	AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE						
>A>	AB	APOTEX INC	EQ 0.125MG BASE/SPRAY; 0.05MG/SPRAY	A207712	001	Apr 28, 2017	Apr NEWA
DYMISTA							
>D>	+!	MYLAN SPECIALITY LP	EQ 0.125MG BASE/SPRAY; 0.05MG/SPRAY	N202236	001	May 01, 2012	Apr CFTG
>A>	AB	+!	EQ 0.125MG BASE/SPRAY; 0.05MG/SPRAY	N202236	001	May 01, 2012	Apr CFTG
		+!	EQ 0.125MG BASE/SPRAY; 0.05MG/SPRAY	N202236	001	May 01, 2012	Mar CAHN

AZITHROMYCIN

INJECTABLE; INJECTION
AZITHROMYCIN

AP	MYLAN LABS LTD	EQ 500MG BASE/VIAL	A204732	001	Jan 26, 2017	Jan NEWA	
TABLET; ORAL							
ZITHROMAX							
>D>	AB	PFIZER	EQ 250MG BASE	N050711	001	Jul 18, 1996	Apr CRLD
>A>	AB	+	EQ 250MG BASE	N050711	001	Jul 18, 1996	Apr CRLD
>D>	AB		EQ 500MG BASE	N050784	001	May 24, 2002	Apr CRLD
>A>	AB	+	EQ 500MG BASE	N050784	001	May 24, 2002	Apr CRLD

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; TOPICAL
CORTISPORIN

+!	MONARCH PHARMS	400 UNITS/GM; 1%; EQ 3.5MG BASE/GM; 5,000 UNITS/GM	N050168	002	May 04, 1984	Feb CAHN
----	----------------	---	---------	-----	--------------	----------

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC
NEOSPORIN

>D>	+ @	CASPER PHARMA LLC	400 UNITS/GM; EQ 3.5MG BASE/GM; 10,000 UNITS/GM	N050417	001		Apr CMFD
>A>	AT	+	400 UNITS/GM; EQ 3.5MG BASE/GM; 10,000 UNITS/GM	N050417	001		Apr CMFD

BACLOFEN

INJECTABLE; INTRATHECAL
BACLOFEN

AP	EMERALD INTL LTD	0.05MG/ML	A091193	001	May 03, 2016	Mar CAHN
AP		0.5MG/ML	A091193	002	May 03, 2016	Mar CAHN
AP		2MG/ML	A091193	003	May 03, 2016	Mar CAHN

INJECTABLE; INTRATHECAL
GABLOFEN

>D>	AP	MALLINCKRODT INC	0.05MG/ML	N022462	001	Nov 19, 2010	Apr	CAHN
>D>	AP		0.5MG/ML	N022462	002	Nov 19, 2010	Apr	CAHN
>D>		+	1MG/ML	N022462	004	Jun 22, 2012	Apr	CAHN
		+	1MG/ML	N022462	004	Jun 22, 2012	Mar	CRLD
>D>	AP		2MG/ML	N022462	003	Nov 19, 2010	Apr	CAHN
>A>	AP	PIRAMAL CRITICAL	0.05MG/ML	N022462	001	Nov 19, 2010	Apr	CAHN
>A>	AP		0.5MG/ML	N022462	002	Nov 19, 2010	Apr	CAHN
>A>		+	1MG/ML	N022462	004	Jun 22, 2012	Apr	CAHN
>A>	AP		2MG/ML	N022462	003	Nov 19, 2010	Apr	CAHN

TABLET; ORAL
BACLOFEN

>A>	AB	OXFORD PHARMS	10MG	A077088	002	Oct 31, 2007	Apr	CMS1
-----	----	---------------	------	---------	-----	--------------	-----	------

BALSALAZIDE DISODIUM

CAPSULE; ORAL
BALSALAZIDE DISODIUM

>D>	AB	WEST-WARD PHARMS INT	750MG	A077806	001	Dec 28, 2007	Apr	CTEC
>A>	BX		750MG	A077806	001	Dec 28, 2007	Apr	CTEC

BARIUM SULFATE

FOR SUSPENSION; ORAL
E-Z-HD

>A>		+	BRACCO	98% (334GM/BOTTLE)	N208036	001	Jan 11, 2016	Apr	CPOT
>D>		+		334GM/BOTTLE	N208036	001	Jan 11, 2016	Apr	CPOT
>A>			E-Z-PAQUE						
>A>		+	BRACCO	96% (169GM/BOTTLE)	N208036	002	Apr 07, 2017	Apr	NEWA
			SUSPENSION; ORAL						
			LIQUID E-Z-PAQUE						
		+	BRACCO	60% (213GM/355ML)	N208143	003	Mar 01, 2017	Mar	NEWA

BENZAEPRIIL HYDROCHLORIDE

TABLET; ORAL
BENZAEPRIIL HYDROCHLORIDE

>A>	AB	AMNEAL PHARMS	5MG	A076820	001	Feb 03, 2006	Apr	CAHN
>A>	AB		10MG	A076820	002	Feb 03, 2006	Apr	CAHN
>A>	AB		20MG	A076820	003	Feb 03, 2006	Apr	CAHN
>A>	AB		40MG	A076820	004	Feb 03, 2006	Apr	CAHN
>D>	AB	AMNEAL PHARMS LLC	5MG	A076820	001	Feb 03, 2006	Apr	CAHN
>D>	AB		10MG	A076820	002	Feb 03, 2006	Apr	CAHN
>D>	AB		20MG	A076820	003	Feb 03, 2006	Apr	CAHN
>D>	AB		40MG	A076820	004	Feb 03, 2006	Apr	CAHN

BENDROFLUMETHIAZIDE; NADOLOL

TABLET; ORAL
CORZIDE

AB	+	KING PHARMS LLC	5MG; 40MG	N018647	001	May 25, 1983	Mar	CAHN
AB	+	+	5MG; 80MG	N018647	002	May 25, 1983	Mar	CAHN

BENZONATATE

CAPSULE; ORAL
TESSALON

>D>	AA	PFIZER	100MG	N011210	001		Apr	CRLD
>A>	AA	+	100MG	N011210	001		Apr	CRLD

BENZPHETAMINE HYDROCHLORIDE

TABLET; ORAL
BENZPHETAMINE HYDROCHLORIDE

AA		TWI PHARMS INC	50MG	A040578	001	Apr 17, 2006	Mar	CAHN
----	--	----------------	------	---------	-----	--------------	-----	------

BENZTROPINE MESYLATE

TABLET; ORAL
BENZTROPINE MESYLATE

AA	!	UPSHER-SMITH LABS	0.5MG	A040103	001	Dec 12, 1996	Feb	CAHN
AA	!		1MG	A040103	002	Dec 12, 1996	Feb	CAHN
AA	!		2MG	A040103	003	Dec 12, 1996	Feb	CAHN

BETAMETHASONE DIPROPIONATE

LOTION; TOPICAL

BETAMETHASONE DIPROPIONATE

AB	!	FOUGERA PHARMS INC	EQ 0.05% BASE	A070275	001	Aug 12, 1985	Jan	CAHN
>D>	@	TARO	EQ 0.05% BASE	A074272	001	Sep 30, 1994	Apr	CAHN
>A>	@		EQ 0.05% BASE	A074272	001	Sep 30, 1994	Apr	CAHN
		DIPROSONE						
	+	@ SCHERING	EQ 0.05% BASE	N017781	001		Jan	CRLD
		OINTMENT; TOPICAL						
		BETAMETHASONE DIPROPIONATE						
>D>	AB	TARO	EQ 0.05% BASE	A074271	001	Sep 15, 1994	Apr	CAHN
>A>	AB		EQ 0.05% BASE	A074271	001	Sep 15, 1994	Apr	CAHN

BETAMETHASONE VALERATE

AEROSOL, FOAM; TOPICAL

BETAMETHASONE VALERATE

>D>	AB	PERRIGO	0.12%	A078337	001	Nov 26, 2012	Apr	CAHN
>A>	AB	PERRIGO UK FINCO	0.12%	A078337	001	Nov 26, 2012	Apr	CAHN
		LUXIQ						
	AB	+! MYLAN PHARMS INC	0.12%	N020934	001	Feb 28, 1999	Jan	CAHN

BETAXOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

BETAXOLOL HYDROCHLORIDE

>A>	AT	TELIGENT	EQ 0.5% BASE	A075630	001	Apr 12, 2001	Apr	CAHN
>D>	AT	TELIGENT PHARMA INC	EQ 0.5% BASE	A075630	001	Apr 12, 2001	Apr	CAHN

BETHANECHOL CHLORIDE

TABLET; ORAL

BETHANECHOL CHLORIDE

@ IMPAX LABS

5MG

A040721 001 Nov 01, 2006 Jan CMS1

@

10MG

A040721 002 Nov 01, 2006 Jan CMS1

@

25MG

A040721 003 Nov 01, 2016 Jan CMS1

BIMATOPROST

SOLUTION/DROPS; OPHTHALMIC

BIMATOPROST

AT		SANDOZ INC	0.03%	A202565	001	May 05, 2015	Mar	CAHN
----	--	------------	-------	---------	-----	--------------	-----	------

BISOPROLOL FUMARATE

TABLET; ORAL

BISOPROLOL FUMARATE

AB		ORIT LABS LLC	5MG	A204891	001	Jan 11, 2017	Jan	NEWA
AB			10MG	A204891	002	Jan 11, 2017	Jan	NEWA

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

ZIAC

AB	+	TEVA BRANDED PHARM	2.5MG; 6.25MG	N020186	003	Mar 26, 1993	Jan	CAHN
AB	+		5MG; 6.25MG	N020186	001	Mar 26, 1993	Jan	CAHN
AB	+!		10MG; 6.25MG	N020186	002	Mar 26, 1993	Jan	CAHN

BRETYLIUM TOSYLATE

INJECTABLE; INJECTION

BRETYLIUM TOSYLATE

@ WEST-WARD PHARMS INT 50MG/ML

A070545 001 May 14, 1986 Jan CAHN

>A> BRIGATINIB

>A> TABLET; ORAL

>A> ALUNBRIG

>A>	+	ARIAD	30MG	N208772	001	Apr 28, 2017	Apr	NEWA
>A>	+!		90MG	N208772	002	Apr 28, 2017	Apr	NEWA

BRIMONIDINE TARTRATE

SOLUTION/DROPS; OPHTHALMIC

BRIMONIDINE TARTRATE

AT		SANDOZ INC	0.2%	A076254	001	Sep 16, 2003	Feb	CAHN
AT			0.2%	A078075	001	Jan 30, 2008	Mar	CAHN
		QOLIANA						
AT		SANDOZ INC	0.15%	N021764	001	May 22, 2006	Mar	CAHN

BROMFENAC SODIUMSOLUTION/DROPS;OPHTHALMIC
BROMFENAC SODIUM

AT1	AMRING PHARMS	EQ 0.09% ACID	A202030	001	Jan 09, 2013	Mar	CAHN
AT1	! APOTEX INC	EQ 0.09% ACID	A202435	001	Jun 19, 2014	Feb	CHRS
	@ COASTAL PHARMS	EQ 0.09% ACID	A201211	001	May 11, 2011	Feb	DISC
AT2	! HI-TECH PHARMACAL	EQ 0.09% ACID	A203395	001	Jan 22, 2014	Mar	CHRS

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SYRUP;ORAL

BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE

AA	TARO PHARM	2MG/5ML;10MG/5ML;30MG/5ML	A205112	001	Feb 27, 2017	Feb	NEWA
----	------------	---------------------------	---------	-----	--------------	-----	------

BUDESONIDE

CAPSULE;ORAL

BUDESONIDE

AB	APPCO PHARMA LLC	3MG	A207367	001	Apr 07, 2017	Mar	NEWA
>A>	AB ZYDUS PHARMS USA INC	3MG	A206134	001	May 04, 2017	Apr	NEWA

BUMETANIDE

INJECTABLE;INJECTION

BUMETANIDE

AP	! ATHENEX INC	0.25MG/ML	A074441	001	Jan 27, 1995	Mar	CAHN
AP	WEST-WARD PHARMS INT	0.25MG/ML	A079196	001	Apr 30, 2008	Jan	CAHN

BUPRENORPHINE HYDROCHLORIDE

FILM;BUCCAL

BELBUCA

+	BDSI	EQ 0.075MG BASE	N207932	001	Oct 23, 2015	Jan	CAHN
+		EQ 0.15MG BASE	N207932	002	Oct 23, 2015	Jan	CAHN
+		EQ 0.3MG BASE	N207932	003	Oct 23, 2015	Jan	CAHN
+		EQ 0.45MG BASE	N207932	004	Oct 23, 2015	Jan	CAHN
+		EQ 0.6MG BASE	N207932	005	Oct 23, 2015	Jan	CAHN
+		EQ 0.75MG BASE	N207932	006	Oct 23, 2015	Jan	CAHN
+	!	EQ 0.9MG BASE	N207932	007	Oct 23, 2015	Jan	CAHN

TABLET;SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE

AB	RHODES PHARMS	EQ 2MG BASE	A207276	001	Mar 27, 2017	Mar	NEWA
AB		EQ 8MG BASE	A207276	002	Mar 27, 2017	Mar	NEWA

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

TABLET;SUBLINGUAL

ZUBSOLV

+	OREXO US INC	EQ 5.7MG BASE;EQ 1.4MG BASE	N204242	002	Jul 03, 2013	Jan	CHRS
+	!	EQ 11.4MG BASE;EQ 2.9MG BASE	N204242	004	Dec 11, 2014	Jan	CHRS

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

BUPROPION HYDROCHLORIDE

AB3	LUPIN LTD	150MG	A090693	001	Apr 06, 2017	Mar	NEWA
AB3		300MG	A090693	002	Apr 06, 2017	Mar	NEWA
AB3	SCIEGEN PHARMS INC	150MG	A207479	001	Apr 12, 2017	Mar	NEWA
AB3		300MG	A207479	002	Apr 12, 2017	Mar	NEWA
	FORFIVO XL						
+	! ALVOGEN	450MG	N022497	001	Nov 10, 2011	Jan	CAHN

BUSPIRONE HYDROCHLORIDE

TABLET;ORAL

BUSPIRONE HYDROCHLORIDE

>D>	AB STRIDES ARCOLAB LTD	5MG	A202330	001	Aug 25, 2014	Apr	CAHN
>D>	AB	10MG	A202330	002	Aug 25, 2014	Apr	CAHN
>D>	AB	15MG	A202330	003	Aug 25, 2014	Apr	CAHN
>D>	AB	30MG	A202330	004	Aug 25, 2014	Apr	CAHN
>A>	AB STRIDES PHARMA	5MG	A202330	001	Aug 25, 2014	Apr	CAHN
>A>	AB	10MG	A202330	002	Aug 25, 2014	Apr	CAHN
>A>	AB	15MG	A202330	003	Aug 25, 2014	Apr	CAHN
>A>	AB	30MG	A202330	004	Aug 25, 2014	Apr	CAHN

BUSULFAN

	INJECTABLE; INJECTION						
	BUSULFAN						
AP	PHARMASCIENCE INC	6MG/ML	A207050	001	Mar 24, 2017	Mar	NEWA

BUTABARBITAL SODIUM

	TABLET; ORAL						
	BUTISOL SODIUM						
	@ MYLAN SPECIALITY LP	15MG	N000793	002		Mar	CAHN
+!		30MG	N000793	004		Mar	CAHN
	@	50MG	N000793	003		Mar	CAHN
	@	100MG	N000793	005		Mar	CAHN

BUTORPHANOL TARTRATE

	INJECTABLE; INJECTION						
	BUTORPHANOL TARTRATE PRESERVATIVE FREE						
AP	WEST-WARD PHARMS INT	1MG/ML	A075045	001	Aug 12, 1998	Jan	CAHN
AP		2MG/ML	A075045	002	Aug 12, 1998	Jan	CAHN

CALCIPOTRIENE

	AEROSOL, FOAM; TOPICAL						
	SORILUX						
+!	MAYNE PHARMA	0.005%	N022563	001	Oct 06, 2010	Jan	CAHN

CALCITONIN SALMON

	SPRAY, METERED; NASAL						
	CALCITONIN-SALMON						
>D>	AB	APOTEX INC	200 IU/SPRAY	A076396	001	Nov 17, 2008	Apr CHRS
>A>	AB	!	200 IU/SPRAY	A076396	001	Nov 17, 2008	Apr CHRS
>D>	AB	MIACALCIN					
>D>	AB	+! MYLAN IRELAND LTD	200 IU/SPRAY	N020313	002	Aug 17, 1995	Apr DISC
>A>	AB	+ @	200 IU/SPRAY	N020313	002	Aug 17, 1995	Apr DISC

CALCIUM ACETATE

	CAPSULE; ORAL						
	CALCIUM ACETATE						
AB		CHARTWELL RX	667MG	A091312	001	Jun 01, 2012	Mar CAHN
	TABLET; ORAL						
	CALCIUM ACETATE						
>D>	AB	PADDOCK LLC	667MG	A091561	001	Apr 13, 2011	Apr CHRS
>A>	AB	!	667MG	A091561	001	Apr 13, 2011	Apr CHRS
	ELIPHOS						
>D>	AB	! CYPRESS PHARM	667MG	A078502	001	Nov 25, 2008	Apr CHRS
>A>	AB		667MG	A078502	001	Nov 25, 2008	Apr CHRS

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

	INJECTABLE; INJECTION						
	DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER						
AP	ICU MEDCL	20MG/100ML; 5GM/100ML; 30MG/100ML; 60	N017608	001		Feb	CAHN
		0MG/100ML; 310MG/100ML					
	POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER						
	@ ICU MEDCL	20MG/100ML; 5GM/100ML; 104MG/100ML; 6	N019685	005	Oct 17, 1988	Feb	CAHN
		00MG/100ML; 310MG/100ML					
	@	20MG/100ML; 5GM/100ML; 179MG/100ML; 6	N019685	006	Oct 17, 1988	Feb	CAHN
		00MG/100ML; 310MG/100ML					
	POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER						
	@ ICU MEDCL	20MG/100ML; 5GM/100ML; 254MG/100ML; 6	N019685	007	Oct 17, 1988	Feb	CAHN
		00MG/100ML; 310MG/100ML					
	POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER						
AP	ICU MEDCL	20MG/100ML; 5GM/100ML; 179MG/100ML; 6	N019685	002	Oct 17, 1988	Feb	CAHN
		00MG/100ML; 310MG/100ML					
AP		20MG/100ML; 5GM/100ML; 328MG/100ML; 6	N019685	008	Oct 17, 1988	Feb	CAHN
		00MG/100ML; 310MG/100ML					
	POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER						
	@ ICU MEDCL	20MG/100ML; 5GM/100ML; 254MG/100ML; 6	N019685	003	Oct 17, 1988	Feb	CAHN
		00MG/100ML; 310MG/100ML					
	POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER						
AP	ICU MEDCL	20MG/100ML; 5GM/100ML; 328MG/100ML; 6	N019685	004	Oct 17, 1988	Feb	CAHN
		00MG/100ML; 310MG/100ML					
	POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER						
	@ ICU MEDCL	20MG/100ML; 5GM/100ML; 104MG/100ML; 6	N019685	001	Oct 17, 1988	Feb	CAHN
		00MG/100ML; 310MG/100ML					

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

	INJECTABLE; INJECTION						
	RINGER'S IN PLASTIC CONTAINER						
AP	ICU MEDCL	33MG/100ML; 30MG/100ML; 860MG/100ML	N018251	001			Feb CAHN
	SOLUTION; IRRIGATION						
	RINGER'S IN PLASTIC CONTAINER						
AT	ICU MEDCL	33MG/100ML; 30MG/100ML; 860MG/100ML	N017635	001			Feb CAHN

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

	INJECTABLE; INJECTION						
	LACTATED RINGER'S IN PLASTIC CONTAINER						
AP	ICU MEDCL	20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML	N017641	001			Feb CAHN
	SOLUTION; IRRIGATION						
	LACTATED RINGER'S IN PLASTIC CONTAINER						
AT	+! ICU MEDCL	20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML	N019416	001	Jan 17, 1986		Feb CAHN

CAPECITABINE

	TABLET; ORAL						
	CAPECITABINE						
AB	AMNEAL PHARMS	150MG	A204741	001	Feb 28, 2017		Feb NEWA
AB		500MG	A204741	002	Feb 28, 2017		Feb NEWA

CAPTOPRIL

	TABLET; ORAL						
	CAPTOPRIL						
AB	MYLAN PHARMS INC	12.5MG	A074434	001	Feb 13, 1996		Mar CAHN
AB		25MG	A074434	002	Feb 13, 1996		Mar CAHN
AB		50MG	A074434	003	Feb 13, 1996		Mar CAHN
AB	!	100MG	A074434	004	Feb 13, 1996		Mar CAHN

CARBAMAZEPINE

	SOLUTION; IV (INFUSION)						
	CARNEXIV						
	+! LUNDBECK PHARMS LLC	200MG/20ML (10MG/ML)	N206030	001	Oct 07, 2016		Jan CAHN
	SUSPENSION; ORAL						
	TERIL						
AB	TARO PHARM	100MG/5ML	A076729	001	Sep 20, 2004		Mar CAHN

CARBOPLATIN

	INJECTABLE; IV (INFUSION)						
	CARBOPLATIN						
AP	ACCORD HLTHCARE	50MG/5ML (10MG/ML)	A206775	001	Feb 09, 2017		Jan NEWA
AP		150MG/15ML (10MG/ML)	A206775	002	Feb 09, 2017		Jan NEWA
AP		450MG/45ML (10MG/ML)	A206775	003	Feb 09, 2017		Jan NEWA
AP		600MG/60ML (10MG/ML)	A206775	004	Feb 09, 2017		Jan NEWA
AP	GLAND PHARMA LTD	50MG/5ML (10MG/ML)	A207324	001	Feb 15, 2017		Jan NEWA
AP		150MG/15ML (10MG/ML)	A207324	002	Feb 15, 2017		Jan NEWA
AP		450MG/45ML (10MG/ML)	A207324	003	Feb 15, 2017		Jan NEWA
AP		600MG/60ML (10MG/ML)	A207324	004	Feb 15, 2017		Jan NEWA
>A>	AP	INGENUS PHARMS LLC	50MG/5ML (10MG/ML)	A208487	001	Apr 26, 2017	Apr NEWA
>A>	AP		150MG/15ML (10MG/ML)	A208487	002	Apr 26, 2017	Apr NEWA
>A>	AP		450MG/45ML (10MG/ML)	A208487	003	Apr 26, 2017	Apr NEWA
>A>	AP		600MG/60ML (10MG/ML)	A208487	004	Apr 26, 2017	Apr NEWA

CARISOPRODOL

	CAPSULE; ORAL						
	SOMA						
	@ MYLAN SPECIALITY LP	250MG	N011792	003			Mar CAHN
	TABLET; ORAL						
	CARISOPRODOL						
>D>	@ HIKMA INTL PHARMS	350MG	A040124	001	Jan 24, 1996		Apr CMFD
>A>	AA	350MG	A040124	001	Jan 24, 1996		Apr CMFD
>A>	AB	NOSTRUM LABS INC	A207237	001	May 11, 2017		Apr NEWA
	SOMA						
AB	+! MYLAN SPECIALITY LP	250MG	N011792	004	Sep 13, 2007		Mar CAHN
AA	+	350MG	N011792	001			Mar CAHN

CARTEOLOL HYDROCHLORIDESOLUTION/DROPS;OPHTHALMIC
CARTEOLOL HYDROCHLORIDE

AT		SANDOZ INC	1%	A075476	001	Jan 03, 2000	Mar	CAHN
----	--	------------	----	---------	-----	--------------	-----	------

CASPOFUNGIN ACETATEPOWDER; IV (INFUSION)
CANCIDAS

AP	+	MERCK	50MG/VIAL	N021227	001	Jan 26, 2001	Mar	CDFR
AP	+		70MG/VIAL	N021227	002	Jan 26, 2001	Mar	CDFR

CEFDINIRCAPSULE; ORAL
OMNICEF

+ @ ABBVIE 300MG

N050739 001 Dec 04, 1997 Jan CRLD

FOR SUSPENSION; ORAL
OMNICEF

+ @ ABBVIE 125MG/5ML

N050749 001 Dec 04, 1997 Jan CRLD

+ @ 250MG/5ML

N050749 002 Jul 29, 2004 Jan CRLD

CEFIXIMEFOR SUSPENSION; ORAL
CEFIXIME

AB		BELCHER PHARMS LLC	100MG/5ML	A206938	001	Feb 06, 2017	Jan	NEWA
----	--	--------------------	-----------	---------	-----	--------------	-----	------

AB			200MG/5ML	A206938	002	Feb 06, 2017	Jan	NEWA
----	--	--	-----------	---------	-----	--------------	-----	------

AB			500MG/5ML	A206939	001	Feb 06, 2017	Jan	NEWA
----	--	--	-----------	---------	-----	--------------	-----	------

SUPRAX

AB	+	LUPIN LTD	500MG/5ML	N202091	001	Feb 20, 2013	Jan	CFTG
----	---	-----------	-----------	---------	-----	--------------	-----	------

CEFOTETAN DISODIUMINJECTABLE; INJECTION
CEFOTAN

>A>	AP	+	TELIGENT	EQ 1GM BASE/VIAL	N050588	001	Dec 27, 1985	Apr	CAHN
-----	----	---	----------	------------------	---------	-----	--------------	-----	------

>A>	AP	+		EQ 2GM BASE/VIAL	N050588	002	Dec 27, 1985	Apr	CAHN
-----	----	---	--	------------------	---------	-----	--------------	-----	------

>A>		@		EQ 10GM BASE/VIAL	N050588	003	Apr 25, 1988	Apr	CAHN
-----	--	---	--	-------------------	---------	-----	--------------	-----	------

>D>	AP	+	TELIGENT PHARMA INC	EQ 1GM BASE/VIAL	N050588	001	Dec 27, 1985	Apr	CAHN
-----	----	---	---------------------	------------------	---------	-----	--------------	-----	------

>D>	AP	+		EQ 2GM BASE/VIAL	N050588	002	Dec 27, 1985	Apr	CAHN
-----	----	---	--	------------------	---------	-----	--------------	-----	------

>D>		@		EQ 10GM BASE/VIAL	N050588	003	Apr 25, 1988	Apr	CAHN
-----	--	---	--	-------------------	---------	-----	--------------	-----	------

CEFOTAN IN PLASTIC CONTAINER

>D>		@	IGI LABS INC	EQ 20MG BASE/ML	N050694	002	Jul 30, 1993	Apr	CAHN
-----	--	---	--------------	-----------------	---------	-----	--------------	-----	------

>D>		@		EQ 40MG BASE/ML	N050694	001	Jul 30, 1993	Apr	CAHN
-----	--	---	--	-----------------	---------	-----	--------------	-----	------

>A>		@	TELIGENT	EQ 20MG BASE/ML	N050694	002	Jul 30, 1993	Apr	CAHN
-----	--	---	----------	-----------------	---------	-----	--------------	-----	------

>A>		@		EQ 40MG BASE/ML	N050694	001	Jul 30, 1993	Apr	CAHN
-----	--	---	--	-----------------	---------	-----	--------------	-----	------

CEFOXITIN SODIUMINJECTABLE; INJECTION
CEFOXITIN

AP		WEST-WARD PHARMS INT	EQ 1GM BASE/VIAL	A065051	001	Sep 11, 2000	Jan	CAHN
----	--	----------------------	------------------	---------	-----	--------------	-----	------

AP			EQ 2GM BASE/VIAL	A065051	002	Sep 11, 2000	Jan	CAHN
----	--	--	------------------	---------	-----	--------------	-----	------

AP			EQ 10GM BASE/VIAL	A065050	001	Sep 11, 2000	Jan	CAHN
----	--	--	-------------------	---------	-----	--------------	-----	------

CEFPROZILTABLET; ORAL
CEFPROZIL

AB		AUROBINDO PHARMA LTD	250MG	A065340	001	May 24, 2007	Jan	CAHN
----	--	----------------------	-------	---------	-----	--------------	-----	------

AB			500MG	A065340	002	May 24, 2007	Jan	CAHN
----	--	--	-------	---------	-----	--------------	-----	------

CEFTAZIDIMEINJECTABLE; INJECTION
FORTAZ

>D>	AP	+	IGI LABS INC	500MG/VIAL	N050578	001	Jul 19, 1985	Apr	CAHN
-----	----	---	--------------	------------	---------	-----	--------------	-----	------

>D>	AP	+		1GM/VIAL	N050578	002	Jul 19, 1985	Apr	CAHN
-----	----	---	--	----------	---------	-----	--------------	-----	------

>D>	AP	+		2GM/VIAL	N050578	003	Jul 19, 1985	Apr	CAHN
-----	----	---	--	----------	---------	-----	--------------	-----	------

>D>	AP	+		6GM/VIAL	N050578	004	Jul 19, 1985	Apr	CAHN
-----	----	---	--	----------	---------	-----	--------------	-----	------

>A>	AP	+	TELIGENT	500MG/VIAL	N050578	001	Jul 19, 1985	Apr	CAHN
-----	----	---	----------	------------	---------	-----	--------------	-----	------

>A>	AP	+		1GM/VIAL	N050578	002	Jul 19, 1985	Apr	CAHN
-----	----	---	--	----------	---------	-----	--------------	-----	------

>A>	AP	+		2GM/VIAL	N050578	003	Jul 19, 1985	Apr	CAHN
-----	----	---	--	----------	---------	-----	--------------	-----	------

>A>	AP	+		6GM/VIAL	N050578	004	Jul 19, 1985	Apr	CAHN
-----	----	---	--	----------	---------	-----	--------------	-----	------

CEFTRIAXONE SODIUMINJECTABLE; INJECTION
CEFTRIAXONE SODIUM

AP	SAGENT PHARMS	EQ 10GM BASE/VIAL	A091117	001	Jan 20, 2017	Jan NEWA
	ROCEPHIN W/ DEXTROSE IN PLASTIC CONTAINER					
	+ @ HOFFMANN LA ROCHE	EQ 10MG BASE/ML	N050624	001	Feb 11, 1987	Jan CRLD
	+ @	EQ 20MG BASE/ML	N050624	002	Feb 11, 1987	Jan CRLD
	+ @	EQ 40MG BASE/ML	N050624	003	Feb 11, 1987	Jan CRLD

CEFUROXIME AXETILTABLET; ORAL
CEFUROXIME AXETIL

AB	AUROBINDO PHARMA LTD	EQ 125MG BASE	A065308	001	Mar 29, 2006	Jan CAHN
AB		EQ 250MG BASE	A065308	002	Mar 29, 2006	Jan CAHN
AB		EQ 500MG BASE	A065308	003	Mar 29, 2006	Jan CAHN

CELECOXIBCAPSULE; ORAL
CELECOXIB

AB	JUBILANT GENERICS	50MG	A207061	001	Apr 04, 2017	Mar NEWA
AB		100MG	A207061	002	Apr 04, 2017	Mar NEWA
AB		200MG	A207061	003	Apr 04, 2017	Mar NEWA
AB		400MG	A207061	004	Apr 04, 2017	Mar NEWA

CEPHALEXINCAPSULE; ORAL
CEPHALEXIN

AB	AUROBINDO PHARMA LTD	EQ 250MG BASE	A065253	001	Nov 16, 2005	Jan CAHN
AB		EQ 500MG BASE	A065253	002	Nov 16, 2005	Jan CAHN

CEPHAPIRIN SODIUMINJECTABLE; INJECTION
CEPHAPIRIN SODIUM

	@ WEST-WARD PHARMS INT	EQ 500MG BASE/VIAL	A062720	001	Jul 02, 1987	Jan CAHN
	@	EQ 1GM BASE/VIAL	A062720	002	Jul 02, 1987	Jan CAHN
	@	EQ 2GM BASE/VIAL	A062720	003	Jul 02, 1987	Jan CAHN
	@	EQ 20GM BASE/VIAL	A062720	004	Jul 02, 1987	Jan CAHN

CETIRIZINE HYDROCHLORIDESYRUP; ORAL
CETIRIZINE HYDROCHLORIDE

>A>	AA	ALLIED PHARMA INC	5MG/5ML	A090191	001	Nov 12, 2009	Apr CAHN
>D>	AA	NOSTRUM LABS INC	5MG/5ML	A090191	001	Nov 12, 2009	Apr CAHN

CHENODIOLTABLET; ORAL
CHENIX

	+ @ LEADIANT BIOSCI INC	250MG	N018513	002	Jul 28, 1983	Feb CAHN
--	-------------------------	-------	---------	-----	--------------	----------

CHLORAMPHENICOL SODIUM SUCCINATEINJECTABLE; INJECTION
CHLOROMYCETIN

	+ @ PARKEDALE	EQ 1GM BASE/VIAL	N050155	001		Mar CRLD
--	---------------	------------------	---------	-----	--	----------

CHLORDIAZEPOXIDE HYDROCHLORIDECAPSULE; ORAL
CHLORDIAZEPOXIDE HYDROCHLORIDE

>D>	AB	USL PHARMA	10MG	A084623	001		Apr DISC
>A>		@	10MG	A084623	001		Apr DISC

CHLORPHENESIN CARBAMATETABLET; ORAL
MAOLATE

	@ PAMLAB LLC	400MG	N014217	002		Mar CAHN
--	--------------	-------	---------	-----	--	----------

CHLORPROPAMIDE

TABLET; ORAL

CHLORPROPAMIDE

@ ANI PHARMS INC

250MG

A 087353 001

Jan CAHN

CHLORTHALIDONE

TABLET; ORAL

CHLORTHALIDONE

AB RICONPHARMA LLC

25MG

A 206904 001 Mar 30, 2017

Mar NEWA

AB 50MG

A 206904 002 Mar 30, 2017 Mar NEWA

CHOLESTYRAMINE

POWDER; ORAL

CHOLESTYRAMINE

>A> AB ZYDUS PHARMS USA INC EQ 4GM RESIN/SCOOPFUL

A 202902 001 Apr 25, 2017 Apr NEWA

CICLOPIROX

CREAM; TOPICAL

CICLOPIROX

>D> AB PERRIGO 0.77%

A 077364 001 Mar 03, 2006 Apr CAHN

>A> AB PERRIGO NEW YORK 0.77%

A 077364 001 Mar 03, 2006 Apr CAHN

SHAMPOO; TOPICAL

CICLOPIROX

>D> AT PERRIGO 1%

A 078594 001 Feb 16, 2010 Apr CAHN

>A> AT PERRIGO CO 1%

A 078594 001 Feb 16, 2010 Apr CAHN

CILOSTAZOL

TABLET; ORAL

CILOSTAZOL

@ MYLAN PHARMS INC

50MG

A 077019 001 Nov 23, 2004 Mar DISC

@ 100MG

A 077019 002 Nov 23, 2004 Mar DISC

@ PLIVA HRVATSKA DOO

50MG

A 077898 001 Oct 29, 2007 Mar DISC

@ 100MG

A 077898 002 Oct 29, 2007 Mar DISC

PLETAL

+ @ OTSUKA 50MG

N 020863 001 Jan 15, 1999 Jan CRLD

+ @ 100MG

N 020863 002 Jan 15, 1999 Jan CRLD

CIMETIDINE

TABLET; ORAL

CIMETIDINE

@ CHARTWELL MOLECULES

200MG

A 074281 001 May 17, 1994 Jan CAHN

@ 300MG

A 074281 002 May 17, 1994 Jan CAHN

@ 400MG

A 074281 003 May 17, 1994 Jan CAHN

@ 800MG

A 074329 001 May 17, 1994 Jan CAHN

@ SANDOZ INC

200MG

A 074250 001 Jun 29, 1995 Mar CAHN

@ 300MG

A 074250 002 Jun 29, 1995 Mar CAHN

@ 400MG

A 074250 003 Jun 29, 1995 Mar CAHN

@ 800MG

A 074250 004 Jun 29, 1995 Mar CAHN

CIPROFLOXACIN

INJECTABLE; INJECTION

CIPRO

+ @ BAYER HLTHCARE 400MG/40ML (10MG/ML)

N 019847 001 Dec 26, 1990 Feb DISC

+ @ 200MG/20ML (10MG/ML)

N 019847 002 Dec 26, 1990 Feb DISC

CIPRO IN DEXTROSE 5% IN PLASTIC CONTAINER

+ @ BAYER HLTHCARE 200MG/100ML

N 019857 001 Dec 26, 1990 Feb DISC

+ @ 400MG/200ML

N 019857 002 Dec 26, 1990 Feb DISC

CIPROFLOXACIN

AP ! CLARIS 200MG/20ML (10MG/ML)

A 078062 001 Apr 29, 2008 Feb CHRS

AP ! 400MG/40ML (10MG/ML)

A 078062 002 Apr 29, 2008 Feb CHRS

CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

AP ! HOSPIRA 200MG/100ML

A 077753 001 Mar 18, 2008 Feb CHRS

AP ! 400MG/200ML

A 077753 002 Mar 18, 2008 Feb CHRS

CIPROFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

CIPROFLOXACIN HYDROCHLORIDE

AT AMRING PHARMS EQ 0.3% BASE

A 078598 001 Jan 16, 2008 Mar CAHN

>A> AT TELIGENT EQ 0.3% BASE

A 076754 001 Jun 09, 2004 Apr CAHN

>D> AT TELIGENT PHARMA INC EQ 0.3% BASE

A 076754 001 Jun 09, 2004 Apr CAHN

TABLET;ORAL

CIPROFLOXACIN HYDROCHLORIDE

AB	TARO PHARM	EQ 100MG BASE	A076912	001	Feb 18, 2005	Mar CAHN
AB		EQ 250MG BASE	A076912	002	Oct 06, 2004	Mar CAHN
AB		EQ 500MG BASE	A076912	003	Oct 06, 2004	Mar CAHN
AB		EQ 750MG BASE	A076912	004	Oct 06, 2004	Mar CAHN

CISATRACURIUM BESYLATE

INJECTABLE;INJECTION

CISATRACURIUM BESYLATE PRESERVATIVE FREE

AP	JIANGSU HENGRUI MED	EQ 2MG BASE/ML	A204960	001	Jan 27, 2017	Jan NEWA
----	---------------------	----------------	---------	-----	--------------	----------

CISPLATIN

INJECTABLE;INJECTION

CISPLATIN

AP	GLAND PHARMA LTD	1MG/ML	A207323	001	Mar 17, 2017	Mar NEWA
AP	+ HQ SPCLT PHARMA	1MG/ML	N018057	004	Nov 08, 1988	Mar CRLD
	PLATINOL					
	+ @ HQ SPCLT PHARMA	10MG/VIAL	N018057	001		Mar CRLD
	+ @	50MG/VIAL	N018057	002		Mar CRLD
	PLATINOL-AQ					
	+ @ HQ SPCLT PHARMA	0.5MG/ML	N018057	003	Jul 18, 1984	Mar CRLD

CITALOPRAM HYDROBROMIDE

CAPSULE;ORAL

CITALOPRAM HYDROBROMIDE

@	MYLAN PHARMS INC	EQ 10MG BASE	A077668	001	Feb 28, 2007	Mar DISC
@		EQ 20MG BASE	A077668	002	Feb 28, 2007	Mar DISC
@		EQ 40MG BASE	A077668	003	Feb 28, 2007	Mar DISC

SOLUTION;ORAL

CITALOPRAM HYDROBROMIDE

AA	AUROBINDO PHARMA LTD	EQ 10MG BASE/5ML	A077812	001	Aug 28, 2006	Jan CAHN
----	----------------------	------------------	---------	-----	--------------	----------

CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE

FOR SOLUTION;ORAL

PREPOPIK

+!	FERRING PHARMS INC	12GM/PACKET;3.5GM/PACKET;10MG/PACK ET	N202535	001	Jul 16, 2012	Mar CAHN
----	--------------------	---------------------------------------	---------	-----	--------------	----------

CLEMASTINE FUMARATE

TABLET;ORAL

CLEMASTINE FUMARATE

@	SANDOZ	2.68MG	A073459	001	Oct 31, 1993	Feb DISC
!	TEVA	2.68MG	A073283	001	Jan 31, 1992	Feb CTEC

CLINDAMYCIN PALMITATE HYDROCHLORIDE

FOR SOLUTION;ORAL

CLINDAMYCIN PALMITATE HYDROCHLORIDE

>A>	AA	INVAGEN PHARMS	EQ 75MG BASE/5ML	A206958	001	May 05, 2017	Apr NEWA
>D>	AA	PADDOCK LABS	EQ 75MG BASE/5ML	A090902	001	Jul 07, 2010	Apr CAHN
>A>	AA	PADDOCK LLC	EQ 75MG BASE/5ML	A090902	001	Jul 07, 2010	Apr CAHN

CLINDAMYCIN PHOSPHATE

AEROSOL, FOAM;TOPICAL

EVOCLIN

AT	+!	MYLAN PHARMS INC	1%	N050801	001	Oct 22, 2004	Jan CAHN
----	----	------------------	----	---------	-----	--------------	----------

INJECTABLE;INJECTION

CLINDAMYCIN PHOSPHATE

>A>	AP	SAGENT PHARMS	EQ 150MG BASE/ML	A090109	001	Sep 30, 2011	Apr CAHN
>D>	AP	SAGENT STRIDES	EQ 150MG BASE/ML	A090109	001	Sep 30, 2011	Apr CAHN
	AP	WEST-WARD PHARMS INT	EQ 150MG BASE/ML	A065206	001	Sep 24, 2004	Jan CAHN

SOLUTION;IV (INFUSION)

CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE

>A>	+!	CELERITY PHARMS	EQ 300MG BASE/50ML (EQ 6MG BASE/ML)	N208083	001	Apr 20, 2017	Apr NEWA
>A>	+!		EQ 600MG BASE/50ML (EQ 12MG BASE/ML)	N208083	002	Apr 20, 2017	Apr NEWA
>A>	+!		EQ 900MG BASE/50ML (EQ 18MG BASE/ML)	N208083	003	Apr 20, 2017	Apr NEWA

SOLUTION;TOPICAL

CLINDAMYCIN PHOSPHATE

AT		FOUGERA PHARMS INC	EQ 1% BASE	A064159	001	Jun 05, 1997	Jan CAHN
----	--	--------------------	------------	---------	-----	--------------	----------

	SWAB;TOPICAL							
	CLINDETS							
>D>	AT	PERRIGO	EQ 1% BASE	A064136	001	Sep 30, 1996	Apr	CAHN
>A>	AT	PERRIGO CO	EQ 1% BASE	A064136	001	Sep 30, 1996	Apr	CAHN
	<u>CLOBAZAM</u>							
	SUSPENSION;ORAL							
	ONFI							
	+	LUNDBECK PHARMS LLC	2.5MG/ML	N203993	001	Dec 14, 2012	Jan	CAHN
	TABLET;ORAL							
	ONFI							
	@	LUNDBECK PHARMS LLC	5MG	N202067	001	Oct 21, 2011	Jan	CAHN
	+		10MG	N202067	002	Oct 21, 2011	Jan	CAHN
	+		20MG	N202067	003	Oct 21, 2011	Jan	CAHN
	<u>CLOBETASOL PROPIONATE</u>							
	AEROSOL, FOAM;TOPICAL							
	OLUX							
AB1	+	MYLAN PHARMS INC	0.05%	N021142	001	May 26, 2000	Jan	CAHN
	OLUX E							
AB2	+	MYLAN PHARMS INC	0.05%	N022013	001	Jan 12, 2007	Jan	CAHN
	CREAM;TOPICAL							
	CLOBETASOL PROPIONATE							
AB1		FOUGERA PHARMS INC	0.05%	A074392	001	Sep 30, 1996	Jan	CAHN
	@	MYLAN PHARMS INC	0.05%	A075338	001	Feb 09, 2001	Jan	CAHN
>D>	AB1	TARO	0.05%	A074249	001	Jul 08, 1996	Apr	CAHN
>A>	AB1		0.05%	A074249	001	Jul 08, 1996	Apr	CAHN
	GEL;TOPICAL							
	CLOBETASOL PROPIONATE							
>D>	AB	PERRIGO	0.05%	A075027	001	Oct 31, 1997	Apr	CAHN
>A>	AB	PERRIGO CO	0.05%	A075027	001	Oct 31, 1997	Apr	CAHN
>D>	AB	TARO	0.05%	A075279	001	May 28, 1999	Apr	CAHN
>A>	AB		0.05%	A075279	001	May 28, 1999	Apr	CAHN
	AB	TELIGENT PHARMA INC	0.05%	A208881	001	Mar 06, 2017	Feb	NEWA
	OINTMENT;TOPICAL							
	CLOBETASOL PROPIONATE							
	AB	GLENMARK PHARMS	0.05%	A208933	001	Mar 20, 2017	Mar	NEWA
	@	MYLAN PHARMS INC	0.05%	A075057	001	Aug 12, 1998	Jan	CAHN
>D>	AB	TARO	0.05%	A074248	001	Jul 12, 1996	Apr	CAHN
>A>	AB		0.05%	A074248	001	Jul 12, 1996	Apr	CAHN
	TEMOVATE							
	+	@ FOUGERA PHARMS	0.05%	N019323	001	Dec 27, 1985	Jan	CRLD
	SOLUTION;TOPICAL							
	CLOBETASOL PROPIONATE							
>D>	AT	TARO	0.05%	A075224	001	Nov 16, 1998	Apr	CAHN
>A>	AT		0.05%	A075224	001	Nov 16, 1998	Apr	CAHN
	SPRAY;TOPICAL							
	CLOBETASOL PROPIONATE							
>A>	AT	AKORN	0.05%	A207218	001	Apr 28, 2017	Apr	NEWA
	AT	ZYDUS PHARMS USA INC	0.05%	A206378	001	Feb 16, 2017	Feb	NEWA
	<u>CLOFARABINE</u>							
	INJECTABLE;IV (INFUSION)							
	CLOFARABINE							
>A>	AP	ABON PHARMS LLC	20MG/20ML (1MG/ML)	A204029	001	May 09, 2017	Apr	NEWA
	CLOLAR							
>D>	+	GENZYME	20MG/20ML (1MG/ML)	N021673	001	Dec 28, 2004	Apr	CFTG
>A>	AP	+	20MG/20ML (1MG/ML)	N021673	001	Dec 28, 2004	Apr	CFTG
	<u>CLOMIPRAMINE HYDROCHLORIDE</u>							
	CAPSULE;ORAL							
	CLOMIPRAMINE HYDROCHLORIDE							
AB		SANDOZ	25MG	A074953	001	Jun 25, 1997	Feb	CMFD
AB			50MG	A074953	002	Jun 25, 1997	Feb	CMFD
AB			75MG	A074953	003	Jun 25, 1997	Feb	CMFD

CLONAZEPAM

TABLET; ORAL		CLONAZEPAM					
	@ MYLAN PHARMS INC	0.5MG	A074940	001	Oct 30, 1997	Mar	DISC
	@	1MG	A074940	002	Oct 30, 1997	Mar	DISC
	@	2MG	A074940	003	Oct 30, 1997	Mar	DISC
AB	PRINSTON INC	0.5MG	A077856	001	Jun 28, 2006	Feb	CAHN
AB		1MG	A077856	002	Jun 28, 2006	Feb	CAHN
AB		2MG	A077856	003	Jun 28, 2006	Feb	CAHN

CLONIDINE HYDROCHLORIDE

TABLET; ORAL		CLONIDINE HYDROCHLORIDE					
	@ CHARTWELL MOLECULES	0.1MG	A071783	001	Apr 05, 1988	Feb	CAHN
	@	0.3MG	A071785	001	Apr 05, 1988	Feb	CAHN
AB	PRINSTON INC	0.1MG	A077901	001	Mar 09, 2007	Feb	CAHN
AB		0.2MG	A077901	002	Mar 09, 2007	Feb	CAHN
AB		0.3MG	A077901	003	Mar 09, 2007	Feb	CAHN
TABLET, EXTENDED RELEASE; ORAL		CLONIDINE HYDROCHLORIDE					
>D>	AB2 ACTAVIS ELIZABETH	0.1MG	A202792	001	May 15, 2015	Apr	CAHN
>A>	AB2	0.1MG	A202792	001	May 15, 2015	Apr	CAHN
>D>	AB1	0.1MG	A203320	001	May 15, 2015	Apr	CAHN
>A>	AB1	0.1MG	A203320	001	May 15, 2015	Apr	CAHN
>D>	@	0.2MG	A202792	002	May 15, 2015	Apr	CAHN
>A>	@	0.2MG	A202792	002	May 15, 2015	Apr	CAHN
>D>	@	0.2MG	A203320	002	May 15, 2015	Apr	CAHN
>A>	@	0.2MG	A203320	002	May 15, 2015	Apr	CAHN

CLOPIDOGREL BISULFATE

TABLET; ORAL		CLOPIDOGREL BISULFATE					
AB	ALLIED PHARMA INC	EQ 75MG BASE	A078004	001	May 17, 2012	Mar	CAHN
AB	CSPC OUYI PHARM CO	EQ 75MG BASE	A204359	001	Feb 02, 2017	Jan	NEWA

CLORAZEPATE DIPOTASSIUM

TABLET; ORAL		CLORAZEPATE DIPOTASSIUM					
AB	TARO PHARM	3.75MG	A075731	003	Apr 27, 2000	Mar	CAHN
AB		7.5MG	A075731	002	Apr 27, 2000	Mar	CAHN
AB		15MG	A075731	001	Apr 27, 2000	Mar	CAHN

CLOTRIMAZOLE

SOLUTION; TOPICAL		CLOTRIMAZOLE					
>D>	AT ! TARO	1%	A074580	001	Jul 29, 1996	Apr	CAHN
>A>	AT !	1%	A074580	001	Jul 29, 1996	Apr	CAHN

CODEINE SULFATE

SOLUTION; ORAL		CODEINE SULFATE					
	@ WEST-WARD PHARMS INT	30MG/5ML	N202245	001	Jun 30, 2011	Jan	CAHN
TABLET; ORAL		CODEINE SULFATE					
AB	+ WEST-WARD PHARMS INT	15MG	N022402	001	Jul 16, 2009	Jan	CAHN
AB	+	30MG	N022402	002	Jul 16, 2009	Jan	CAHN
AB	+!	60MG	N022402	003	Jul 16, 2009	Jan	CAHN

CORTISONE ACETATE

TABLET; ORAL		CORTONE					
	+ @ MERCK	25MG	N007750	003		Mar	CRLD

CROMOLYN SODIUM

CONCENTRATE; ORAL		GASTROCROM					
AA	+! MYLAN SPECIALITY LP	100MG/5ML	N020479	001	Feb 29, 1996	Mar	CAHN
SOLUTION; INHALATION		CROMOLYN SODIUM					
AN	BAUSCH AND LOMB	10MG/ML	A075585	001	Dec 21, 2000	Feb	CAHN

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET; ORAL

CYCLOBENZAPRINE HYDROCHLORIDE

AB	PRINSTON INC	5MG	A077797	001	Feb 28, 2007	Feb	CAHN
AB		10MG	A077797	002	Feb 28, 2007	Feb	CAHN

CYCLOPHOSPHAMIDE

CAPSULE; ORAL

CYCLOPHOSPHAMIDE

+	WEST-WARD PHARMS INT	25MG	N203856	001	Sep 16, 2013	Jan	CAHN
+	!	50MG	N203856	002	Sep 16, 2013	Jan	CAHN

INJECTABLE; INJECTION

CYTOXAN (LYOPHILIZED)

+	@	BAXTER HLTHCARE	500MG/VIAL	N012142	003		Feb	CRLD
+	@		1GM/VIAL	N012142	004	Aug 30, 1982	Feb	CRLD
+	@		2GM/VIAL	N012142	005	Aug 30, 1982	Feb	CRLD

CYPROHEPTADINE HYDROCHLORIDE

SYRUP; ORAL

PERIACTIN

+	@	MERCK	2MG/5ML	N013220	002		Jan	CRLD
---	---	-------	---------	---------	-----	--	-----	------

TABLET; ORAL

CYPROHEPTADINE HYDROCHLORIDE

AA	APNAR PHARMA LP	4MG	A207555	001	Jan 31, 2017	Jan	NEWA
AA	IMPAX LABS INC	4MG	A040537	001	Sep 30, 2003	Feb	CAHN

CYSTEAMINE BITARTRATE

CAPSULE, DELAYED RELEASE; ORAL

PROCYSBI

+	HORIZON PHARMA USA	EQ 25MG BASE	N203389	001	Apr 30, 2013	Mar	CAHN
+	!	EQ 75MG BASE	N203389	002	Apr 30, 2013	Mar	CAHN

CYSTEAMINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

CYSTARAN

+	!	LEADIANT BIOSCI INC	EQ 0.44% BASE	N200740	001	Oct 02, 2012	Feb	CAHN
---	---	---------------------	---------------	---------	-----	--------------	-----	------

CYTARABINE

INJECTABLE; INJECTION

CYTARABINE

AP	MYLAN LABS LTD	20MG/ML	A200915	001	Dec 13, 2011	Mar	CAHN
	WEST-WARD PHARMS INT	100MG/VIAL	A071471	001	Aug 02, 1989	Mar	CTEC
	!	500MG/VIAL	A071472	001	Aug 02, 1989	Mar	CHRS
	!	1GM/VIAL	A074245	001	Aug 31, 1994	Mar	CHRS
	!	2GM/VIAL	A074245	002	Aug 31, 1994	Mar	CHRS

CYTOSAR-U

@ TEVA PHARMS USA

@ 100MG/VIAL

@ 500MG/VIAL

@ 1GM/VIAL

@ 2GM/VIAL

A075206	001	Dec 30, 1998	Mar	DISC
A075206	002	Dec 30, 1998	Mar	DISC
A075206	004	Dec 30, 1998	Mar	DISC
A075206	003	Dec 30, 1998	Mar	DISC

DACARBAZINE

INJECTABLE; INJECTION

DACARBAZINE

AP	!	FRESENIUS KABI USA	100MG/VIAL	A075371	001	Aug 27, 1999	Feb	CHRS
AP	!		200MG/VIAL	A075371	002	Aug 27, 1999	Feb	CHRS

>D> DTIC-DOME

>D>	AP	+	BAYER HLTHCARE	100MG/VIAL	N017575	001	Apr	DISC
>A>		+	@	100MG/VIAL	N017575	001	Apr	DISC
>D>	AP	+	!	200MG/VIAL	N017575	002	Apr	DISC
>A>		+	@	200MG/VIAL	N017575	002	Apr	DISC

DALFAMPRIDINE

TABLET, EXTENDED RELEASE; ORAL

AMPYRA

AB	+	!	ACORDA	10MG	N022250	001	Jan 22, 2010	Jan	CFTG
----	---	---	--------	------	---------	-----	--------------	-----	------

DALFAMPRIDINE

AB			ACTAVIS LABS FL INC	10MG	A206836	001	Jan 23, 2017	Jan	NEWA
AB			AUROBINDO PHARMA LTD	10MG	A206811	001	Jan 23, 2017	Jan	NEWA

DAPAGLIFLOZIN PROPANEDIOL; SAXAGLIPTIN HYDROCHLORIDE

TABLET;ORAL

QTERN

+!	ASTRAZENECA AB	EQ 10MG BASE;EQ 5MG BASE	N209091	001	Feb 27, 2017	Feb	NEWA
----	----------------	--------------------------	---------	-----	--------------	-----	------

DAPSONE

TABLET;ORAL

DAPSONE

AB	ACTAVIS LLC	25MG	A204380	001	Mar 23, 2017	Mar	NEWA
AB		100MG	A204380	002	Mar 23, 2017	Mar	NEWA

DECITABINE

INJECTABLE;INTRAVENOUS

DECITABINE

AP	ACCORD HLTHCARE	50MG/VIAL	A203475	001	Feb 27, 2017	Feb	NEWA
----	-----------------	-----------	---------	-----	--------------	-----	------

DEFLAZACORT

SUSPENSION;ORAL

EMFLAZA

>D>	+!	MARATHON PHARMS LLC	22.75MG/ML	N208685	001	Feb 09, 2017	Apr	CAHN
	+!		22.75MG/ML	N208685	001	Feb 09, 2017	Feb	NEWA
>A>	+!	PTC THERAP	22.75MG/ML	N208685	001	Feb 09, 2017	Apr	CAHN

TABLET;ORAL

EMFLAZA

>D>	+	MARATHON PHARMS LLC	6MG	N208684	001	Feb 09, 2017	Apr	CAHN
	+		6MG	N208684	001	Feb 09, 2017	Feb	NEWA
>D>	+		18MG	N208684	002	Feb 09, 2017	Apr	CAHN
	+		18MG	N208684	002	Feb 09, 2017	Feb	NEWA
>D>	+		30MG	N208684	003	Feb 09, 2017	Apr	CAHN
	+		30MG	N208684	003	Feb 09, 2017	Feb	NEWA
>D>	+!		36MG	N208684	004	Feb 09, 2017	Apr	CAHN
	+!		36MG	N208684	004	Feb 09, 2017	Feb	NEWA
>A>	+	PTC THERAP	6MG	N208684	001	Feb 09, 2017	Apr	CAHN
>A>	+		18MG	N208684	002	Feb 09, 2017	Apr	CAHN
>A>	+		30MG	N208684	003	Feb 09, 2017	Apr	CAHN
>A>	+!		36MG	N208684	004	Feb 09, 2017	Apr	CAHN

DESIPRAMINE HYDROCHLORIDE

TABLET;ORAL

DESIPRAMINE HYDROCHLORIDE

AB	IMPAX LABS INC	10MG	A205153	001	Oct 28, 2016	Feb	CAHN
AB		25MG	A205153	002	Oct 28, 2016	Feb	CAHN
AB		50MG	A205153	003	Oct 28, 2016	Feb	CAHN
AB		75MG	A205153	004	Oct 28, 2016	Feb	CAHN
AB		100MG	A205153	005	Oct 28, 2016	Feb	CAHN
AB		150MG	A205153	006	Oct 28, 2016	Feb	CAHN

DESMETHYL PIROXICAM

CAPSULE;ORAL

PIROXICAM

	SUN PHARM INDS	10MG	A073536	002	Jan 23, 2008	Mar	CMS1
--	----------------	------	---------	-----	--------------	-----	------

DESMOPRESSIN ACETATE

SPRAY, METERED;NASAL

NOCTIVA

+	SERENITY PHARMS LLC	0.00083MG/SPRAY	N201656	001	Mar 03, 2017	Mar	NEWA
+!		0.00166MG/SPRAY	N201656	002	Mar 03, 2017	Mar	NEWA

DESOGESTREL; ETHINYL ESTRADIOL

TABLET;ORAL-28

DESOGESTREL AND ETHINYL ESTRADIOL

AB	AUROBINDO PHARMA LTD	0.15MG,N/A;0.02MG,0.01MG	A206853	001	Mar 22, 2017	Mar	NEWA
----	----------------------	--------------------------	---------	-----	--------------	-----	------

DESONIDE

OINTMENT;TOPICAL

DESONIDE

AB	HI-TECH PHARMACAL	0.05%	A208836	001	Mar 27, 2017	Mar	NEWA
----	-------------------	-------	---------	-----	--------------	-----	------

DESOXIMETASONECREAM; TOPICAL
TOPICORT

>D>	AB	!	TARO	0.05%	A073210	001	Nov 30, 1990	Apr	CAHN
>A>	AB	!		0.05%	A073210	001	Nov 30, 1990	Apr	CAHN
>D>	AB	!		0.25%	A073193	001	Nov 30, 1990	Apr	CAHN
>A>	AB	!		0.25%	A073193	001	Nov 30, 1990	Apr	CAHN

GEL; TOPICAL
TOPICORT

>D>	AB	!	TARO	0.05%	A074904	001	Jul 14, 1998	Apr	CAHN
>A>	AB	!		0.05%	A074904	001	Jul 14, 1998	Apr	CAHN
		+	@ TARO PHARMS NORTH	0.05%	N018586	001	Mar 29, 1982	Jan	CRLD

OINTMENT; TOPICAL
TOPICORT

>D>	AB	!	TARO	0.25%	A074286	001	Jun 07, 1996	Apr	CAHN
>A>	AB	!		0.25%	A074286	001	Jun 07, 1996	Apr	CAHN

SPRAY; TOPICAL
DESOXIMETASONE

AT			PERRIGO ISRAEL	0.25%	A206441	001	Jan 20, 2017	Jan	NEWA
AT	+	!	TARO	0.25%	N204141	001	Apr 11, 2013	Jan	CFTG

>A> DEUTETRABENAZINE>A> TABLET; ORAL
>A> AUSTEDO

>A>		+	TEVA BRANDED PHARM	6MG	N208082	001	Apr 03, 2017	Apr	NEWA
>A>		+		9MG	N208082	002	Apr 03, 2017	Apr	NEWA
>A>		+	!	12MG	N208082	003	Apr 03, 2017	Apr	NEWA

DEXAMETHASONE SODIUM PHOSPHATESOLUTION/DROPS; OPHTHALMIC, OTIC
DEXAMETHASONE SODIUM PHOSPHATE

AT	!		SANDOZ INC	EQ 0.1% PHOSPHATE	A088771	001	Jan 16, 1985	Feb	CAHN
----	---	--	------------	-------------------	---------	-----	--------------	-----	------

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATESUSPENSION/DROPS; OPHTHALMIC
MAXITROL

AT			SANDOZ INC	0.1%; EQ 3.5MG BASE/ML; 10,000 UNITS/ML	A062341	001	May 22, 1984	Feb	CAHN
----	--	--	------------	---	---------	-----	--------------	-----	------

DEXLANSOPRAZOLECAPSULE, DELAYED RELEASE; ORAL
DEXILANT

>D>		+	!	TAKEDA PHARMS USA	60MG	N022287	002	Jan 30, 2009	Apr	CFTG
>A>	AB	+	!		60MG	N022287	002	Jan 30, 2009	Apr	CFTG
>A>				DEXLANSOPRAZOLE						
>A>	AB			PAR PHARM INC	60MG	A202294	001	Apr 19, 2017	Apr	NEWA

DEXMEDETOMIDINE HYDROCHLORIDEINJECTABLE; INJECTION
DEXMEDETOMIDINE HYDROCHLORIDE

AP			ACCORD HLTHCARE	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A204023	001	Feb 09, 2016	Mar	CAHN
>A>	AP		WEST-WARD PHARMS INT	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A205046	001	Apr 26, 2017	Apr	NEWA

DEXTROSEINJECTABLE; INJECTION
DEXTROSE 10% IN PLASTIC CONTAINER

AP	+	!	ICU MEDCL	10GM/100ML	N018080	001		Feb	CAHN	
AP	+	!	ICU MEDCL	20GM/100ML	N018564	001	Mar 23, 1982	Feb	CAHN	
AP	+	!	ICU MEDCL	30GM/100ML	N019345	001	Jan 26, 1985	Feb	CAHN	
AP	+	!	ICU MEDCL	50MG/ML	N016367	002		Feb	CAHN	
AP	+	!	ICU MEDCL	50GM/100ML	N018563	001	Mar 23, 1982	Feb	CAHN	
>D>	AP	+	!	HOSPIRA	70GM/100ML	N018561	001	Mar 23, 1982	Apr	CAHN
>A>	AP	+	!	ICU MEDCL	70GM/100ML	N018561	001	Mar 23, 1982	Apr	CAHN

INJECTABLE; INJECTION

	DEXTROSE 70% IN PLASTIC CONTAINER						
AP	+	70GM/100ML	N019893	001	Dec 26, 1989	Feb	CAHN

DEXTROSE; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

NORMOSOL-M AND DEXTROSE 5% IN PLASTIC CONTAINER

	ICU MEDCL	5GM/100ML; 21MG/100ML; 128MG/100ML; 2	N017610	001		Feb	CAHN
		34MG/100ML					

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC ANHYDROUS

INJECTABLE; INJECTION

IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER

	ICU MEDCL	5GM/100ML; 30MG/100ML; 141MG/100ML; 1	N019513	001	May 08, 1986	Feb	CAHN
		5MG/100ML; 260MG/100ML; 25MG/100ML					

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE; INJECTION

NORMOSOL-R AND DEXTROSE 5% IN PLASTIC CONTAINER

	ICU MEDCL	5GM/100ML; 30MG/100ML; 37MG/100ML; 22	N017609	001		Feb	CAHN
		2MG/100ML; 526MG/100ML; 502MG/100ML					

DEXTROSE; POTASSIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER

>D>	HOSPIRA	5GM/100ML; 149MG/100ML	N018371	001		Apr	CAHN
>A>	ICU MEDCL	5GM/100ML; 149MG/100ML	N018371	001		Apr	CAHN

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER

>D>	AP	HOSPIRA	5GM/100ML; 224MG/100ML	N018371	003	Apr	CAHN
>A>	AP	ICU MEDCL	5GM/100ML; 224MG/100ML	N018371	003	Apr	CAHN

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER

>D>	HOSPIRA	5GM/100ML; 298MG/100ML	N018371	002		Apr	CAHN
>A>	ICU MEDCL	5GM/100ML; 298MG/100ML	N018371	002		Apr	CAHN

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

	ICU MEDCL	5GM/100ML; 74.5MG/100ML; 225MG/100ML	N018365	002	Jul 05, 1983	Feb	CAHN
		5GM/100ML; 149MG/100ML; 225MG/100ML	N018365	006	Mar 28, 1988	Feb	CAHN

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	ICU MEDCL	5GM/100ML; 74.5MG/100ML; 450MG/100ML	N018362	005	Mar 28, 1988	Feb	CAHN
AP		5GM/100ML; 74.5MG/100ML; 450MG/100ML	N018362	009	Jul 05, 1983	Feb	CAHN

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

>D>	AP	HOSPIRA	5GM/100ML; 74.5MG/100ML; 900MG/100ML	N019691	002	Mar 24, 1988	Apr	CAHN
>D>	AP		5GM/100ML; 149MG/100ML; 900MG/100ML	N019691	004	Mar 24, 1988	Apr	CAHN
>A>	AP	ICU MEDCL	5GM/100ML; 74.5MG/100ML; 900MG/100ML	N019691	002	Mar 24, 1988	Apr	CAHN
>A>	AP		5GM/100ML; 149MG/100ML; 900MG/100ML	N019691	004	Mar 24, 1988	Apr	CAHN

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

	ICU MEDCL	5GM/100ML; 224MG/100ML; 225MG/100ML	N018365	008	Mar 28, 1988	Feb	CAHN
--	-----------	-------------------------------------	---------	-----	--------------	-----	------

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	ICU MEDCL	5GM/100ML; 224MG/100ML; 450MG/100ML	N018362	006	Mar 28, 1988	Feb	CAHN
----	-----------	-------------------------------------	---------	-----	--------------	-----	------

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

>D>	AP	HOSPIRA	5GM/100ML; 224MG/100ML; 900MG/100ML	N019691	006	Mar 24, 1988	Apr	CAHN
>A>	AP	ICU MEDCL	5GM/100ML; 224MG/100ML; 900MG/100ML	N019691	006	Mar 24, 1988	Apr	CAHN

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

	ICU MEDCL	5GM/100ML; 149MG/100ML; 225MG/100ML	N018365	001		Feb	CAHN
		5GM/100ML; 298MG/100ML; 225MG/100ML	N018365	009	Mar 28, 1988	Feb	CAHN

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	ICU MEDCL	5GM/100ML; 149MG/100ML; 450MG/100ML	N018362	010	Jul 05, 1983	Feb	CAHN
----	-----------	-------------------------------------	---------	-----	--------------	-----	------

AP		5GM/100ML; 298MG/100ML; 450MG/100ML	N018362	007	Mar 28, 1988	Feb	CAHN
----	--	-------------------------------------	---------	-----	--------------	-----	------

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

>D>	AP	HOSPIRA	5GM/100ML; 149MG/100ML; 900MG/100ML	N019691	005	Mar 24, 1988	Apr	CAHN
>D>	AP		5GM/100ML; 298MG/100ML; 900MG/100ML	N019691	008	Mar 24, 1988	Apr	CAHN
>A>	AP	ICU MEDCL	5GM/100ML; 149MG/100ML; 900MG/100ML	N019691	005	Mar 24, 1988	Apr	CAHN
>A>	AP		5GM/100ML; 298MG/100ML; 900MG/100ML	N019691	008	Mar 24, 1988	Apr	CAHN

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

	ICU MEDCL	5GM/100ML; 224MG/100ML; 225MG/100ML	N018365	003	Jul 05, 1983	Feb	CAHN
--	-----------	-------------------------------------	---------	-----	--------------	-----	------

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	ICU MEDCL	5GM/100ML; 224MG/100ML; 450MG/100ML	N018362	002		Feb	CAHN
----	-----------	-------------------------------------	---------	-----	--	-----	------

INJECTABLE; INJECTION

		POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
>D>	AP	HOSPIRA	5GM/100ML;224MG/100ML;900MG/100ML	N019691	007	Mar 24, 1988	Apr CAHN
>A>	AP	ICU MEDCL	5GM/100ML;224MG/100ML;900MG/100ML	N019691	007	Mar 24, 1988	Apr CAHN
		POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER					
		ICU MEDCL	5GM/100ML;298MG/100ML;225MG/100ML	N018365	004	Jul 05, 1983	Feb CAHN
		POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER					
	AP	ICU MEDCL	5GM/100ML;298MG/100ML;450MG/100ML	N018362	003		Feb CAHN
		POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
>D>	AP	HOSPIRA	5GM/100ML;298MG/100ML;900MG/100ML	N019691	009	Mar 24, 1988	Apr CAHN
>A>	AP	ICU MEDCL	5GM/100ML;298MG/100ML;900MG/100ML	N019691	009	Mar 24, 1988	Apr CAHN
		POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER					
		ICU MEDCL	5GM/100ML;74.5MG/100ML;225MG/100ML	N018365	005	Mar 28, 1988	Feb CAHN
			5GM/100ML;149MG/100ML;225MG/100ML	N018365	007	Mar 28, 1988	Feb CAHN
		POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER					
	AP	ICU MEDCL	5GM/100ML;74.5MG/100ML;450MG/100ML	N018362	008	Mar 28, 1988	Feb CAHN
	AP		5GM/100ML;149MG/100ML;450MG/100ML	N018362	004	Mar 28, 1988	Feb CAHN
		POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
>D>	AP	HOSPIRA	5GM/100ML;74.5MG/100ML;900MG/100ML	N019691	001	Mar 24, 1988	Apr CAHN
>D>	AP		5GM/100ML;149MG/100ML;900MG/100ML	N019691	003	Mar 24, 1988	Apr CAHN
>A>	AP	ICU MEDCL	5GM/100ML;74.5MG/100ML;900MG/100ML	N019691	001	Mar 24, 1988	Apr CAHN
>A>	AP		5GM/100ML;149MG/100ML;900MG/100ML	N019691	003	Mar 24, 1988	Apr CAHN

DEXTROSE; SODIUM CHLORIDE

INJECTABLE; INJECTION

		DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER					
		+! ICU MEDCL	5GM/100ML;225MG/100ML	N017606	001		Feb CAHN
		DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER					
		+! ICU MEDCL	5GM/100ML;300MG/100ML	N017799	001		Feb CAHN
		DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER					
	AP	ICU MEDCL	5GM/100ML;450MG/100ML	N017607	001		Feb CAHN
		DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
	AP	ICU MEDCL	5GM/100ML;900MG/100ML	N017585	001		Feb CAHN

DIAZEPAM

TABLET; ORAL

DIAZEPAM

	@	VIRTUS PHARMS	2MG	A070462	001	Feb 25, 1986	Feb CAHN
	@		5MG	A070463	001	Feb 25, 1986	Feb CAHN
	@		10MG	A070464	001	Feb 25, 1986	Feb CAHN

DICLOFENAC SODIUM

SOLUTION; TOPICAL

DICLOFENAC SODIUM

	AT	TWI PHARMS INC	1.5%	A202393	001	Nov 24, 2014	Mar CAHN
		PENNSAID					
>A>		+ @ NUVO PHARMS INC	1.5%	N020947	001	Nov 04, 2009	Apr CAHN
>D>		+ @ NUVO RES INC	1.5%	N020947	001	Nov 04, 2009	Apr CAHN
		+ @	1.5%	N020947	001	Nov 04, 2009	Feb DISC

SOLUTION/DROPS; OPHTHALMIC

DICLOFENAC SODIUM

	AT	SANDOZ INC	0.1%	A078031	001	Feb 06, 2008	Feb CAHN
--	----	------------	------	---------	-----	--------------	----------

TABLET, DELAYED RELEASE; ORAL

DICLOFENAC SODIUM

>A>		@ ALLIED PHARMA INC	50MG	A074986	001	Feb 26, 1999	Apr CAHN
>A>		@	75MG	A074986	002	Feb 26, 1999	Apr CAHN
>D>		@ NOSTRUM LABS	50MG	A074986	001	Feb 26, 1999	Apr CAHN
>D>		@	75MG	A074986	002	Feb 26, 1999	Apr CAHN

TABLET, EXTENDED RELEASE; ORAL

DICLOFENAC SODIUM

>D>	AB	! ACTAVIS ELIZABETH	100MG	A075910	001	Jan 07, 2002	Apr DISC
>A>		@	100MG	A075910	001	Jan 07, 2002	Apr DISC
>D>	AB	DEXCEL LTD	100MG	A076201	001	Nov 06, 2002	Apr CHRS
>A>	AB	!	100MG	A076201	001	Nov 06, 2002	Apr CHRS

DICLOFENAC SODIUM; MISOPROSTOL

TABLET, DELAYED RELEASE; ORAL

DICLOFENAC SODIUM AND MISOPROSTOL

AB	EAGLE PHARMS	50MG;0.2MG	A200540	001	Mar 14, 2014	Jan CAHN
AB		75MG;0.2MG	A200540	002	Mar 14, 2014	Jan CAHN
AB	EXELA HOLDINGS	50MG;0.2MG	A200540	001	Mar 14, 2014	Mar CAHN

TABLET, DELAYED RELEASE;ORAL									
DICLOFENAC SODIUM AND MISOPROSTOL									
AB		75MG;0.2MG		A200540	002	Mar 14, 2014	Mar	CAHN	
<u>DICYCLOMINE HYDROCHLORIDE</u>									
INJECTABLE;INJECTION									
DICYCLOMINE HYDROCHLORIDE									
AP		LUITPOLD PHARMS INC	10MG/ML	A208353	001	Feb 17, 2017	Feb	NEWA	
<u>DIENOGEST; ESTRADIOL VALERATE</u>									
TABLET;ORAL									
NATAZIA									
>D>	AB	+!	BAYER HLTHCARE	N/A, 2MG, 3MG, N/A, N/A; 3MG, 2MG, 2MG, 1M	N022252	001	May 06, 2010	Apr	CTEC
>A>		+!		G, N/A	N022252	001	May 06, 2010	Apr	CTEC
>A>		+!		N/A, 2MG, 3MG, N/A, N/A; 3MG, 2MG, 2MG, 1M	N022252	001	May 06, 2010	Apr	CTEC
>A>		+!		G, N/A	N022252	001	May 06, 2010	Apr	CTEC
<u>DIFLORASONE DIACETATE</u>									
OINTMENT;TOPICAL									
DIFLORASONE DIACETATE									
AB			RICONPHARMA LLC	0.05%	A207440	001	Feb 27, 2017	Feb	NEWA
>D>	AB	!	TARO	0.05%	A075331	001	May 14, 1999	Apr	CAHN
>A>	AB	!		0.05%	A075331	001	May 14, 1999	Apr	CAHN
PSORCON									
		+ @	PHARMACIA AND UPJOHN	0.05%	N019260	001	Aug 28, 1985	Mar	CRLD
<u>DIGOXIN</u>									
ELIXIR;ORAL									
DIGOXIN									
		+!	WEST-WARD PHARMS INT	0.05MG/ML	N021648	001	Aug 26, 2004	Jan	CAHN
INJECTABLE;INJECTION									
DIGOXIN									
AP			SANDOZ INC	0.25MG/ML	A040481	001	Aug 21, 2003	Mar	CAHN
<u>DIHYDROERGOTAMINE MESYLATE</u>									
INJECTABLE;INJECTION									
DIHYDROERGOTAMINE MESYLATE									
AP			WEST-WARD PHARMS INT	1MG/ML	A040453	001	Jun 09, 2003	Jan	CAHN
<u>DILTIAZEM HYDROCHLORIDE</u>									
INJECTABLE;INJECTION									
DILTIAZEM HYDROCHLORIDE									
AP	!		ATHENEX INC	5MG/ML	A074617	001	Feb 28, 1996	Mar	CAHN
AP			WEST-WARD PHARMS INT	5MG/ML	A078538	001	Dec 17, 2008	Jan	CAHN
TABLET;ORAL									
DILTIAZEM HYDROCHLORIDE									
		@	CHARTWELL MOLECULES	30MG	A074093	001	Nov 05, 1992	Feb	CAHN
		@		60MG	A074093	002	Nov 05, 1992	Feb	CAHN
		@		90MG	A074093	003	Nov 05, 1992	Feb	CAHN
		@		120MG	A074093	004	Nov 05, 1992	Feb	CAHN
<u>DIPYRIDAMOLE</u>									
INJECTABLE;INJECTION									
DIPYRIDAMOLE									
AP	!		ATHENEX INC	5MG/ML	A074939	001	Apr 13, 1998	Mar	CAHN
<u>DISULFIRAM</u>									
TABLET;ORAL									
DISULFIRAM									
AB			CHARTWELL MOLECULES	250MG	A091563	001	Dec 31, 2012	Jan	CAHN
AB				500MG	A091563	002	Dec 31, 2012	Jan	CAHN
<u>DIVALPROEX SODIUM</u>									
TABLET, DELAYED RELEASE;ORAL									
DIVALPROEX SODIUM									
AB			PRINSTON INC	EQ 125MG VALPROIC ACID	A090210	001	Nov 30, 2009	Feb	CAHN
AB				EQ 250MG VALPROIC ACID	A090210	002	Nov 30, 2009	Feb	CAHN
AB				EQ 500MG VALPROIC ACID	A090210	003	Nov 30, 2009	Feb	CAHN

DOCETAXELINJECTABLE; INJECTION
DOCETAXEL

AP	ACTAVIS LLC	20MG/ML (20MG/ML)	N203551	001	Apr 12, 2013	Feb	CAHN
AP		80MG/4ML (20MG/ML)	N203551	002	Apr 12, 2013	Feb	CAHN
		140MG/7ML (20MG/ML)	N203551	003	Apr 12, 2013	Feb	CAHN
AP	DFB ONCOLOGY LTD	20MG/ML (20MG/ML)	A206177	001	Jan 20, 2017	Jan	NEWA
AP		80MG/4ML (20MG/ML)	A206177	002	Jan 20, 2017	Jan	NEWA
		200MG/10ML (20MG/ML)	A206177	003	Jan 20, 2017	Jan	NEWA
+	HOSPIRA INC	160MG/8ML (20MG/ML)	N022234	007	Jan 24, 2017	Jan	NEWA
!	JIANGSU HENGRUI MED	40MG/ML	A203170	001	Feb 15, 2017	Jan	NEWA
@	PFIZER LABS	20MG/2ML (10MG/ML)	N202356	001	Mar 13, 2014	Jan	DISC
@		80MG/8ML (10MG/ML)	N202356	002	Mar 13, 2014	Jan	DISC
@		130MG/13ML (10MG/ML)	N202356	003	Mar 13, 2014	Jan	DISC
@		200MG/20ML (10MG/ML)	N202356	004	Mar 13, 2014	Jan	DISC

DOFETILIDECAPSULE; ORAL
DOFETILIDE

AB	MAYNE PHARMA INC	0.125MG	A207058	001	Jun 06, 2016	Feb	CAHN
AB		0.25MG	A207058	002	Jun 06, 2016	Feb	CAHN
AB		0.5MG	A207058	003	Jun 06, 2016	Feb	CAHN

DONEPEZIL HYDROCHLORIDE

TABLET; ORAL

DONEPEZIL HYDROCHLORIDE

AB	ALLIED PHARMA INC	5MG	A078662	001	May 31, 2011	Mar	CAHN
AB		10MG	A078662	002	May 31, 2011	Mar	CAHN
AB	ZHEJIANG HISUN PHARM	23MG	A202410	001	Mar 24, 2017	Mar	NEWA

DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE

AB	AMNEAL PHARMS	10MG;14MG	A208328	001	Jan 27, 2017	Jan	NEWA
AB		10MG;28MG	A208328	002	Jan 27, 2017	Jan	NEWA
	NAMZARIC						
AB	+ FOREST LABS LLC	10MG;14MG	N206439	001	Dec 23, 2014	Jan	CFTG
AB	+	10MG;28MG	N206439	002	Dec 23, 2014	Jan	CFTG

DORZOLAMIDE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE

AT	SANDOZ INC	EQ 2% BASE	A078748	001	Nov 06, 2008	Mar	CAHN
AT		EQ 2% BASE	A078981	001	Apr 13, 2009	Feb	CAHN

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

AT	SANDOZ INC	EQ 2% BASE; EQ 0.5% BASE	A090604	001	Nov 18, 2009	Mar	CAHN
----	------------	--------------------------	---------	-----	--------------	-----	------

DOXAPRAM HYDROCHLORIDE

INJECTABLE; INJECTION

DOXAPRAM HYDROCHLORIDE

AP	ATHENEX INC	20MG/ML	A076266	001	Jan 10, 2003	Mar	CAHN
----	-------------	---------	---------	-----	--------------	-----	------

DOXEPIN HYDROCHLORIDE

CREAM; TOPICAL

ZONALON

+	MYLAN PHARMS INC	5%	N020126	001	Apr 01, 1994	Jan	CAHN
---	------------------	----	---------	-----	--------------	-----	------

DOXORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

DOXORUBICIN HYDROCHLORIDE

AP	AMNEAL PHARMS CO	20MG/VIAL	A208888	001	Feb 17, 2017	Feb	NEWA
AP		50MG/VIAL	A208888	002	Feb 17, 2017	Feb	NEWA

DOXYCYCLINE HYCLATE

	INJECTABLE; INJECTION						
	VIBRAMYCIN						
	+ @ PFIZER	EQ 100MG BASE/VIAL		N050442	002		Jan CRLD
	+ @	EQ 200MG BASE/VIAL		N050442	001		Jan CRLD
	TABLET; ORAL						
	DOXYCYCLINE HYCLATE						
	CARIBE HOLDINGS	EQ 50MG BASE		A062269	003		Mar CMFD
	@	EQ 50MG BASE		A062269	003		Jan CAHN
AB		EQ 100MG BASE		A062269	002	Nov 08, 1982	Jan CAHN

DRONABINOL

	SOLUTION; ORAL						
	SYNDROS						
	+! INSYS DEV CO INC	5MG/ML		N205525	001	Mar 23, 2017	Mar NEWA

DULOXETINE HYDROCHLORIDE

	CAPSULE, DELAYED REL PELLETS; ORAL						
	DULOXETINE HYDROCHLORIDE						
AB	MACLEODS PHARMS LTD	EQ 20MG BASE		A204815	001	Mar 23, 2017	Mar NEWA
AB		EQ 30MG BASE		A204815	002	Mar 23, 2017	Mar NEWA
AB		EQ 60MG BASE		A204815	003	Mar 23, 2017	Mar NEWA
>A> AB	ZYDUS HLTHCARE	EQ 20MG BASE		A090739	001	Jan 08, 2014	Apr CAHN
>A> AB		EQ 30MG BASE		A090739	002	Jan 08, 2014	Apr CAHN
>A> AB		EQ 60MG BASE		A090739	003	Jan 08, 2014	Apr CAHN
>D> AB	ZYDUS PHARMS USA INC	EQ 20MG BASE		A090739	001	Jan 08, 2014	Apr CAHN
>D> AB		EQ 30MG BASE		A090739	002	Jan 08, 2014	Apr CAHN
>D> AB		EQ 60MG BASE		A090739	003	Jan 08, 2014	Apr CAHN

DUTASTERIDE

	CAPSULE; ORAL						
	DUTASTERIDE						
AB	MARKSANS PHARMA	0.5MG		A204376	001	Apr 07, 2017	Mar NEWA

DYPHYLLINE

	TABLET; ORAL						
	LUFYLLIN						
	@ MYLAN SPECIALITY LP	200MG		A084566	001		Mar CAHN
	@	400MG		A084566	002		Mar CAHN

ECONAZOLE NITRATE

	CREAM; TOPICAL						
	SPECTAZOLE						
	+ @ ALVOGEN MALTA	1%		N018751	001	Dec 23, 1982	Mar CMS1

EDROPHONIUM CHLORIDE

	INJECTABLE; INJECTION						
	TENSILON						
>A>	+ @ TELIGENT	10MG/ML		N007959	001		Apr CAHN
>D>	+ @ TELIGENT PHARMA INC	10MG/ML		N007959	001		Apr CAHN
	TENSILON PRESERVATIVE FREE						
>A>	+ @ TELIGENT	10MG/ML		N007959	002		Apr CAHN
>D>	+ @ TELIGENT PHARMA INC	10MG/ML		N007959	002		Apr CAHN

ENALAPRILAT

	INJECTABLE; INJECTION						
	ENALAPRILAT						
AP	! ATHENEX INC	1.25MG/ML		A075634	001	Aug 22, 2000	Mar CAHN
	VASOTEC						
	+ @ BIOVAIL LABS INTL	1.25MG/ML		N019309	001	Feb 09, 1988	Mar CRLD

EPHEDRINE SULFATE

	SOLUTION; INTRAVENOUS						
	AKOVAZ						
AP	+! FLAMEL IRELAND LTD	50MG/ML (50MG/ML)		N208289	001	Apr 29, 2016	Mar CTEC
	EPHEDRINE SULFATE						
AP	AKORN INC	50MG/ML (50MG/ML)		N208609	001	Mar 01, 2017	Mar NEWA
	SOLUTION; IV (INFUSION)						
	CORPHEDRA						
	PAR STERILE PRODUCTS	50MG/ML (50MG/ML)		N208943	001	Jan 27, 2017	Jan NEWA

EPINASTINE HYDROCHLORIDESOLUTION/DROPS;OPHTHALMIC
EPINASTINE HYDROCHLORIDE

>A>	AT	AKORN	0.05%	A204055	001	May 05, 2017	Apr	NEWA
	AT	SANDOZ INC	0.05%	A203384	001	Dec 07, 2016	Mar	CAHN

EPINEPHRINE; LIDOCAINE HYDROCHLORIDEINJECTABLE; INJECTION
LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE

		@ BELMORA LLC	0.01MG/ML;2%	A080504	004	Oct 19, 1983	Feb	CAHN
		@	0.02MG/ML;2%	A080504	005	Oct 19, 1983	Feb	CAHN
		@ WEST-WARD PHARMS INT	0.01MG/ML;1%	A080406	001		Mar	CAHN
		@	0.01MG/ML;2%	A080406	002		Mar	CAHN

EPLERENONETABLET; ORAL
EPLERENONE

AB		MYLAN PHARMS INC	25MG	A203896	001	Feb 02, 2017	Jan	NEWA
AB			50MG	A203896	002	Feb 02, 2017	Jan	NEWA

EPTIFIBATIDEINJECTABLE; INJECTION
EPTIFIBATIDE

>A>	AP	AKORN	2MG/ML	A204589	001	Apr 18, 2017	Apr	NEWA
>A>	AP		75MG/100ML	A204589	002	Apr 18, 2017	Apr	NEWA

ERYTHROMYCINGEL; TOPICAL
E-GLADES

		@ MYLAN PHARMS INC	2%	A065009	001	Mar 18, 2002	Jan	CAHN
		ERYGEL						
AT	+!	MYLAN PHARMS INC	2%	N050617	001	Oct 21, 1987	Jan	CAHN
		ERYTHROMYCIN						
>D>	AT	PERRIGO	2%	A063211	001	Jan 29, 1993	Apr	CAHN
>A>	AT	PERRIGO CO	2%	A063211	001	Jan 29, 1993	Apr	CAHN
		SOLUTION; TOPICAL						
		A/T/S						
>A>		@ TARO	2%	A062405	001	Nov 18, 1982	Apr	CAHN
>D>		@ TARO PHARMS NORTH	2%	A062405	001	Nov 18, 1982	Apr	CAHN
		SWAB; TOPICAL						
		ERYTHROMYCIN						
		@ MYLAN PHARMS INC	2%	A064128	001	Jul 03, 1996	Jan	CAHN
>D>	AT	! PERRIGO	2%	A064126	001	Jul 03, 1996	Apr	CAHN
>A>	AT	! PERRIGO CO	2%	A064126	001	Jul 03, 1996	Apr	CAHN

ESOMEPRAZOLE SODIUMINJECTABLE; INTRAVENOUS
ESOMEPRAZOLE SODIUM

AP		DEVA HOLDING AS	EQ 40MG BASE/VIAL	A207181	001	Mar 06, 2017	Feb	NEWA
----	--	-----------------	-------------------	---------	-----	--------------	-----	------

ESTRADIOLGEL, METERED; TRANSDERMAL
ELESTRIN

		+! MYLAN SPECIALITY LP	0.06% (0.87GM/ACTIVATION)	N021813	001	Dec 15, 2006	Mar	CAHN
--	--	------------------------	---------------------------	---------	-----	--------------	-----	------

ESTRADIOL VALERATEINJECTABLE; INJECTION
ESTRADIOL VALERATE

>D>		@ SANDOZ	10MG/ML	A040628	001	Oct 04, 2007	Apr	CAHN
>D>		@	20MG/ML	A040628	002	Oct 04, 2007	Apr	CAHN
>D>		@	40MG/ML	A040628	003	Oct 04, 2007	Apr	CAHN
>A>		@ SANDOZ INC	10MG/ML	A040628	001	Oct 04, 2007	Apr	CAHN
>A>		@	20MG/ML	A040628	002	Oct 04, 2007	Apr	CAHN
>A>		@	40MG/ML	A040628	003	Oct 04, 2007	Apr	CAHN

ESTRADIOL; NORETHINDRONE ACETATE

TABLET;ORAL

ESTRADIOL AND NORETHINDRONE ACETATE

AB	MYLAN LABS LTD	0.5MG;0.1MG	A207261	001	Feb 10, 2017	Jan NEWA
AB		1MG;0.5MG	A207261	002	Feb 10, 2017	Jan NEWA

ESTROGENS, CONJUGATED SYNTHETIC B

TABLET;ORAL

ENJUVIA

>A>	TEVA BRANDED PHARM	0.3MG	N021443	001	Dec 20, 2004	Apr CAHN
>A>		0.45MG	N021443	002	Dec 20, 2004	Apr CAHN
>A>	@	0.625MG	N021443	003	May 10, 2004	Apr CAHN
>A>		0.9MG	N021443	005	Apr 27, 2007	Apr CAHN
>A>	@	1.25MG	N021443	004	May 10, 2004	Apr CAHN
>D>	TEVA WOMENS	0.3MG	N021443	001	Dec 20, 2004	Apr CAHN
>D>		0.45MG	N021443	002	Dec 20, 2004	Apr CAHN
>D>	@	0.625MG	N021443	003	May 10, 2004	Apr CAHN
>D>		0.9MG	N021443	005	Apr 27, 2007	Apr CAHN
>D>	@	1.25MG	N021443	004	May 10, 2004	Apr CAHN

ESTROPIPATE

TABLET;ORAL

ESTROPIPATE

AB	WATSON LABS TEVA	3MG	A081215	001	Sep 23, 1993	Feb CAHN
----	------------------	-----	---------	-----	--------------	----------

ETELCALCETIDE

SOLUTION;INTRAVENOUS

PARSABIV

+	KAI PHARMS INC	2.5MG/0.5ML (2.5MG/0.5ML)	N208325	001	Feb 07, 2017	Feb NEWA
+		5MG/ML (5MG/ML)	N208325	002	Feb 07, 2017	Feb NEWA
+		10MG/2ML (5MG/ML)	N208325	003	Feb 07, 2017	Feb NEWA

ETHACRYNIC ACID

TABLET;ORAL

ETHACRYNIC ACID

AB	WEST-WARD PHARMS INT	25MG	A207262	001	Feb 23, 2017	Feb NEWA
----	----------------------	------	---------	-----	--------------	----------

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE

TABLET;ORAL-21

ZOVIA 1/35E-21

@	WATSON PHARMS TEVA	0.035MG;1MG	A072720	001	Dec 30, 1991	Mar CAHN
---	--------------------	-------------	---------	-----	--------------	----------

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET;ORAL

>A>	LO SIMPESE					
>A>	AB AUROBINDO PHARMA LTD	0.02MG,0.01MG;0.01MG,N/A	A206852	001	Apr 28, 2017	Apr NEWA
		SIMPESE				
AB	AUROBINDO PHARMA LTD	0.03MG,0.01MG;0.15MG,N/A	A206851	001	Apr 07, 2017	Mar NEWA
		TABLET;ORAL-28				
		ELIFEMME				
AB	LABS LEON FARMA	0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG	A202507	001	Dec 04, 2015	Feb CAHN

ETHINYL ESTRADIOL; NORELGESTROMIN

FILM, EXTENDED RELEASE;TRANSDERMAL

XULANE

AB	!	MYLAN TECHNOLOGIES	0.035MG/24HR;0.15MG/24HR	A200910	001	Apr 16, 2014	Mar CAHN
----	---	--------------------	--------------------------	---------	-----	--------------	----------

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET;ORAL-21

NORETHIN 1/35E-21

@	WATSON PHARMS TEVA	0.035MG;1MG	A071480	001	Apr 12, 1988	Mar CAHN
---	--------------------	-------------	---------	-----	--------------	----------

NORETHINDRONE AND ETHINYL ESTRADIOL

@	WATSON PHARMS TEVA	0.035MG;1MG	A070685	001	Jan 29, 1987	Mar CAHN
---	--------------------	-------------	---------	-----	--------------	----------

TABLET;ORAL-28

NORETHINDRONE AND ETHINYL ESTRADIOL

>A>	AB	ACCORD HLTHCARE	0.035MG;1MG	A206864	001	Apr 28, 2017	Apr NEWA
		TABLET, CHEWABLE;ORAL					
		NEXESTA FE					
AB		AUROBINDO PHARMA LTD	0.035MG;0.4MG	A207535	001	Feb 02, 2017	Jan NEWA

TABLET, CHEWABLE;ORAL

NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE
 AB ACCORD HLTHCARE 0.035MG;0.4MG A207066 001 Mar 29, 2017 Mar NEWA

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET;ORAL

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL
 AB MYLAN LABS LTD 0.0025MG;0.5MG A207260 001 Feb 02, 2017 Jan NEWA

ETHINYL ESTRADIOL; NORGESTREL

TABLET;ORAL-28

NORGESTREL AND ETHINYL ESTRADIOL
 >A> AB MYLAN LABS LTD 0.05MG;0.5MG A202875 001 May 08, 2017 Apr NEWA

ETHOSUXIMIDE

SYRUP;ORAL

ZARONTIN
 AA ! PARKE-DAVIS 250MG/5ML A080258 001 Mar CAHN

ETODOLAC

CAPSULE;ORAL

ETODOLAC

@ CHARTWELL MOLECULES 200MG A074842 001 Jul 17, 1997 Mar CAHN
 @ 300MG A074842 002 Jul 17, 1997 Mar CAHN
 @ CHARTWELL PHARMS LLC 200MG A074842 001 Jul 17, 1997 Jan CAHN
 @ 300MG A074842 002 Jul 17, 1997 Jan CAHN
 >A> @ ECI PHARMS LLC 300MG A074929 001 Jan 30, 1998 Apr CAHN
 >D> @ LEHIGH VALLEY 300MG A074929 001 Jan 30, 1998 Apr CAHN

TABLET;ORAL

ETODOLAC

@ CHARTWELL MOLECULES 400MG A074841 001 Jun 27, 1997 Jan CAHN
 >A> @ ECI PHARMS LLC 400MG A074927 001 Oct 30, 1997 Apr CAHN
 >D> @ LEHIGH VALLEY 400MG A074927 001 Oct 30, 1997 Apr CAHN
 AB MYLAN PHARMS INC 400MG A075104 001 Feb 06, 1998 Mar CAHN
 AB 500MG A075104 002 Nov 20, 1998 Mar CAHN

ETOMIDATE

INJECTABLE;INJECTION

ETOMIDATE

AP AUROBINDO PHARMA LTD 2MG/ML A206126 001 Feb 24, 2017 Feb NEWA
 >A> AP GLAND PHARMA LTD 2MG/ML A209058 001 Apr 18, 2017 Apr NEWA
 AP MYLAN LABS LTD 2MG/ML A201044 001 Feb 07, 2017 Jan NEWA
 AP WEST-WARD PHARMS INT 2MG/ML A074593 001 Nov 04, 1996 Jan CAHN

EXEMESTANE

TABLET;ORAL

EXEMESTANE

AB MYLAN PHARMS INC 25MG A203315 001 Mar 10, 2017 Feb NEWA

EZETIMIBE; SIMVASTATIN

TABLET;ORAL

EZETIMIBE AND SIMVASTATIN

>A> AB DR REDDYS LABS INTL 10MG;10MG A200909 001 Apr 26, 2017 Apr NEWA
 >A> AB 10MG;20MG A200909 002 Apr 26, 2017 Apr NEWA
 >A> AB 10MG;40MG A200909 003 Apr 26, 2017 Apr NEWA
 >A> AB 10MG;80MG A200909 004 Apr 26, 2017 Apr NEWA
 >A> AB IMPAX LABS INC 10MG;10MG A201890 001 Apr 26, 2017 Apr NEWA
 >A> AB 10MG;20MG A201890 002 Apr 26, 2017 Apr NEWA
 >A> AB 10MG;40MG A201890 003 Apr 26, 2017 Apr NEWA
 >A> AB 10MG;80MG A201890 004 Apr 26, 2017 Apr NEWA
 >A> AB WATSON LABS INC 10MG;10MG A202968 001 Apr 26, 2017 Apr NEWA
 >A> AB 10MG;20MG A202968 002 Apr 26, 2017 Apr NEWA
 >A> AB 10MG;40MG A202968 003 Apr 26, 2017 Apr NEWA
 >A> AB 10MG;80MG A202968 004 Apr 26, 2017 Apr NEWA

VYTORIN

>D> + MSD INTL 10MG;10MG N021687 001 Jul 23, 2004 Apr CFTG
 >A> AB + 10MG;10MG N021687 001 Jul 23, 2004 Apr CFTG
 >D> + 10MG;20MG N021687 002 Jul 23, 2004 Apr CFTG
 >A> AB + 10MG;20MG N021687 002 Jul 23, 2004 Apr CFTG
 >D> + 10MG;40MG N021687 003 Jul 23, 2004 Apr CFTG
 >A> AB + 10MG;40MG N021687 003 Jul 23, 2004 Apr CFTG
 >D> +! 10MG;80MG N021687 004 Jul 23, 2004 Apr CFTG

	TABLET;ORAL								
	VYTORIN								
>A>	AB	+!	10MG;80MG	N021687	004	Jul 23, 2004	Apr	CFTG	
	<u>FAMCICLOVIR</u>								
	TABLET;ORAL								
	FAMCICLOVIR								
AB	!	TEVA PHARMS	500MG	A077487	003	Aug 24, 2007	Jan	CHRS	
	FAMVIR								
	+	@ NOVARTIS	125MG	N020363	003	Dec 11, 1995	Jan	DISC	
	+	@	250MG	N020363	001	Apr 26, 1996	Jan	DISC	
	+	@	500MG	N020363	002	Jun 29, 1994	Jan	DISC	
	<u>FAMOTIDINE</u>								
	INJECTABLE;INJECTION								
	FAMOTIDINE								
AP		ATHENEX INC	10MG/ML	A075651	001	Apr 16, 2001	Mar	CAHN	
AP			10MG/ML	A075684	001	Apr 16, 2001	Mar	CAHN	
	FAMOTIDINE PRESERVATIVE FREE								
AP		ATHENEX INC	10MG/ML	A075622	001	Apr 16, 2001	Mar	CAHN	
AP			10MG/ML	A075825	001	Apr 17, 2001	Mar	CAHN	
	TABLET;ORAL								
	FAMOTIDINE								
>D>	AB	PERRIGO	20MG	A077352	002	Jul 27, 2005	Apr	CAHN	
>D>	AB		40MG	A077352	001	Jul 27, 2005	Apr	CAHN	
>A>	AB	PERRIGO R AND D	20MG	A077352	002	Jul 27, 2005	Apr	CAHN	
>A>	AB		40MG	A077352	001	Jul 27, 2005	Apr	CAHN	
	<u>FELBAMATE</u>								
	SUSPENSION;ORAL								
	FELBATOL								
AB	+	MYLAN SPECIALITY LP	600MG/5ML	N020189	003	Jul 29, 1993	Mar	CAHN	
	TABLET;ORAL								
	FELBAMATE								
AB		IMPAX LABS INC	400MG	A202284	001	Nov 04, 2015	Feb	CAHN	
AB			600MG	A202284	002	Nov 04, 2015	Feb	CAHN	
>A>	AB	TARO PHARM	400MG	A207093	001	Apr 20, 2017	Apr	NEWA	
>A>	AB		600MG	A207093	002	Apr 20, 2017	Apr	NEWA	
	FELBATOL								
AB	+	MYLAN SPECIALITY LP	400MG	N020189	001	Jul 29, 1993	Mar	CAHN	
AB	+	!	600MG	N020189	002	Jul 29, 1993	Mar	CAHN	
	<u>FENOFIBRATE</u>								
	CAPSULE;ORAL								
	FENOFIBRATE (MICRONIZED)								
AB		GLENMARK PHARMS LTD	67MG	A205566	001	Apr 07, 2017	Mar	NEWA	
AB			134MG	A205566	002	Apr 07, 2017	Mar	NEWA	
AB			200MG	A205566	003	Apr 07, 2017	Mar	NEWA	
AB		INVAGEN PHARMS	67MG	A207378	001	Mar 28, 2017	Mar	NEWA	
AB			134MG	A207378	002	Mar 28, 2017	Mar	NEWA	
AB			200MG	A207378	003	Mar 28, 2017	Mar	NEWA	
	TABLET;ORAL								
	FENOFIBRATE								
AB	!	IMPAX LABS	160MG	A076509	002	Mar 26, 2008	Mar	CHRS	
AB		RHODES PHARMS	160MG	A076433	002	May 13, 2005	Mar	CHRS	
	<u>FENOLDOPAM MESYLATE</u>								
	INJECTABLE;INJECTION								
	FENOLDOPAM MESYLATE								
AP		SANDOZ INC	EQ 10MG BASE/ML	A077155	001	Feb 15, 2005	Mar	CAHN	
	<u>FENTANYL</u>								
	FILM, EXTENDED RELEASE;TRANSDERMAL								
	FENTANYL-100								
AB		3M DRUG DELIVERY	100MCG/HR	A202097	005	Nov 04, 2016	Mar	CAHN	
AB		ACTAVIS LABS UT INC	100MCG/HR	A076709	004	Aug 20, 2007	Mar	CAHN	
AB		MAYNE PHARMA	100MCG/HR	A077062	004	Aug 20, 2007	Mar	CAHN	
	FENTANYL-12								
AB		3M DRUG DELIVERY	12.5MCG/HR	A202097	001	Nov 04, 2016	Mar	CAHN	
	FENTANYL-25								
AB		3M DRUG DELIVERY	25MCG/HR	A202097	002	Nov 04, 2016	Mar	CAHN	
AB		ACTAVIS LABS UT INC	25MCG/HR	A076709	001	Aug 20, 2007	Mar	CAHN	

FILM, EXTENDED RELEASE;TRANSDERMAL
FENTANYL-25

AB	MAYNE PHARMA	25MCG/HR	A 077062	001	Aug 20, 2007	Mar	CAHN
	FENTANYL-50						
AB	3M DRUG DELIVERY	50MCG/HR	A 202097	003	Nov 04, 2016	Mar	CAHN
AB	ACTAVIS LABS UT INC	50MCG/HR	A 076709	002	Aug 20, 2007	Mar	CAHN
AB	MAYNE PHARMA	50MCG/HR	A 077062	002	Aug 20, 2007	Mar	CAHN
	FENTANYL-75						
AB	3M DRUG DELIVERY	75MCG/HR	A 202097	004	Nov 04, 2016	Mar	CAHN
AB	ACTAVIS LABS UT INC	75MCG/HR	A 076709	003	Aug 20, 2007	Mar	CAHN
AB	MAYNE PHARMA	75MCG/HR	A 077062	003	Aug 20, 2007	Mar	CAHN

FESOTERODINE FUMARATE

TABLET, EXTENDED RELEASE;ORAL
FESOTERODINE FUMARATE

AB	AUROBINDO PHARMA LTD	4MG	A 205007	001	Feb 17, 2017	Feb	NEWA
AB		8MG	A 205007	002	Feb 17, 2017	Feb	NEWA

FINASTERIDE

TABLET;ORAL
FINASTERIDE

AB	ACCORD HLTHCARE	1MG	A 091643	001	Nov 05, 2013	Mar	CAHN
----	-----------------	-----	----------	-----	--------------	-----	------

FLUCONAZOLE

FOR SUSPENSION;ORAL
FLUCONAZOLE

AB	AUROBINDO PHARMA LTD	50MG/5ML	A 079150	001	Sep 18, 2009	Jan	CAHN
AB		200MG/5ML	A 079150	002	Sep 18, 2009	Jan	CAHN

INJECTABLE;INJECTION

DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER

+ @	PFIZER	200MG/100ML (2MG/ML)	N 019950	003	Sep 29, 1992	Mar	DISC
+ @		400MG/200ML (2MG/ML)	N 019950	005	Jul 08, 1994	Mar	DISC
	DIFLUCAN IN SODIUM CHLORIDE 0.9%						
+ @	PFIZER	200MG/100ML (2MG/ML)	N 019950	001	Jan 29, 1990	Mar	DISC
+ @		400MG/200ML (2MG/ML)	N 019950	006	Jan 29, 1990	Mar	DISC
	DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
+ @	PFIZER	200MG/100ML (2MG/ML)	N 019950	002	Jan 29, 1990	Mar	DISC
+ @		400MG/200ML (2MG/ML)	N 019950	004	Jan 29, 1990	Mar	DISC
	FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER						
AP	! HOSPIRA	200MG/100ML (2MG/ML)	A 076304	001	Jul 29, 2004	Mar	CHRS
AP	!	400MG/200ML (2MG/ML)	A 076304	002	Jul 29, 2004	Mar	CHRS
	FLUCONAZOLE IN SODIUM CHLORIDE 0.9%						
	WEST-WARD PHARMS INT	100MG/50ML (2MG/ML)	A 076087	002	Sep 26, 2008	Jan	CAHN
AP		200MG/100ML (2MG/ML)	A 076087	001	Jul 29, 2004	Jan	CAHN
AP		400MG/200ML (2MG/ML)	A 076087	003	Jul 29, 2004	Jan	CAHN
	FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
AP	! ACS DOBFAR INFO SA	200MG/100ML (2MG/ML)	A 079104	001	Jul 30, 2009	Mar	CHRS
AP	!	400MG/200ML (2MG/ML)	A 079104	002	Jul 30, 2009	Mar	CHRS
AP	WEST-WARD PHARMS INT	200MG/100ML (2MG/ML)	A 078107	001	Jul 30, 2008	Jan	CAHN
AP		400MG/200ML (2MG/ML)	A 078107	002	Jul 30, 2008	Jan	CAHN

TABLET;ORAL

FLUCONAZOLE

AB	UNIQUE PHARM LABS	150MG	A 076957	004	Feb 27, 2017	Feb	NEWA
AB	ZYDUS PHARMS USA INC	50MG	A 208963	001	Feb 16, 2017	Feb	NEWA
AB		100MG	A 208963	002	Feb 16, 2017	Feb	NEWA
AB		150MG	A 208963	003	Feb 16, 2017	Feb	NEWA
AB		200MG	A 208963	004	Feb 16, 2017	Feb	NEWA

FLUDARABINE PHOSPHATE

INJECTABLE;INJECTION
FLUDARABINE PHOSPHATE

AP	ACTAVIS LLC	50MG/2ML (25MG/ML)	A 203738	001	Feb 28, 2017	Feb	NEWA
----	-------------	--------------------	----------	-----	--------------	-----	------

FLUMAZENIL

INJECTABLE;INJECTION
FLUMAZENIL

>D>	AP	SANDOZ	0.5MG/5ML (0.1MG/ML)	A 077071	001	May 03, 2005	Apr	CAHN
>D>	AP		1MG/10ML (0.1MG/ML)	A 077071	002	May 03, 2005	Apr	CAHN
>A>	AP	SANDOZ INC	0.5MG/5ML (0.1MG/ML)	A 077071	001	May 03, 2005	Apr	CAHN
>A>	AP		1MG/10ML (0.1MG/ML)	A 077071	002	May 03, 2005	Apr	CAHN
	AP	WEST-WARD PHARMS INT	0.5MG/5ML (0.1MG/ML)	A 076256	002	Oct 12, 2004	Jan	CAHN
	AP		0.5MG/5ML (0.1MG/ML)	A 076787	002	Oct 12, 2004	Jan	CAHN

INJECTABLE; INJECTION
FLUMAZENIL

AP		1MG/10ML (0.1MG/ML)	A076256	001	Oct 12, 2004	Jan	CAHN
AP		1MG/10ML (0.1MG/ML)	A076787	001	Oct 12, 2004	Jan	CAHN

FLUNISOLIDE

AEROSOL, METERED; INHALATION
AEROSPAN HFA

+!	MYLAN SPECIALITY LP	0.078MG/INH	N021247	001	Jan 27, 2006	Mar	CAHN
----	---------------------	-------------	---------	-----	--------------	-----	------

FLUOCINOLONE ACETONIDE

CREAM; TOPICAL
FLUOCINOLONE ACETONIDE

AT	FOUGERA PHARMS INC	0.01%	A088170	001	Dec 16, 1982	Jan	CAHN
AT		0.025%	A088169	001	Dec 16, 1982	Jan	CAHN
>D>	@ TARO	0.01%	A040035	001	Oct 31, 1994	Apr	CAHN
>A>	@	0.01%	A040035	001	Oct 31, 1994	Apr	CAHN
>D>	@	0.025%	A040042	001	Oct 31, 1994	Apr	CAHN
>A>	@	0.025%	A040042	001	Oct 31, 1994	Apr	CAHN

OINTMENT; TOPICAL

FLUOCINOLONE ACETONIDE

AT	FOUGERA PHARMS INC	0.025%	A088168	001	Dec 16, 1982	Jan	CAHN
>D>	AT TARO	0.025%	A040041	001	Sep 15, 1994	Apr	CAHN
>A>	AT	0.025%	A040041	001	Sep 15, 1994	Apr	CAHN

SOLUTION; TOPICAL

FLUOCINOLONE ACETONIDE

AT	FOUGERA PHARMS INC	0.01%	A088167	001	Dec 16, 1982	Jan	CAHN
----	--------------------	-------	---------	-----	--------------	-----	------

FLUOCINONIDE

CREAM; TOPICAL

FLUOCINONIDE

AB1	FOUGERA PHARMS INC	0.05%	A073030	001	Oct 17, 1994	Jan	CAHN
>D>	AB PERRIGO ISRAEL	0.1%	A090256	001	Jan 14, 2014	Apr	CAHN
>A>	AB	0.1%	A090256	001	Jan 14, 2014	Apr	CAHN
AB1	TARO	0.05%	A071500	001	Jun 10, 1987	Mar	CMFD

GEL; TOPICAL

FLUOCINONIDE

AB	FOUGERA PHARMS INC	0.05%	A072933	001	Dec 30, 1994	Jan	CAHN
>D>	AB ! TARO	0.05%	A074935	001	Jul 29, 1997	Apr	CAHN
>A>	AB !	0.05%	A074935	001	Jul 29, 1997	Apr	CAHN

OINTMENT; TOPICAL

FLUOCINONIDE

>D>	AB ! TARO	0.05%	A075008	001	Jun 30, 1999	Apr	CAHN
>A>	AB !	0.05%	A075008	001	Jun 30, 1999	Apr	CAHN

SOLUTION; TOPICAL

FLUOCINONIDE

>D>	AT ! TARO	0.05%	A074799	001	Dec 31, 1996	Apr	CAHN
>A>	AT !	0.05%	A074799	001	Dec 31, 1996	Apr	CAHN

LIDEX

AT	+ CNTY LINE PHARMS	0.05%	N018849	001	Apr 06, 1984	Mar	CRLD
----	--------------------	-------	---------	-----	--------------	-----	------

FLUOROURACIL

INJECTABLE; INJECTION

FLUOROURACIL

+ @	SPECTRUM PHARMS	500MG/10ML (50MG/ML)	N012209	001		Jan	CRLD
-----	-----------------	----------------------	---------	-----	--	-----	------

SOLUTION; TOPICAL

FLUOROURACIL

AT	TARO PHARM	2%	A076526	001	Nov 05, 2003	Mar	CAHN
AT		5%	A076526	002	Nov 05, 2003	Mar	CAHN

FLUOXETINE HYDROCHLORIDE

SOLUTION; ORAL

FLUOXETINE HYDROCHLORIDE

AA	AUROBINDO PHARMA LTD	EQ 20MG BASE/5ML	A079209	001	Mar 20, 2009	Jan	CAHN
----	----------------------	------------------	---------	-----	--------------	-----	------

TABLET; ORAL

FLUOXETINE HYDROCHLORIDE

AB	ALEMBIC PHARMS LTD	EQ 10MG BASE	A208698	001	Apr 05, 2017	Mar	NEWA
AB		EQ 20MG BASE	A208698	002	Apr 05, 2017	Mar	NEWA
+!	ALVOGEN	EQ 60MG BASE	N202133	001	Oct 06, 2011	Jan	CAHN

FLUPHENAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

FLUPHENAZINE HYDROCHLORIDE

@ ANI PHARMS INC	5MG/ML	A073058	001	Aug 30, 1991	Jan	CAHN
------------------	--------	---------	-----	--------------	-----	------

FLURAZEPAM HYDROCHLORIDE

CAPSULE; ORAL

FLURAZEPAM HYDROCHLORIDE

@ AUROLIFE PHARMA LLC	15MG	A071717	002	Jul 31, 1991	Jan	CMS1
-----------------------	------	---------	-----	--------------	-----	------

FLUTICASONE PROPIONATE

POWDER; INHALATION

ARMONAIR RESPICLICK

+ TEVA PHARM	0.055MG/INH	N208798	001	Jan 27, 2017	Jan	NEWA
+	0.113MG/INH	N208798	002	Jan 27, 2017	Jan	NEWA
+!	0.232MG/INH	N208798	003	Jan 27, 2017	Jan	NEWA

FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE

POWDER; INHALATION

AIRDUO RESPICLICK

+ TEVA PHARM	0.055MG/INH;EQ 0.014MG BASE/INH	N208799	001	Jan 27, 2017	Jan	NEWA
+	0.113MG/INH;EQ 0.014MG BASE/INH	N208799	002	Jan 27, 2017	Jan	NEWA
+!	0.232MG/INH;EQ 0.014MG BASE/INH	N208799	003	Jan 27, 2017	Jan	NEWA

FLUVOXAMINE MALEATE

CAPSULE, EXTENDED RELEASE; ORAL

FLUVOXAMINE MALEATE

>D> AB	ACTAVIS ELIZABETH	150MG	A091482	002	Nov 18, 2013	Apr	CHRS
>A> AB	!	150MG	A091482	002	Nov 18, 2013	Apr	CHRS
>D>	LUVOX CR						
>D> AB	+ JAZZ PHARMS	100MG	N022033	001	Feb 28, 2008	Apr	DISC
>A>	+ @	100MG	N022033	001	Feb 28, 2008	Apr	DISC
>D> AB	+!	150MG	N022033	002	Feb 28, 2008	Apr	DISC
>A>	+ @	150MG	N022033	002	Feb 28, 2008	Apr	DISC

FOLIC ACID

TABLET; ORAL

FOLIC ACID

@ CONTRACT PHARMACAL	1MG	A085061	001		Mar	DISC
----------------------	-----	---------	-----	--	-----	------

FORMOTEROL FUMARATE

POWDER; INHALATION

FORADIL

+ @ NOVARTIS	0.012MG/INH	N020831	001	Feb 16, 2001	Feb	DISC
--------------	-------------	---------	-----	--------------	-----	------

FORMOTEROL FUMARATE; GLYCOPYRROLATE

AEROSOL, METERED; INHALATION

BEVESPI AEROSPHERE

+! ASTRAZENECA PHARMS	0.0048MG/INH;0.0090MG/INH	N208294	001	Apr 25, 2016	Mar	CAHN
-----------------------	---------------------------	---------	-----	--------------	-----	------

FOSINOPRIL SODIUM

TABLET; ORAL

MONOPRIL

+ @ BRISTOL MYERS SQUIBB	10MG	N019915	002	May 16, 1991	Jan	CRLD
+ @	20MG	N019915	003	May 16, 1991	Jan	CRLD
+ @	40MG	N019915	004	Mar 28, 1995	Jan	CRLD

FOSPHENYTOIN SODIUM

INJECTABLE; INJECTION

FOSPHENYTOIN SODIUM

@ HOSPIRA	EQ 50MG PHENYTOIN NA/ML	A078158	001	Aug 06, 2007	Mar	DISC
AP WEST-WARD PHARMS INT	EQ 50MG PHENYTOIN NA/ML	A077481	001	Aug 06, 2007	Jan	CAHN
AP	EQ 50MG PHENYTOIN NA/ML	A077989	001	Aug 06, 2007	Jan	CAHN

FUROSEMIDE

TABLET; ORAL

FUROSEMIDE

>D> AB	IPCA LABS LTD	20MG	A078010	001	Sep 18, 2006	Apr	CTEC
>A> BX		20MG	A078010	001	Sep 18, 2006	Apr	CTEC
>D> AB		40MG	A078010	002	Sep 18, 2006	Apr	CTEC
>A> BX		40MG	A078010	002	Sep 18, 2006	Apr	CTEC

TABLET;ORAL
FUROSEMIDE

>D>	AB		80MG	A078010	003	Sep 18, 2006	Apr	CTEC
>A>	BX		80MG	A078010	003	Sep 18, 2006	Apr	CTEC
	AB	PRINSTON INC	20MG	A076796	001	Mar 26, 2004	Feb	CAHN
	AB		40MG	A076796	002	Mar 26, 2004	Feb	CAHN
	AB		80MG	A076796	003	Mar 26, 2004	Feb	CAHN
	AB	WEST-WARD PHARMS INT	20MG	N018823	001	Nov 10, 1983	Jan	CAHN
	AB		40MG	N018823	002	Nov 10, 1983	Jan	CAHN

GABAPENTIN

CAPSULE;ORAL
GABAPENTIN

	AB	AUROBINDO PHARMA LTD	100MG	A078787	001	Jan 31, 2008	Jan	CAHN
	AB		300MG	A078787	002	Jan 31, 2008	Jan	CAHN
	AB		400MG	A078787	003	Jan 31, 2008	Jan	CAHN
	AB	EPIC PHARMA LLC	100MG	A207099	001	Mar 24, 2017	Mar	NEWA
	AB		300MG	A207099	002	Mar 24, 2017	Mar	NEWA
	AB		400MG	A207099	003	Mar 24, 2017	Mar	NEWA

TABLET;ORAL
GABAPENTIN

	AB	TEVA PHARMS USA	600MG	A205807	001	Mar 10, 2017	Feb	NEWA
	AB		800MG	A205807	002	Mar 10, 2017	Feb	NEWA

GANCICLOVIR

SOLUTION;IV (INFUSION)
GANCICLOVIR

	+	!	EXELA PHARMA SCS LLC	500MG/250ML (2MG/ML)	N209347	001	Feb 17, 2017	Feb	NEWA
--	---	---	----------------------	----------------------	---------	-----	--------------	-----	------

GATIFLOXACIN

SOLUTION/DROPS;OPHTHALMIC
GATIFLOXACIN

	AT		SANDOZ INC	0.5%	A204227	001	Jul 11, 2016	Feb	CAHN
--	----	--	------------	------	---------	-----	--------------	-----	------

GEMFIBROZIL

TABLET;ORAL
GEMFIBROZIL

	AB		CARIBE HOLDINGS	600MG	A078012	001	Mar 26, 2007	Jan	CAHN
--	----	--	-----------------	-------	---------	-----	--------------	-----	------

GEMIFLOXACIN MESYLATE

TABLET;ORAL
FACTIVE

	AB	+	!	LG CHEM LTD	EQ 320MG BASE	N021158	001	Apr 04, 2003	Mar	CAHN
--	----	---	---	-------------	---------------	---------	-----	--------------	-----	------

GENTAMICIN SULFATE

CREAM;TOPICAL
GENTAMICIN SULFATE

			@	FOUGERA PHARMS INC	EQ 0.1% BASE	A062531	001	Jul 05, 1984	Jan	DISC
	AT	!		PERRIGO NEW YORK	EQ 0.1% BASE	A062307	001		Jan	CHRS
			@	TARO	EQ 0.1% BASE	A062427	001	May 26, 1983	Jan	DISC

OINTMENT;TOPICAL
GENTAMICIN SULFATE

	AT			FOUGERA PHARMS INC	EQ 0.1% BASE	A062533	001	Oct 05, 1984	Jan	CAHN
--	----	--	--	--------------------	--------------	---------	-----	--------------	-----	------

SOLUTION/DROPS;OPHTHALMIC
GENTAMICIN SULFATE

	AT			SANDOZ INC	EQ 0.3% BASE	A062196	001		Mar	CAHN
--	----	--	--	------------	--------------	---------	-----	--	-----	------

GLIMEPIRIDE

TABLET;ORAL
GLIMEPIRIDE

	AB			PRINSTON INC	1MG	A077370	001	Dec 23, 2005	Feb	CAHN
	AB				2MG	A077370	002	Dec 23, 2005	Feb	CAHN
	AB				4MG	A077370	003	Dec 23, 2005	Feb	CAHN
	AB				8MG	A077370	004	Dec 23, 2005	Feb	CAHN

GLIPIZIDE; METFORMIN HYDROCHLORIDE

TABLET;ORAL
METAGLIP

			+	@	BRISTOL MYERS SQUIBB	2.5MG;250MG	N021460	001	Oct 21, 2002	Jan	CRLD
			+	@		2.5MG;500MG	N021460	002	Oct 21, 2002	Jan	CRLD
			+	@		5MG;500MG	N021460	003	Oct 21, 2002	Jan	CRLD

GLYBURIDE

TABLET; ORAL

GLYBURIDE

AB2	IMPAX LABS INC	1.25MG	A206079	001	Sep 30, 2015	Feb	CAHN
AB2		2.5MG	A206079	002	Sep 30, 2015	Feb	CAHN
AB2		5MG	A206079	003	Sep 30, 2015	Feb	CAHN

GLYBURIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

GLYBURIDE AND METFORMIN HYDROCHLORIDE

@ IMPAX LABS INC

1.25MG; 250MG

A076731 001 Nov 19, 2004 Feb CAHN

@

2.5MG; 500MG

A076731 002 Nov 19, 2004 Feb CAHN

@

5MG; 500MG

A076731 003 Nov 19, 2004 Feb CAHN

GLYCINE

SOLUTION; IRRIGATION

GLYCINE 1.5% IN PLASTIC CONTAINER

AT ICU MEDCL

1.5GM/100ML

N018315 001

Feb CAHN

GLYCOPYRROLATE

POWDER; INHALATION

SEEBRI

+! SUNOVION PHARMS INC 15.6MCG/INH

N207923 001 Oct 29, 2015 Jan CAHN

GLYCOPYRROLATE ; INDACATEROL MALEATE

POWDER; INHALATION

UTIBRON

+! SUNOVION PHARMS INC 15.6MCG/INH; 27.5MCG/INH

N207930 001 Oct 29, 2015 Jan CAHN

GONADORELIN HYDROCHLORIDE

INJECTABLE; INJECTION

FACTREL

@ WEST-WARD PHARMS INT

EQ 0.1MG BASE/VIAL

N018123 001 Sep 30, 1982 Mar CAHN

@

EQ 0.2MG BASE/VIAL

N018123 002 Sep 30, 1982 Mar CAHN

@

EQ 0.5MG BASE/VIAL

N018123 003 Sep 30, 1982 Mar CAHN

GONADOTROPIN, CHORIONIC

INJECTABLE; INJECTION

CHORIONIC GONADOTROPIN

+! FERRING 5,000 UNITS/VIAL

N017016 006

Jan CMFD

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN

AT AMRING PHARMS

0.025MG/ML; EQ 1.75MG
BASE/ML; 10,000 UNITS/ML

A065187 001 Oct 28, 2005 Mar CAHN

NEOSPORIN

>D> AT ! MONARCH PHARMS

0.025MG/ML; EQ 1.75MG
BASE/ML; 10,000 UNITS/ML

A060582 001

Apr CAHN

>A> AT !

0.025MG/ML; EQ 1.75MG
BASE/ML; 10,000 UNITS/ML

A060582 001

Apr CAHN

GRANISETRON HYDROCHLORIDE

INJECTABLE; INJECTION

GRANISETRON HYDROCHLORIDE

AP MYLAN LABS LTD

EQ 0.1MG BASE/ML (EQ 0.1MG
BASE/ML)

A203454 001 Apr 04, 2017 Mar NEWA

AP

EQ 1MG BASE/ML (EQ 1MG BASE/ML)

A203454 002 Apr 04, 2017 Mar NEWA

AP

EQ 4MG BASE/4ML (EQ 1MG BASE/ML)

A203453 001 Jan 31, 2017 Jan NEWA

AP

SANDOZ INC

EQ 0.1MG BASE/ML (EQ 0.1MG
BASE/ML)

A078534 001 Apr 30, 2009 Mar CAHN

AP

EQ 1MG BASE/ML (EQ 1MG BASE/ML)

A078531 001 Apr 30, 2009 Mar CAHN

AP

EQ 4MG BASE/4ML (EQ 1MG BASE/ML)

A078531 002 Apr 30, 2009 Mar CAHN

AP

WEST-WARD PHARMS INT

EQ 0.1MG BASE/ML (EQ 0.1MG
BASE/ML)

A077913 001 Jun 26, 2008 Jan CAHN

AP

EQ 4MG BASE/4ML (EQ 1MG BASE/ML)

A077186 001 Jun 30, 2008 Jan CAHN

AP

EQ 1MG BASE/ML (EQ 1MG BASE/ML)

A077187 001 Jun 30, 2008 Jan CAHN

AP

EQ 4MG BASE/4ML (EQ 1MG BASE/ML)

A077177 001 Dec 31, 2007 Jan CAHN

TABLET; ORAL

GRANISETRON HYDROCHLORIDE

AB TARO PHARM

EQ 1MG BASE

A090817 001 May 28, 2010 Mar CAHN

HALOBETASOL PROPIONATE

CREAM; TOPICAL

HALOBETASOL PROPIONATE

>D>	AB	G AND W LABS	0.05%	A078162	001	Apr 24, 2007	Apr	CHRS	
>A>	AB	!	0.05%	A078162	001	Apr 24, 2007	Apr	CHRS	
		ULTRAVATE							
>D>	AB	+!	SUN PHARM INDS LTD	0.05%	N019967	001	Dec 27, 1990	Apr	CHRS
>A>	AB	+		0.05%	N019967	001	Dec 27, 1990	Apr	CHRS
	AB	+!		0.05%	N019967	001	Dec 27, 1990	Mar	CAHN
		OINTMENT; TOPICAL							
		HALOBETASOL PROPIONATE							
>D>	AB	PERRIGO	0.05%	A076872	001	Dec 16, 2004	Apr	CAHN	
>A>	AB	PERRIGO ISRAEL	0.05%	A076872	001	Dec 16, 2004	Apr	CAHN	

HALOPERIDOL

TABLET; ORAL

HALOPERIDOL

		@ FRONTIDA BIOPHARM	20MG	A071177	001	Jan 07, 1988	Feb	CAHN
--	--	---------------------	------	---------	-----	--------------	-----	------

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION

HALOPERIDOL DECANOATE

		@ SANDOZ INC	EQ 50MG BASE/ML	A076463	001	Jun 24, 2005	Mar	CAHN
		@	EQ 100MG BASE/ML	A076463	002	Jun 24, 2005	Mar	CAHN

HALOPERIDOL LACTATE

INJECTABLE; INJECTION

HALOPERIDOL

		@ SANDOZ INC	EQ 5MG BASE/ML	A076464	001	Sep 29, 2004	Mar	CAHN
--	--	--------------	----------------	---------	-----	--------------	-----	------

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM

AP		GLAND PHARMA LTD	5,000 UNITS/ML	A205323	001	Feb 06, 2017	Jan	NEWA
----	--	------------------	----------------	---------	-----	--------------	-----	------

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP; ORAL

HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE

AA		ABHAI LLC	1.5MG/5ML; 5MG/5ML	A207487	001	Feb 21, 2017	Feb	NEWA
AA		BIO-PHARM INC	1.5MG/5ML; 5MG/5ML	A204765	001	Mar 06, 2017	Feb	NEWA
AA		NOVEL LABS INC	1.5MG/5ML; 5MG/5ML	A203535	001	Feb 13, 2017	Jan	NEWA
AA		PADDOCK LLC	1.5MG/5ML; 5MG/5ML	A205731	001	Feb 15, 2017	Jan	NEWA

TABLET; ORAL

TUSSIGON

AA		! KING PHARMS	1.5MG; 5MG	A088508	001	Jul 30, 1985	Feb	CAHN
----	--	---------------	------------	---------	-----	--------------	-----	------

HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

HYDROCHLOROTHIAZIDE

AB		PRINSTON INC	12.5MG	A075907	001	Sep 17, 2002	Feb	CAHN
----	--	--------------	--------	---------	-----	--------------	-----	------

TABLET; ORAL

HYDROCHLOROTHIAZIDE

AB		PRINSTON INC	25MG	A040412	001	Mar 29, 2002	Feb	CAHN
AB			50MG	A040412	002	Mar 29, 2002	Feb	CAHN

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL

IRBESARTAN AND HYDROCHLOROTHIAZIDE

AB		ATLAS PHARMS LLC	12.5MG; 150MG	A203036	001	Jan 15, 2016	Mar	CAHN
AB			12.5MG; 300MG	A203036	002	Jan 15, 2016	Mar	CAHN
AB			25MG; 300MG	A203036	003	Jan 15, 2016	Mar	CAHN

HYDROCHLOROTHIAZIDE; LISINAPRIL

TABLET; ORAL

PRINZIDE

		+ @ MERCK	12.5MG; 10MG	N019778	003	Nov 18, 1993	Jan	CRLD
		+ @	12.5MG; 20MG	N019778	001	Feb 16, 1989	Jan	CRLD

HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL

		MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE							
	@	CHARTWELL RX	12.5MG; 7.5MG	A090096	001	Sep 25, 2008	Mar	CAHN	
	@		12.5MG; 15MG	A090096	002	Sep 25, 2008	Mar	CAHN	
	@		25MG; 15MG	A090096	003	Sep 25, 2008	Mar	CAHN	
AB		HERITAGE PHARMS INC	12.5MG; 7.5MG	A202150	001	Mar 07, 2014	Jan	CMS1	
AB			12.5MG; 15MG	A202150	002	Mar 07, 2014	Jan	CMS1	
AB			25MG; 15MG	A202150	003	Mar 07, 2014	Jan	CMS1	

HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET; ORAL

		OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE							
>A>	AB	ALEMBIC PHARMS LTD	12.5MG; 20MG	A204233	001	Apr 24, 2017	Apr	NEWA	
>A>	AB		12.5MG; 40MG	A204233	002	Apr 24, 2017	Apr	NEWA	
>A>	AB		25MG; 40MG	A204233	003	Apr 24, 2017	Apr	NEWA	
>A>	AB	AUROBINDO PHARMA LTD	12.5MG; 20MG	A205391	001	Apr 24, 2017	Apr	NEWA	
>A>	AB		12.5MG; 40MG	A205391	002	Apr 24, 2017	Apr	NEWA	
>A>	AB		25MG; 40MG	A205391	003	Apr 24, 2017	Apr	NEWA	
>A>	AB	PRINSTON INC	12.5MG; 20MG	A207804	001	Apr 24, 2017	Apr	NEWA	
>A>	AB		12.5MG; 40MG	A207804	002	Apr 24, 2017	Apr	NEWA	
>A>	AB		25MG; 40MG	A207804	003	Apr 24, 2017	Apr	NEWA	
>A>	AB	TEVA PHARMS USA	12.5MG; 20MG	A200532	001	Apr 24, 2017	Apr	NEWA	
>A>	AB		12.5MG; 40MG	A200532	002	Apr 24, 2017	Apr	NEWA	
>A>	AB		25MG; 40MG	A200532	003	Apr 24, 2017	Apr	NEWA	
>A>	AB	TORRENT PHARMS LTD	12.5MG; 20MG	A206515	001	May 03, 2017	Apr	NEWA	
>A>	AB		12.5MG; 40MG	A206515	002	May 03, 2017	Apr	NEWA	
>A>	AB		25MG; 40MG	A206515	003	May 03, 2017	Apr	NEWA	

HYDROCODONE BITARTRATE

TABLET, EXTENDED RELEASE; ORAL

VANTRELA ER

+	TEVA BRANDED PHARM	15MG	N207975	001	Jan 17, 2017	Jan	NEWA	
+		30MG	N207975	002	Jan 17, 2017	Jan	NEWA	
+		45MG	N207975	003	Jan 17, 2017	Jan	NEWA	
+		60MG	N207975	004	Jan 17, 2017	Jan	NEWA	
+		90MG	N207975	005	Jan 17, 2017	Jan	NEWA	

HYDROCORTISONE

CREAM; TOPICAL

HYDROCORTISONE

AT	!	FOUGERA PHARMS INC	1%	A080693	003		Jan	CAHN	
AT	!		2.5%	A089414	001	Dec 16, 1986	Jan	CAHN	

LOTION; TOPICAL

STIE-CORT

>D>	AT	PERRIGO	2.5%	A089074	001	Nov 26, 1985	Apr	CAHN	
>D>		@ PERRIGO CO	1%	A089066	001	Nov 25, 1985	Apr	CAHN	
>A>		@	1%	A089066	001	Nov 25, 1985	Apr	CAHN	
>A>	AT		2.5%	A089074	001	Nov 26, 1985	Apr	CAHN	

OINTMENT; TOPICAL

HYDROCORTISONE

AT	!	FOUGERA PHARMS INC	2.5%	A081203	001	May 28, 1993	Jan	CAHN	
----	---	--------------------	------	---------	-----	--------------	-----	------	--

HYDROCORTISONE IN ABSORBASE

>D>	AT	CAROLINA MEDCL	1%	A088138	001	Sep 06, 1985	Apr	CAHN	
>A>	AT	CMP PHARMA INC	1%	A088138	001	Sep 06, 1985	Apr	CAHN	

TABLET; ORAL

HYDROCORTISONE

>A>	AB	PHARMACEUTICS INTL	5MG	A207029	001	Apr 27, 2017	Apr	NEWA	
>A>	AB		10MG	A207029	002	Apr 27, 2017	Apr	NEWA	
>A>	AB		20MG	A207029	003	Apr 27, 2017	Apr	NEWA	

HYDROCORTISONE ACETATE

AEROSOL, METERED; RECTAL

CORTIFOAM

+	!	MYLAN SPECIALITY LP	10%	N017351	001	Feb 10, 1982	Mar	CAHN	
---	---	---------------------	-----	---------	-----	--------------	-----	------	--

HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATECREAM; TOPICAL
CORTISPORIN

+!	MONARCH PHARMS	0.5%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	N050218	001	Aug 09, 1985	Feb	CAHN
----	----------------	---------------------------------------	---------	-----	--------------	-----	------

HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDEAEROSOL, METERED; TOPICAL
EPIFOAM

BX	MYLAN SPECIALITY LP	1%;1%	A086457	001		Mar	CAHN
----	---------------------	-------	---------	-----	--	-----	------

BX	MYLAN SPECIALITY LP	1%;1%	A086195	001		Mar	CAHN
----	---------------------	-------	---------	-----	--	-----	------

HYDROCORTISONE VALERATECREAM; TOPICAL
HYDROCORTISONE VALERATE

>D>	AB	!	TARO	0.2%	A075042	001	Aug 25, 1998	Apr	CAHN
-----	----	---	------	------	---------	-----	--------------	-----	------

>A>	AB	!		0.2%	A075042	001	Aug 25, 1998	Apr	CAHN
-----	----	---	--	------	---------	-----	--------------	-----	------

OINTMENT; TOPICAL
HYDROCORTISONE VALERATE

>D>		!	TARO	0.2%	A075043	001	Aug 25, 1998	Apr	CAHN
-----	--	---	------	------	---------	-----	--------------	-----	------

>A>		!		0.2%	A075043	001	Aug 25, 1998	Apr	CAHN
-----	--	---	--	------	---------	-----	--------------	-----	------

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATESOLUTION/DROPS; OTIC
CORTISPORIN

>D>	AT	+!	MONARCH PHARMS	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N050479	001		Apr	CAHN
-----	----	----	----------------	-------------------------------------	---------	-----	--	-----	------

>A>	AT	+!		1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N050479	001		Apr	CAHN
-----	----	----	--	-------------------------------------	---------	-----	--	-----	------

AT	AMRING PHARMS	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A065216	001	Oct 31, 2005	Mar	CAHN
----	---------------	-------------------------------------	---------	-----	--------------	-----	------

AT	SANDOZ INC	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062423	001	Aug 25, 1983	Feb	CAHN
----	------------	-------------------------------------	---------	-----	--------------	-----	------

SUSPENSION/DROPS; OPHTHALMIC
CORTISPORIN

>D>		@	MONARCH PHARMS	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N050169	001		Apr	CAHN
-----	--	---	----------------	-------------------------------------	---------	-----	--	-----	------

>A>		@		1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N050169	001		Apr	CAHN
-----	--	---	--	-------------------------------------	---------	-----	--	-----	------

NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE
!

!	SANDOZ INC	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062874	001	May 11, 1988	Feb	CAHN
---	------------	-------------------------------------	---------	-----	--------------	-----	------

SUSPENSION/DROPS; OTIC
NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE

AT	AMRING PHARMS	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A065219	001	May 01, 2006	Mar	CAHN
----	---------------	-------------------------------------	---------	-----	--------------	-----	------

AT	SANDOZ INC	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062488	001	Nov 06, 1985	Feb	CAHN
----	------------	-------------------------------------	---------	-----	--------------	-----	------

PEDIOTIC

>D>		@	MONARCH PHARMS	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062822	001	Sep 29, 1987	Apr	CAHN
-----	--	---	----------------	-------------------------------------	---------	-----	--------------	-----	------

>A>		@		1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062822	001	Sep 29, 1987	Apr	CAHN
-----	--	---	--	-------------------------------------	---------	-----	--------------	-----	------

HYDROMORPHINE HYDROCHLORIDEINJECTABLE; INJECTION
DILAUDID

AP	+!	FRESENIUS KABI USA	1MG/ML	N019034	003	Apr 30, 2009	Jan	CAHN
----	----	--------------------	--------	---------	-----	--------------	-----	------

AP	+!		2MG/ML	N019034	004	Apr 30, 2009	Jan	CAHN
----	----	--	--------	---------	-----	--------------	-----	------

AP	+!		4MG/ML	N019034	005	Apr 30, 2009	Jan	CAHN
----	----	--	--------	---------	-----	--------------	-----	------

DILAUDID-HP

AP	+!	FRESENIUS KABI USA	10MG/ML	N019034	001	Jan 11, 1984	Jan	CAHN
----	----	--------------------	---------	---------	-----	--------------	-----	------

	@		250MG/VIAL	N019034	002	Aug 04, 1994	Jan	CAHN
--	---	--	------------	---------	-----	--------------	-----	------

HYDROXOCOBALAMININJECTABLE; INJECTION
HYDROXOCOBALAMIN

!	ACTAVIS LLC	1MG/ML	A085998	001		Feb	CAHN
---	-------------	--------	---------	-----	--	-----	------

HYDROXYZINE HYDROCHLORIDE

INJECTABLE; INJECTION

VISTARIL

	+ @ PFIZER	25MG/ML	N011111	001		Jan	CRLD
	+ @	50MG/ML	N011111	002		Jan	CRLD

TABLET; ORAL

HYDROXYZINE HYDROCHLORIDE

	@ AUROLIFE PHARMA LLC	10MG	A087871	002	Dec 20, 1982	Jan	CMS1
	@	25MG	A087871	003	Dec 20, 1982	Jan	CMS1
AB	NUVO PHARM INC	10MG	A207120	001	Mar 29, 2017	Mar	NEWA
AB		25MG	A207121	001	Mar 29, 2017	Mar	NEWA
AB		50MG	A207122	001	Mar 29, 2017	Mar	NEWA
AB	PRINSTON INC	10MG	A040579	001	May 27, 2005	Feb	CAHN
AB		25MG	A040574	001	May 27, 2005	Feb	CAHN
AB		50MG	A040580	001	May 27, 2005	Feb	CAHN
>D> AB	SUN PHARM INDS INC	10MG	A040899	001	Jun 10, 2008	Apr	DISC
>A>	@	10MG	A040899	001	Jun 10, 2008	Apr	DISC
>D> AB		25MG	A040899	002	Jun 10, 2008	Apr	DISC
>A>	@	25MG	A040899	002	Jun 10, 2008	Apr	DISC
>D> AB		50MG	A040899	003	Jun 10, 2008	Apr	DISC
>A>	@	50MG	A040899	003	Jun 10, 2008	Apr	DISC

IBUPROFEN

SUSPENSION; ORAL

MOTRIN

	+ @ MCNEIL CONSUMER	100MG/5ML	N019842	001	Sep 19, 1989	Jan	CRLD
--	---------------------	-----------	---------	-----	--------------	-----	------

TABLET; ORAL

IBUPROFEN

	@ MYLAN PHARMS INC	400MG	A070045	001	Sep 24, 1985	Mar	CAHN
--	--------------------	-------	---------	-----	--------------	-----	------

IBUPROFEN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL

OXYCODONE HYDROCHLORIDE AND IBUPROFEN

>D> AB	WATSON LABS	400MG; 5MG	A078394	001	Nov 26, 2007	Apr	CTEC
>A> BX		400MG; 5MG	A078394	001	Nov 26, 2007	Apr	CTEC

ICOSAPENT ETHYL

CAPSULE; ORAL

VASCEPA

	+ AMARIN PHARMS	500MG	N202057	002	Feb 16, 2017	Mar	NEWA
--	-----------------	-------	---------	-----	--------------	-----	------

IFOSFAMIDE; MESNA

INJECTABLE; INTRAVENOUS

IFOSFAMIDE/MESNA KIT

	@ TEVA PHARMS USA	1GM/20ML; 1GM/10ML (50MG/ML; 100MG/ML)	A075874	001	Feb 26, 2002	Mar	DISC
	@	3GM/60ML; 1GM/10ML (50MG/ML; 100MG/ML)	A075874	002	Feb 26, 2002	Mar	DISC

INDACATEROL MALEATE

POWDER; INHALATION

ARCAPTA NEOHALER

	+! SUNOVION PHARMS INC	EQ 75MCG BASE	N022383	001	Jul 01, 2011	Jan	CAHN
--	------------------------	---------------	---------	-----	--------------	-----	------

INDOMETHACIN

CAPSULE; ORAL

INDOMETHACIN

	@ CHARTWELL MOLECULES	25MG	N018829	002	Aug 06, 1984	Feb	CAHN
>A>	@	50MG	A070651	001	Mar 05, 1986	Apr	CAHN
	@	50MG	N018829	001	Aug 06, 1984	Feb	CAHN
>D>	@ VINTAGE	50MG	A070651	001	Mar 05, 1986	Apr	CAHN

CAPSULE, EXTENDED RELEASE; ORAL

INDOMETHACIN

>A> AB	NOVAST LABS LTD	75MG	A204853	001	May 08, 2017	Apr	NEWA
	@ WATSON LABS INC	75MG	A202572	001	Dec 09, 2013	Feb	DISC

IOPAMIDOL

	INJECTABLE; INJECTION							
	SCANLUX-300							
AP	MYLAN IRELAND LTD	61%		A 090394	001	Jun 18, 2010	Jan	CAHN
AP	SANOCHEMIA CORP USA	61%		A 090394	001	Jun 18, 2010	Feb	CAHN
	SCANLUX-370							
AP	MYLAN IRELAND LTD	76%		A 090394	002	Jun 18, 2010	Jan	CAHN
AP	SANOCHEMIA CORP USA	76%		A 090394	002	Jun 18, 2010	Feb	CAHN

IRINOTECAN HYDROCHLORIDE

	INJECTABLE; INJECTION							
	IRINOTECAN HYDROCHLORIDE							
AP	WEST-WARD PHARMS INT	40MG/2ML (20MG/ML)		A 078753	001	Dec 24, 2008	Jan	CAHN
AP		100MG/5ML (20MG/ML)		A 078753	002	Dec 24, 2008	Jan	CAHN
	INJECTABLE, LIPOSOMAL; IV (INFUSION)							
	ONIVYDE							
>A>	+! IPSEN INC	EQ 43MG BASE/10ML (EQ 4.3MG BASE/ML)		N 207793	001	Oct 22, 2015	Apr	CAHN
>D>	+! MERRIMACK PHARMS	EQ 43MG BASE/10ML (EQ 4.3MG BASE/ML)		N 207793	001	Oct 22, 2015	Apr	CAHN

ISONIAZID

	INJECTABLE; INJECTION							
	ISONIAZID							
	! SANDOZ INC	100MG/ML		A 040648	001	Jul 05, 2005	Mar	CAHN
	SYRUP; ORAL							
	ISONIAZID							
>D>	! CAROLINA MEDCL	50MG/5ML		A 088235	001	Nov 10, 1983	Apr	CAHN
>A>	! CMP PHARMA INC	50MG/5ML		A 088235	001	Nov 10, 1983	Apr	CAHN

ISOSORBIDE DINITRATE

	TABLET, EXTENDED RELEASE; ORAL							
	ISOSORBIDE DINITRATE							
	@ IMPAX LABS INC	40MG		A 040723	001	Mar 17, 2008	Feb	CAHN

ITRACONAZOLE

	CAPSULE; ORAL							
	ITRACONAZOLE							
AB	JUBILANT GENERICS	100MG		A 203445	001	Feb 23, 2017	Feb	NEWA

KANAMYCIN SULFATE

	INJECTABLE; INJECTION							
	KANAMYCIN							
	@ WEST-WARD PHARMS INT	EQ 75MG BASE/2ML		A 062324	001		Jan	CAHN
	@	EQ 500MG BASE/2ML		A 062324	002		Jan	CAHN
	@	EQ 1GM BASE/3ML		A 062324	003		Jan	CAHN

KETOCONAZOLE

	AEROSOL, FOAM; TOPICAL							
	EXTINA							
AT	+! MYLAN PHARMS INC	2%		N 021738	001	Jun 12, 2007	Jan	CAHN

KETOPROFEN

	CAPSULE; ORAL							
	KETOPROFEN							
	HERITAGE PHARMS INC	25MG		A 074014	001	Jan 29, 1993	Feb	CAHN
AB		50MG		A 074014	002	Jan 29, 1993	Feb	CAHN
AB		75MG		A 074014	003	Jan 29, 1993	Feb	CAHN

KETOROLAC TROMETHAMINE

	INJECTABLE; INJECTION							
	KETOROLAC TROMETHAMINE							
	@ SANDOZ INC	15MG/ML		A 076271	001	Oct 06, 2004	Mar	CAHN
AP		30MG/ML		A 076271	002	Oct 06, 2004	Mar	CAHN
	SOLUTION/DROPS; OPHTHALMIC							
	KETOROLAC TROMETHAMINE							
AT	SANDOZ INC	0.5%		A 076583	001	Nov 05, 2009	Feb	CAHN

LABETALOL HYDROCHLORIDEINJECTABLE; INJECTION
LABETALOL HYDROCHLORIDE

AP	SAGENT AGILA	5MG/ML	A079134	001	Feb 03, 2010	Feb	CAHN
----	--------------	--------	---------	-----	--------------	-----	------

LAMIVUDINETABLET; ORAL
LAMIVUDINE

AB	CIPLA LTD	150MG	A077221	001	Mar 03, 2017	Feb	NEWA
AB		300MG	A077221	002	Mar 03, 2017	Feb	NEWA

LAMIVUDINE; ZIDOVUDINETABLET; ORAL
LAMIVUDINE AND ZIDOVUDINE

>A>	AB	AUROBINDO PHARMA LTD	150MG;300MG	A077558	001	May 05, 2017	Apr	NEWA
	BX	PHARMACARE	150MG;300MG	N022018	001	Mar 17, 2017	Mar	NEWA

LAMOTRIGINETABLET; ORAL
LAMOTRIGINE

	@	MYLAN LABS LTD	25MG	A078443	001	Feb 11, 2009	Mar	CAHN
	@		100MG	A078443	002	Feb 11, 2009	Mar	CAHN
	@		150MG	A078443	003	Feb 11, 2009	Mar	CAHN
	@		200MG	A078443	004	Feb 11, 2009	Mar	CAHN

TABLET, EXTENDED RELEASE; ORAL
LAMOTRIGINE

>D>	AB	ACTAVIS ELIZABETH	250MG	A203733	001	Nov 13, 2013	Apr	CAHN
>A>	AB		250MG	A203733	001	Nov 13, 2013	Apr	CAHN
	AB	HANDA PHARMS LLC	25MG	A202887	001	Jun 17, 2013	Jan	CAHN
	AB		50MG	A202887	002	Jun 17, 2013	Jan	CAHN
	AB		100MG	A202887	003	Jun 17, 2013	Jan	CAHN
	AB		200MG	A202887	004	Jun 17, 2013	Jan	CAHN

LATANOPROSTSOLUTION/DROPS; OPHTHALMIC
LATANOPROST

AT	AMRING PHARMS	0.005%	A200925	001	Mar 22, 2011	Mar	CAHN
AT	SANDOZ INC	0.005%	A091449	001	Mar 22, 2011	Feb	CAHN

LEVALBUTEROL HYDROCHLORIDESOLUTION; INHALATION
LEVALBUTEROL HYDROCHLORIDE

AN	AUROBINDO PHARMA LTD	EQ 0.25% BASE	A207628	001	Jan 31, 2017	Jan	NEWA
----	----------------------	---------------	---------	-----	--------------	-----	------

LEVETIRACETAMSOLUTION; ORAL
LEVETIRACETAM

AA	ALLIED PHARMA INC	100MG/ML	A078582	001	Jan 15, 2009	Mar	CAHN
AA	AUROBINDO PHARMA LTD	100MG/ML	A079063	001	Jan 15, 2009	Jan	CAHN

TABLET; ORAL

LEVETIRACETAM

	AB	ALLIED PHARMA INC	250MG	A078042	001	Jan 15, 2009	Mar	CAHN
	AB		500MG	A078042	002	Jan 15, 2009	Mar	CAHN
	AB		750MG	A078042	003	Jan 15, 2009	Mar	CAHN
	AB		1GM	A078042	004	Jan 15, 2009	Mar	CAHN
>D>	AB	LOTUS PHARM CO LTD	500MG	A090906	001	Nov 05, 2010	Apr	CTNA
		ROWEEPRA						
>A>	AB	LOTUS PHARM CO LTD	250MG	A090906	002	Oct 31, 2016	Apr	NEWA
>A>	AB		500MG	A090906	001	Nov 05, 2010	Apr	CTNA
>A>	AB		750MG	A090906	003	Oct 31, 2016	Apr	NEWA
>A>	AB		1GM	A090906	004	Oct 31, 2016	Apr	NEWA

TABLET, EXTENDED RELEASE; ORAL

LEVETIRACETAM

	AB	ECI PHARMS LLC	500MG	A204754	001	Aug 26, 2016	Mar	CAHN
	AB		750MG	A204754	002	Aug 26, 2016	Mar	CAHN
>D>	AB	MYLAN PHARMS INC	500MG	A200475	001	Dec 19, 2011	Apr	DISC
>A>		@	500MG	A200475	001	Dec 19, 2011	Apr	DISC
>D>	AB		750MG	A200475	002	Dec 19, 2011	Apr	DISC
>A>		@	750MG	A200475	002	Dec 19, 2011	Apr	DISC
>D>			1GM	A200475	003	Dec 07, 2015	Apr	DISC
>A>		@	1GM	A200475	003	Dec 07, 2015	Apr	DISC

TABLET, EXTENDED RELEASE;ORAL

LEVETIRACETAM									
AB	PRINSTON INC	500MG	A202533	001	Jul 20, 2012	Feb	CAHN		
AB		750MG	A202533	002	Jul 20, 2012	Feb	CAHN		
AB	VIRTUS PHARMS	500MG	A091291	001	Sep 12, 2011	Feb	CAHN		
AB		750MG	A091291	002	Sep 12, 2011	Feb	CAHN		

LEVOBUNOLOL HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC									
LEVOBUNOLOL HYDROCHLORIDE									
	@ ALCON LABS INC	0.25%	A074851	001	Oct 28, 1996	Feb	DISC		
AT	SANDOZ INC	0.5%	A074850	001	Oct 28, 1996	Feb	CAHN		

LEVOCARNITINE

INJECTABLE;INJECTION									
CARNITOR									
AP	+! LEADIANT BIOSCI INC	200MG/ML	N020182	001	Dec 16, 1992	Mar	CAHN		
SOLUTION;ORAL									
CARNITOR									
	@ LEADIANT BIOSCI INC	1GM/10ML	N018948	002	Apr 27, 1988	Mar	CAHN		
AA	+!	1GM/10ML	N019257	001	Apr 10, 1986	Mar	CAHN		
CARNITOR SF									
AA	+ LEADIANT BIOSCI INC	1GM/10ML	N019257	002	Mar 28, 2007	Mar	CAHN		
TABLET;ORAL									
CARNITOR									
AB	+! LEADIANT BIOSCI INC	330MG	N018948	001	Dec 27, 1985	Mar	CAHN		
LEVOCARNITINE									
AB	IMPAX LABS INC	330MG	A076858	001	Sep 20, 2004	Feb	CAHN		

LEVOCETIRIZINE DIHYDROCHLORIDE

TABLET;ORAL									
LEVOCETIRIZINE DIHYDROCHLORIDE									
>A>	AB ALLIED PHARMA INC	5MG	A204323	001	Dec 20, 2016	Apr	CAHN		
>D>	AB NOSTRUM LABS INC	5MG	A204323	001	Dec 20, 2016	Apr	CAHN		

LEVOFLOXACIN

INJECTABLE;INJECTION									
LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER									
	+ @ JANSSEN PHARMS	EQ 250MG/50ML (EQ 5MG/ML)	N020635	002	Dec 20, 1996	Jan	CRLD		
	+ @	EQ 500MG/100ML (EQ 5MG/ML)	N020635	003	Dec 20, 1996	Jan	CRLD		
	+ @	EQ 750MG/150ML (EQ 5MG/ML)	N020635	005	Dec 20, 1996	Jan	CRLD		
SOLUTION/DROPS;OPHTHALMIC									
LEVOFLOXACIN									
AT	WATSON LABS TEVA	0.5%	A076826	001	Feb 10, 2011	Feb	CAHN		

LEVOLEUCOVORIN CALCIUM

POWDER;IV (INFUSION)									
LEVOLEUCOVORIN CALCIUM									
AP	ACTAVIS LLC	EQ 50MG BASE/VIAL	A206516	001	Feb 13, 2017	Jan	NEWA		
AP	AMNEAL PHARMS CO	EQ 50MG BASE/VIAL	A207547	001	Feb 13, 2017	Jan	NEWA		

LEVONORDEFRIN; MEPIVACAINE HYDROCHLORIDE

INJECTABLE;INJECTION									
MEPIVACAINE HYDROCHLORIDE W/ LEVONORDEFRIN									
	@ BELMORA LLC	0.05MG/ML;2%	A084850	002	Oct 21, 1983	Feb	CAHN		

LEVORPHANOL TARTRATE

TABLET;ORAL									
LEVO-DROMORAN									
>D>	@ VALEANT PHARM INTL	2MG	N008720	001	Dec 19, 1991	Apr	CRLD		
>A>	+ @	2MG	N008720	001	Dec 19, 1991	Apr	CRLD		

LIDOCAINE

OINTMENT;TOPICAL									
LIDOCAINE									
AT	ALKEM LABS LTD	5%	A207810	001	Mar 10, 2017	Feb	NEWA		
AT	! FOUGERA PHARMS INC	5%	A080198	001		Jan	CAHN		
XYLOCAINE									
	+ @ ASTRAZENECA	5%	N008048	001		Jan	CRLD		

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION
LIDOCAINE HYDROCHLORIDE
@ BELMORA LLC 2%

A080504 001 Feb CAHN

LINACLOTIDE

CAPSULE; ORAL
LINZESS

+ FOREST LABS LLC 72MCG

N202811 003 Jan 25, 2017 Jan NEWA

LINEZOLID

SOLUTION; IV (INFUSION)
LINEZOLID

AP SAGENT PHARMS 200MG/100ML (2MG/ML)
AP 600MG/300ML (2MG/ML)

A204696 001 Mar 02, 2017 Feb NEWA
A204696 002 Mar 02, 2017 Feb NEWA

TABLET; ORAL
LINEZOLID

AB ZYDUS PHARMS USA INC 600MG

A206097 001 Feb 22, 2017 Feb NEWA

LIOETHYRONINE SODIUM

TABLET; ORAL
CYTOMEL

AB + KING PHARMS EQ 0.005MG BASE
AB + EQ 0.025MG BASE
AB +! EQ 0.05MG BASE

N010379 001 Mar CAHN
N010379 002 Mar CAHN
N010379 003 Mar CAHN

LISDEXAMFETAMINE DIMESYLATE

TABLET, CHEWABLE; ORAL
VYVANSE

+ SHIRE DEV LLC 10MG
+ 20MG
+ 30MG
+ 40MG
+ 50MG
>D> + 60MG
>A> +! 60MG
+ 60MG

N208510 001 Jan 28, 2017 Jan NEWA
N208510 002 Jan 28, 2017 Jan NEWA
N208510 003 Jan 28, 2017 Jan NEWA
N208510 004 Jan 28, 2017 Jan NEWA
N208510 005 Jan 28, 2017 Jan NEWA
N208510 006 Jan 28, 2017 Apr CHRS
N208510 006 Jan 28, 2017 Apr CHRS
N208510 006 Jan 28, 2017 Jan NEWA

LISINAPRIL

TABLET; ORAL
LISINAPRIL

AB PRINSTON INC 2.5MG
AB 5MG
AB 10MG
AB 20MG
AB 30MG
AB 40MG

A075743 001 Jul 01, 2002 Feb CAHN
A075743 002 Jul 01, 2002 Feb CAHN
A075743 003 Jul 01, 2002 Feb CAHN
A075743 004 Jul 01, 2002 Feb CAHN
A075743 005 Jul 01, 2002 Feb CAHN
A075743 006 Jul 01, 2002 Feb CAHN

LITHIUM CARBONATE

CAPSULE; ORAL
LITHIUM CARBONATE

AB MYLAN PHARMS INC 150MG
AB 300MG
AB 600MG
AB + WEST-WARD PHARMS INT 150MG
AB + 300MG
AB +! 600MG

A076243 002 Feb 24, 2003 Jan CAHN
A076243 001 Jun 27, 2002 Jan CAHN
A078763 001 Apr 15, 2008 Jan CAHN
N017812 002 Jan 28, 1987 Jan CAHN
N017812 001 Jan CAHN
N017812 003 Jan 28, 1987 Jan CAHN

TABLET; ORAL
LITHIUM CARBONATE

AB +! WEST-WARD PHARMS INT 300MG

N018558 001 Jan 29, 1982 Jan CAHN

LITHIUM CITRATE

SYRUP; ORAL
LITHIUM CITRATE

AA +! WEST-WARD PHARMS INT EQ 300MG CARBONATE/5ML

N018421 001 Jan CAHN

LORAZEPAM

INJECTABLE; INJECTION

LORAZEPAM

AP	SAGENT AGILA	2MG/ML	A200217	001	Apr 04, 2017	Mar	NEWA
>A>	AP	2MG/ML	A200542	001	Apr 28, 2017	Apr	NEWA
	AP	4MG/ML	A200217	002	Apr 04, 2017	Mar	NEWA
>A>	AP	4MG/ML	A200542	002	Apr 28, 2017	Apr	NEWA
	@ WEST-WARD PHARMS INT	2MG/ML	A074496	001	Sep 28, 1998	Mar	CAHN
	@	4MG/ML	A074496	002	Sep 28, 1998	Mar	CAHN

TABLET; ORAL

LORAZEPAM

>A>	AB	SANDOZ	0.5	A071141	002	Apr 21, 1987	Apr	CMS1
>A>	AB		1MG	A071141	003	Apr 21, 1987	Apr	CMS1

LOVASTATIN

TABLET; ORAL

LOVASTATIN

@ MYLAN

10MG

A075935 001 Dec 17, 2001 Mar DISC

@

20MG

A075935 002 Dec 17, 2001 Mar DISC

@

40MG

A075935 003 Dec 17, 2001 Mar DISC

TABLET, EXTENDED RELEASE; ORAL

ALTOPREV

>A>	@ COVIS PHARMA BV	10MG	N021316	001	Jun 26, 2002	Apr	CAHN
>A>	+	20MG	N021316	002	Jun 26, 2002	Apr	CAHN
>A>	+	40MG	N021316	003	Jun 26, 2002	Apr	CAHN
>A>	+	60MG	N021316	004	Jun 26, 2002	Apr	CAHN
>D>	@ COVIS PHARMA SARL	10MG	N021316	001	Jun 26, 2002	Apr	CAHN
>D>	+	20MG	N021316	002	Jun 26, 2002	Apr	CAHN
>D>	+	40MG	N021316	003	Jun 26, 2002	Apr	CAHN
>D>	+	60MG	N021316	004	Jun 26, 2002	Apr	CAHN

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE; INJECTION

NORMOSOL-R IN PLASTIC CONTAINER

ICU MEDCL

30MG/100ML; 37MG/100ML; 222MG/100ML; 526MG/100ML; 502MG/100ML

N017586 001

Feb CAHN

SOLUTION; IRRIGATION

PHYSIOSOL IN PLASTIC CONTAINER

ICU MEDCL

30MG/100ML; 37MG/100ML; 222MG/100ML; 526MG/100ML; 502MG/100ML

N017637 002 Jul 08, 1982

Feb CAHN

MAGNESIUM SULFATE ANHYDROUS; POTASSIUM SULFATE; SODIUM SULFATE

SOLUTION; ORAL

SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE

AA NOVEL LABS INC

1.6GM/BOT; 3.13GM/BOT; 17.5GM/BOT

A202511 001 Feb 23, 2017

Feb NEWA

SUPREP BOWEL PREP KIT

AA +! BRAINTREE LABS

1.6GM/BOT; 3.13GM/BOT; 17.5GM/BOT

N022372 001 Aug 05, 2010

Feb CFTG

MANNITOL

INJECTABLE; INJECTION

MANNITOL 10% IN PLASTIC CONTAINER

AP ICU MEDCL

10GM/100ML

N019603 002 Jan 08, 1987

Feb CAHN

MANNITOL 15% IN PLASTIC CONTAINER

AP ICU MEDCL

15GM/100ML

N019603 003 Jan 08, 1990

Feb CAHN

MANNITOL 20% IN PLASTIC CONTAINER

AP ICU MEDCL

20GM/100ML

N019603 004 Jan 08, 1990

Feb CAHN

MANNITOL 5% IN PLASTIC CONTAINER

AP ICU MEDCL

5GM/100ML

N019603 001 Jan 08, 1987

Feb CAHN

MANNITOL; SORBITOL

SOLUTION; IRRIGATION

SORBITOL-MANNITOL IN PLASTIC CONTAINER

ICU MEDCL

540MG/100ML; 2.7GM/100ML

N018316 001

Feb CAHN

MEDROXYPROGESTERONE ACETATE

INJECTABLE; INJECTION

MEDROXYPROGESTERONE ACETATE

AB SANDOZ INC

150MG/ML

A078711 001 May 20, 2009

Mar CAHN

AB TEVA PHARMS USA

150MG/ML

A076553 001 Jul 28, 2004

Jan CAHN

MEFLOQUINE HYDROCHLORIDE

TABLET; ORAL

MEFLOQUINE HYDROCHLORIDE

>D>	AB	BARR	250MG	A076392	001	Dec 29, 2003	Apr	CHRS
>A>	AB	!	250MG	A076392	001	Dec 29, 2003	Apr	CHRS
>D>	AB	! SANDOZ	250MG	A076175	001	Feb 20, 2002	Apr	DISC
>A>		@	250MG	A076175	001	Feb 20, 2002	Apr	DISC

MEGESTROL ACETATE

SUSPENSION; ORAL

MEGACE

		+ @ BRISTOL MYERS SQUIBB	40MG/ML	N020264	001	Sep 10, 1993	Feb	DISC
		MEGESTROL ACETATE						
AB	!	WEST-WARD PHARMS INT	40MG/ML	A075997	001	Feb 15, 2002	Feb	CHRS

MELOXICAM

TABLET; ORAL

MELOXICAM

>D>	AB	SUN PHARM INDS INC	7.5MG	A077937	001	Jul 19, 2006	Apr	DISC
>A>		@	7.5MG	A077937	001	Jul 19, 2006	Apr	DISC
>D>	AB		15MG	A077937	002	Jul 19, 2006	Apr	DISC
>A>		@	15MG	A077937	002	Jul 19, 2006	Apr	DISC

MELPHALAN

TABLET; ORAL

ALKERAN

AB	+	! APOTEX INC	2MG	N014691	002		Mar	CFTG
		MELPHALAN						
AB		ALVOGEN MALTA	2MG	A207809	001	Mar 22, 2017	Mar	NEWA

MELPHALAN HYDROCHLORIDE

INJECTABLE; INJECTION

MELPHALAN HYDROCHLORIDE

AP		SAGENT PHARMS	EQ 50MG BASE/VIAL	A201379	001	Feb 28, 2017	Feb	NEWA
----	--	---------------	-------------------	---------	-----	--------------	-----	------

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

MEPERIDINE HYDROCHLORIDE

AP		WEST-WARD PHARMS INT	25MG/ML	A080445	001		Jan	CAHN
AP			25MG/ML	A080455	007		Jan	CAHN
AP			50MG/ML	A080445	002		Jan	CAHN
AP			50MG/ML	A080455	008		Jan	CAHN
AP			75MG/ML	A080445	003		Jan	CAHN
AP			75MG/ML	A080455	009		Jan	CAHN
AP			100MG/ML	A080445	004		Jan	CAHN
AP			100MG/ML	A080455	010		Jan	CAHN
		MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE						
>D>	AP	EUROHLTH INTL SARL	10MG/ML	A081002	001	Jul 30, 1993	Apr	CAHN
>D>	AP	! HOSPIRA	10MG/ML	A088432	001	Aug 16, 1984	Apr	CAHN
>A>	AP	! ICU MEDCL	10MG/ML	A088432	001	Aug 16, 1984	Apr	CAHN
		@ MALLINCKRODT INC	10MG/ML	A040163	001	May 12, 1997	Mar	CAHN
>A>	AP	WEST-WARD PHARMS INT	10MG/ML	A081002	001	Jul 30, 1993	Apr	CAHN

MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

MEPIVACAINE HYDROCHLORIDE

		@ BELMORA LLC	3%	A083559	001		Feb	CAHN
--	--	---------------	----	---------	-----	--	-----	------

MEROPENEM

INJECTABLE; INJECTION

MEROPENEM

AP		AUROBINDO PHARMA LTD	500MG/VIAL	A205835	001	Mar 27, 2017	Mar	NEWA
AP			1GM/VIAL	A205835	002	Mar 27, 2017	Mar	NEWA

MESALAMINE

ENEMA; RECTAL

ROWASA

AB	+	! MYLAN SPECIALITY LP	4GM/60ML	N019618	001	Dec 24, 1987	Mar	CAHN
		SFROWASA						
AB	+	MYLAN SPECIALITY LP	4GM/60ML	N019618	002	Jun 20, 2008	Mar	CAHN

METAXALONETABLET; ORAL
METAXALONE

	IMPAX LABS INC	400MG	A040486	001	Feb 27, 2015	Feb	CAHN
--	----------------	-------	---------	-----	--------------	-----	------

METFORMIN HYDROCHLORIDETABLET; ORAL
METFORMIN HYDROCHLORIDE

	@ WATSON LABS FLORIDA	500MG	A075961	001	Jan 25, 2002	Mar	DISC
	@	850MG	A075961	002	Jan 25, 2002	Mar	DISC
	@	1GM	A075961	003	Jan 25, 2002	Mar	DISC

TABLET, EXTENDED RELEASE; ORAL
METFORMIN HYDROCHLORIDE

AB1	INTELLIPHARMACEUTICS	500MG	A202306	001	Feb 23, 2017	Feb	NEWA
AB		750MG	A202306	002	Feb 23, 2017	Feb	NEWA
>D>	AB1	TORRENT PHARM	A090014	001	Dec 30, 2009	Apr	CAHN
>A>	AB1	TORRENT PHARMS LTD	A090014	001	Dec 30, 2009	Apr	CAHN

METHADONE HYDROCHLORIDECONCENTRATE; ORAL
METHADOSE

>D>	AA	+! MALLINCKRODT	10MG/ML	N017116	002		Apr	CAHN
>A>	AA	+! MALLINCKRODT INC	10MG/ML	N017116	002		Apr	CAHN

POWDER; FOR RX COMPOUNDING
METHADONE HYDROCHLORIDE

>D>		MALLINCKRODT	50GM/BOT	N006383	002		Apr	CAHN
>D>			100GM/BOT	N006383	003		Apr	CAHN
>D>			500GM/BOT	N006383	004		Apr	CAHN
>A>		MALLINCKRODT INC	50GM/BOT	N006383	002		Apr	CAHN
>A>			100GM/BOT	N006383	003		Apr	CAHN
>A>			500GM/BOT	N006383	004		Apr	CAHN

SYRUP; ORAL

DOLOPHINE HYDROCHLORIDE
@ WEST-WARD PHARMS INT

	10MG/30ML	N006134	004		Jan	CAHN
--	-----------	---------	-----	--	-----	------

TABLET; ORAL

DOLOPHINE HYDROCHLORIDE

AA	+!	WEST-WARD PHARMS INT	5MG	N006134	002		Jan	CAHN
AA	+!		10MG	N006134	010		Jan	CAHN

TABLET, FOR SUSPENSION; ORAL

METHADONE HYDROCHLORIDE

AA	+!	WEST-WARD PHARMS INT	40MG	N017058	001		Jan	CAHN
----	----	----------------------	------	---------	-----	--	-----	------

METHENAMINE HIPPURATE

TABLET; ORAL

METHENAMINE HIPPURATE

AB		IMPAX LABS INC	1GM	A076411	001	Jun 20, 2003	Feb	CAHN
----	--	----------------	-----	---------	-----	--------------	-----	------

METHIMAZOLE

TABLET; ORAL

TAPAZOLE

AB		KING PHARMS LLC	5MG	A040320	001	Mar 31, 2000	Feb	CAHN
AB			10MG	A040320	002	Mar 31, 2000	Feb	CAHN

METHOCARBAMOL

SOLUTION; IM-IV

METHOCARBAMOL

AP		RENAISSANCE PHARMA	1GM/10ML (100MG/ML)	A208116	001	Jan 19, 2017	Jan	NEWA
AP		RENAISSANCE SSA LLC	1GM/10ML (100MG/ML)	A208116	001	Jan 19, 2017	Mar	CAHN

TABLET; ORAL

METHOCARBAMOL

AA		ATLAS PHARMS LLC	500MG	A203550	001	Feb 08, 2017	Jan	NEWA
AA			750MG	A203550	002	Feb 08, 2017	Jan	NEWA

METHOTREXATE SODIUM

INJECTABLE; INJECTION

METHOTREXATE SODIUM PRESERVATIVE FREE

>A>	AP	PHARMACHEMIE BV	EQ 50MG BASE/2ML (EQ 25MG BASE/ML)	A040843	002	Jan 11, 2010	Apr	CMS1
>A>	AP		EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	A040843	003	Feb 27, 2012	Apr	CMS1
>A>	AP		EQ 250MG BASE/10ML (EQ 25MG BASE/ML)	A040843	004	Jan 11, 2010	Apr	CMS1

>A>	SOLUTION;ORAL								
>A>	XATMEP								
>A>	+! SILVERGATE PHARMS	EQ 2.5MG BASE/ML		N208400	001	Apr 25, 2017	Apr	NEWA	
	TABLET;ORAL								
	METHOTREXATE SODIUM								
AB	ZYDUS PHARMS USA INC	EQ 2.5MG BASE		A207812	001	Jan 13, 2017	Jan	NEWA	
	<u>METHYLDOPATE HYDROCHLORIDE</u>								
	INJECTABLE;INJECTION								
	METHYLDOPATE HYDROCHLORIDE								
!	LUITPOLD	50MG/ML		A071279	001	Oct 02, 1987	Jan	CTEC	
	<u>METHYLPHENIDATE HYDROCHLORIDE</u>								
	CAPSULE, EXTENDED RELEASE;ORAL								
	METHYLPHENIDATE HYDROCHLORIDE								
AB2	IMPAX LABS INC	10MG		A205105	001	Jul 28, 2016	Feb	CAHN	
AB2		20MG		A205105	002	Jul 28, 2016	Feb	CAHN	
AB2		30MG		A205105	003	Jul 28, 2016	Feb	CAHN	
AB2		40MG		A205105	004	Jul 28, 2016	Feb	CAHN	
AB2		50MG		A205105	005	Jul 28, 2016	Feb	CAHN	
AB2		60MG		A205105	006	Jul 28, 2016	Feb	CAHN	
!	MAYNE PHARMA	60MG		A078458	004	Jun 23, 2016	Feb	CHRS	
	RITALIN LA								
+ @	NOVARTIS	60MG		N021284	005	Oct 27, 2014	Feb	DISC	
	TABLET;ORAL								
	METHYLPHENIDATE HYDROCHLORIDE								
>A> AB	ABHAI INC	5MG		A206932	001	May 11, 2017	Apr	NEWA	
>A> AB		10MG		A206932	002	May 11, 2017	Apr	NEWA	
>A> AB		20MG		A206932	003	May 11, 2017	Apr	NEWA	
AB	IMPAX LABS INC	5MG		A091159	001	Mar 12, 2014	Feb	CAHN	
AB		10MG		A091159	002	Mar 12, 2014	Feb	CAHN	
AB		20MG		A091159	003	Mar 12, 2014	Feb	CAHN	
AB	NOSTRUM LABS INC	5MG		A207587	001	Mar 03, 2017	Feb	NEWA	
AB		10MG		A207587	002	Mar 03, 2017	Feb	NEWA	
AB		20MG		A207587	003	Mar 03, 2017	Feb	NEWA	
	TABLET, CHEWABLE;ORAL								
	METHYLPHENIDATE HYDROCHLORIDE								
AB	NOSTRUM LABS INC	2.5MG		A204954	001	Jan 26, 2017	Jan	NEWA	
AB		5MG		A204954	002	Jan 26, 2017	Jan	NEWA	
AB		10MG		A204954	003	Jan 26, 2017	Jan	NEWA	
	TABLET, EXTENDED RELEASE;ORAL								
	RITALIN-SR								
AB	+ NOVARTIS	20MG		N018029	001	Mar 30, 1982	Feb	CRLD	
	<u>METHYLPREDNISOLONE ACETATE</u>								
	INJECTABLE;INJECTION								
	METHYLPREDNISOLONE ACETATE								
AB	SANDOZ INC	40MG/ML		A040719	001	Jan 29, 2009	Mar	CAHN	
AB		80MG/ML		A040719	002	Jan 29, 2009	Mar	CAHN	
	<u>METHYLPREDNISOLONE SODIUM SUCCINATE</u>								
	INJECTABLE;INJECTION								
	A-METHAPRED								
@	HOSPIRA INC	EQ 40MG BASE/VIAL		A040793	001	Nov 25, 2008	Jan	DISC	
@		EQ 125MG BASE/VIAL		A040827	001	Nov 25, 2008	Jan	DISC	
	<u>METIPRANOLOL HYDROCHLORIDE</u>								
	SOLUTION/DROPS;OPHTHALMIC								
	METIPRANOLOL								
AT	SANDOZ INC	0.3%		A075720	001	Aug 06, 2001	Feb	CAHN	
	<u>METOCLOPRAMIDE HYDROCHLORIDE</u>								
	TABLET;ORAL								
	METOCLOPRAMIDE HYDROCHLORIDE								
@	NORTHSTAR HLTHCARE	EQ 5MG BASE		A078374	001	Nov 30, 2007	Feb	DISC	
@		EQ 10MG BASE		A078374	002	Nov 30, 2007	Feb	DISC	

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE;ORAL
TOPROL-XL

AB	+	ARALEZ PHARMS	EQ 25MG TARTRATE	N019962	004	Feb 05, 2001	Jan CAHN
AB	+	!	EQ 50MG TARTRATE	N019962	001	Jan 10, 1992	Jan CAHN
AB	+		EQ 100MG TARTRATE	N019962	002	Jan 10, 1992	Jan CAHN
AB	+	!	EQ 200MG TARTRATE	N019962	003	Jan 10, 1992	Jan CAHN

METOPROLOL TARTRATE

INJECTABLE; INJECTION
METOPROLOL TARTRATE

AP		SANDOZ INC	1MG/ML	A077360	001	Oct 02, 2007	Mar CAHN
AP		WEST-WARD PHARMS INT	1MG/ML	A076495	001	Jul 07, 2003	Jan CAHN

METRONIDAZOLE

GEL; TOPICAL
METRONIDAZOLE

AB		TARO PHARM	1%	A204651	001	Mar 14, 2017	Feb NEWA
----	--	------------	----	---------	-----	--------------	----------

INJECTABLE; INJECTION
METRONIDAZOLE IN PLASTIC CONTAINER

>A>	AP	MYLAN LABS LTD	500MG/100ML	A205531	001	May 09, 2017	Apr NEWA
-----	----	----------------	-------------	---------	-----	--------------	----------

MICONAZOLE NITRATE; PETROLATUM, WHITE; ZINC OXIDE

OINTMENT; TOPICAL
VUSION

+	!	MYLAN PHARMS INC	0.25%;81.35%;15%	N021026	001	Feb 16, 2006	Jan CAHN
---	---	------------------	------------------	---------	-----	--------------	----------

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION
MIDAZOLAM HYDROCHLORIDE

AP		FRESENIUS KABI USA	EQ 5MG BASE/ML	A208878	001	Mar 28, 2017	Mar NEWA
AP		WEST-WARD PHARMS INT	EQ 1MG BASE/ML	A075243	001	Jun 20, 2000	Jan CAHN
AP			EQ 1MG BASE/ML	A075247	002	Jun 23, 2000	Jan CAHN
AP			EQ 1MG BASE/ML	A075324	001	Jun 20, 2000	Mar CAHN
AP			EQ 1MG BASE/ML	A075421	002	Jun 20, 2000	Jan CAHN
AP			EQ 5MG BASE/ML	A075243	002	Jun 20, 2000	Jan CAHN
AP			EQ 5MG BASE/ML	A075247	001	Jun 23, 2000	Jan CAHN
AP			EQ 5MG BASE/ML	A075324	002	Jun 20, 2000	Mar CAHN
AP			EQ 5MG BASE/ML	A075421	001	Jun 20, 2000	Jan CAHN

MIDODRINE HYDROCHLORIDE

TABLET; ORAL
PROAMATINE

+	@	SHIRE LLC	2.5MG	N019815	001	Sep 06, 1996	Feb CRLD
+	@		5MG	N019815	002	Sep 06, 1996	Feb CRLD
+	@		10MG	N019815	003	Mar 20, 2002	Feb CRLD

>A> MIDOSTAURIN

>A> CAPSULE; ORAL
>A> RYDAPT

>A>	+	!	NOVARTIS PHARMS CORP	25MG	N207997	001	Apr 28, 2017	Apr NEWA
-----	---	---	----------------------	------	---------	-----	--------------	----------

MILNACIPRAN HYDROCHLORIDE

TABLET; ORAL
SAVELLA

AB	+	ALLERGAN SALES LLC	12.5MG	N022256	001	Jan 14, 2009	Feb CAHN
AB	+		25MG	N022256	002	Jan 14, 2009	Feb CAHN
AB	+	!	50MG	N022256	003	Jan 14, 2009	Feb CAHN
AB	+		100MG	N022256	004	Jan 14, 2009	Feb CAHN

MILRINONE LACTATE

INJECTABLE; INJECTION
MILRINONE LACTATE

AP		WEST-WARD PHARMS INT	EQ 1MG BASE/ML	A075530	001	May 28, 2002	Jan CAHN	
AP			EQ 1MG BASE/ML	A075660	001	May 28, 2002	Jan CAHN	
		@	EQ 1MG BASE/ML	A075852	001	May 28, 2002	Mar CAHN	
			MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER					
		@	WEST-WARD PHARMS INT	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A075510	001	May 28, 2002	Mar CAHN
AP			EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A078113	001	May 21, 2008	Jan CAHN	

INJECTABLE; INJECTION

MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER						
AP		EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)	A078113	002	May 21, 2008	Jan CAHN
PRIMACOR IN DEXTROSE 5% IN PLASTIC CONTAINER						
+ @	SANOVI AVENTIS US	EQ 10MG BASE/100ML	N020343	001	Aug 09, 1994	Jan CRLD
+ @		EQ 15MG BASE/100ML	N020343	002	Aug 09, 1994	Jan CRLD
+ @		EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	N020343	003	Aug 09, 1994	Jan CRLD
+ @		EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)	N020343	004	Aug 09, 1994	Jan CRLD

MINOCYCLINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

XIMINO

>D>	@ SUN PHARM INDS LTD	EQ 45MG BASE	N201922	001	Jul 11, 2012	Apr CMFD
>A>		EQ 45MG BASE	N201922	001	Jul 11, 2012	Apr CMFD
>D>	@	EQ 90MG BASE	N201922	003	Jul 11, 2012	Apr CMFD
>A>		EQ 90MG BASE	N201922	003	Jul 11, 2012	Apr CMFD
>D>	@	EQ 135MG BASE	N201922	005	Jul 11, 2012	Apr CMFD
>A>		EQ 135MG BASE	N201922	005	Jul 11, 2012	Apr CMFD

TABLET, EXTENDED RELEASE; ORAL

MINOCYCLINE HYDROCHLORIDE

>A>	@ BARR LABS INC	EQ 80MG BASE	A065485	007	Apr 26, 2017	Apr DISC
>A>		EQ 80MG BASE	A065485	007	Apr 26, 2017	Apr NEWA
>A>	@	EQ 105MG BASE	A065485	008	Apr 26, 2017	Apr DISC
>A>		EQ 105MG BASE	A065485	008	Apr 26, 2017	Apr NEWA

MIRABEGRON

TABLET, EXTENDED RELEASE; ORAL

MYRBETRIQ

+!	APGDI	25MG	N202611	001	Jun 28, 2012	Feb CHRS
----	-------	------	---------	-----	--------------	----------

MIRTAZAPINE

TABLET, ORALLY DISINTEGRATING; ORAL

MIRTAZAPINE

AB	AUROBINDO PHARMA LTD	15MG	A077376	002	Dec 08, 2005	Jan CAHN
AB		30MG	A077376	003	Dec 08, 2005	Jan CAHN
AB		45MG	A077376	004	Feb 28, 2006	Jan CAHN

MITOMYCIN

INJECTABLE; INJECTION

MITOMYCIN

AP	WEST-WARD PHARMS INT	5MG/VIAL	A064117	001	Apr 19, 1995	Jan CAHN
AP		5MG/VIAL	A064180	001	Dec 23, 1999	Jan CAHN
AP		20MG/VIAL	A064117	002	Apr 19, 1995	Jan CAHN
AP		20MG/VIAL	A064180	002	Dec 23, 1999	Jan CAHN
MUTAMYCIN						
+ @	BRISTOL	5MG/VIAL	N050450	001		Jan CRLD
+ @		20MG/VIAL	N050450	002		Jan CRLD

MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL

MOEXIPRIL HYDROCHLORIDE

>A>	AB	CHARTWELL RX	7.5MG	A077536	001	Nov 30, 2006	Apr CAHN
>A>	AB		15MG	A077536	002	Nov 30, 2006	Apr CAHN
>D>	AB	PADDOCK LLC	7.5MG	A077536	001	Nov 30, 2006	Apr CAHN
>D>	AB		15MG	A077536	002	Nov 30, 2006	Apr CAHN

MOMETASONE FUROATE

LOTION; TOPICAL

MOMETASONE FUROATE

>D>	AB	PERRIGO	0.1%	A077180	001	Apr 06, 2005	Apr CAHN
>A>	AB	PERRIGO ISRAEL	0.1%	A077180	001	Apr 06, 2005	Apr CAHN

SPRAY, METERED; NASAL

MOMETASONE FUROATE

AB	AMNEAL PHARMS	EQ 0.05MG BASE/SPRAY	A207989	001	Apr 03, 2017	Mar NEWA
----	---------------	----------------------	---------	-----	--------------	----------

MONTELUKAST SODIUM

TABLET;ORAL

MONTELUKAST SODIUM

>A>	AB	CSPC OUYI PHARM CO	EQ 10MG BASE	A209012	001	Apr 24, 2017	Apr	NEWA
>A>	AB	PERRIGO R AND D	EQ 10MG BASE	A206112	001	Apr 26, 2017	Apr	NEWA

TABLET, CHEWABLE;ORAL

MONTELUKAST SODIUM

>A>	AB	CSPC OUYI PHARM CO	EQ 4MG BASE	A209011	001	Apr 18, 2017	Apr	NEWA
>A>	AB		EQ 5MG BASE	A209011	002	Apr 18, 2017	Apr	NEWA

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

MORPHINE SULFATE

>D>		ACTAVIS ELIZABETH	30MG	A079040	001	Jan 16, 2013	Apr	CAHN
>A>			30MG	A079040	001	Jan 16, 2013	Apr	CAHN
>D>			45MG	A079040	002	Jan 16, 2013	Apr	CAHN
>A>			45MG	A079040	002	Jan 16, 2013	Apr	CAHN
>D>			60MG	A079040	003	Jan 16, 2013	Apr	CAHN
>A>			60MG	A079040	003	Jan 16, 2013	Apr	CAHN
>D>			75MG	A079040	004	Jan 16, 2013	Apr	CAHN
>A>			75MG	A079040	004	Jan 16, 2013	Apr	CAHN
>D>			90MG	A079040	005	Jan 16, 2013	Apr	CAHN
>A>			90MG	A079040	005	Jan 16, 2013	Apr	CAHN
>D>	!		120MG	A079040	006	Jan 16, 2013	Apr	CAHN
>A>	!		120MG	A079040	006	Jan 16, 2013	Apr	CAHN

INJECTABLE;INJECTION

MORPHINE SULFATE

>D>	AP	! HOSPIRA	1MG/ML	N019916	001	Oct 30, 1992	Apr	CAHN
>D>		! HOSPIRA	5MG/ML	N019916	002	Oct 27, 2006	Apr	CAHN
>A>	AP	! ICU MEDCL	1MG/ML	N019916	001	Oct 30, 1992	Apr	CAHN
>A>		! ICU MEDCL	5MG/ML	N019916	002	Oct 27, 2006	Apr	CAHN
>D>		@ MALLINCKRODT	1MG/ML	N020631	001	Jul 03, 1996	Apr	CAHN
>D>		@ MALLINCKRODT	2MG/ML	N020631	002	Jul 03, 1996	Apr	CAHN
>A>		@ MALLINCKRODT INC	1MG/ML	N020631	001	Jul 03, 1996	Apr	CAHN
>A>		@ MALLINCKRODT INC	2MG/ML	N020631	002	Jul 03, 1996	Apr	CAHN

SOLUTION;ORAL

MORPHINE SULFATE

AA	+	WEST-WARD PHARMS INT	10MG/5ML	N022195	001	Mar 17, 2008	Jan	CAHN
AA	+	WEST-WARD PHARMS INT	20MG/5ML	N022195	002	Mar 17, 2008	Jan	CAHN
AA	!+	WEST-WARD PHARMS INT	100MG/5ML	N022195	003	Jan 25, 2010	Jan	CAHN

TABLET;ORAL

MORPHINE SULFATE

+		WEST-WARD PHARMS INT	15MG	N022207	001	Mar 17, 2008	Jan	CAHN
!+		WEST-WARD PHARMS INT	30MG	N022207	002	Mar 17, 2008	Jan	CAHN

TABLET, EXTENDED RELEASE;ORAL

ARYMO ER

+		EGALET	15MG	N208603	001	Jan 09, 2017	Jan	NEWA
+		EGALET	30MG	N208603	002	Jan 09, 2017	Jan	NEWA
+		EGALET	60MG	N208603	003	Jan 09, 2017	Jan	NEWA

MORPHABOND ER

+		DAIICHI SANKYO INC	15MG	N206544	001	Oct 02, 2015	Jan	CTNA
+		DAIICHI SANKYO INC	30MG	N206544	002	Oct 02, 2015	Jan	CTNA
+		DAIICHI SANKYO INC	60MG	N206544	003	Oct 02, 2015	Jan	CTNA
!+		DAIICHI SANKYO INC	100MG	N206544	004	Oct 02, 2015	Jan	CTNA

MORPHINE SULFATE

>D>	AB	ACTAVIS ELIZABETH	15MG	A203849	001	Apr 06, 2015	Apr	CAHN
>A>	AB	ACTAVIS ELIZABETH	15MG	A203849	001	Apr 06, 2015	Apr	CAHN
>D>	AB	ACTAVIS ELIZABETH	30MG	A203849	002	Apr 06, 2015	Apr	CAHN
>A>	AB	ACTAVIS ELIZABETH	30MG	A203849	002	Apr 06, 2015	Apr	CAHN
>D>	AB	ACTAVIS ELIZABETH	60MG	A203849	003	Apr 06, 2015	Apr	CAHN
>A>	AB	ACTAVIS ELIZABETH	60MG	A203849	003	Apr 06, 2015	Apr	CAHN
>D>	AB	ACTAVIS ELIZABETH	100MG	A203849	004	Apr 06, 2015	Apr	CAHN
>A>	AB	ACTAVIS ELIZABETH	100MG	A203849	004	Apr 06, 2015	Apr	CAHN
>D>	AB	ACTAVIS ELIZABETH	200MG	A203849	005	Apr 06, 2015	Apr	CAHN
>A>	AB	ACTAVIS ELIZABETH	200MG	A203849	005	Apr 06, 2015	Apr	CAHN
	AB	SUN PHARM INDS	15MG	A205634	001	Aug 25, 2016	Mar	CAHN
	AB	SUN PHARM INDS	30MG	A205634	002	Aug 25, 2016	Mar	CAHN
	AB	SUN PHARM INDS	60MG	A205634	003	Aug 25, 2016	Mar	CAHN
	AB	SUN PHARM INDS	100MG	A205634	004	Aug 25, 2016	Mar	CAHN
	AB	SUN PHARM INDS	200MG	A205634	005	Aug 25, 2016	Mar	CAHN

MOXIFLOXACIN HYDROCHLORIDE

SOLUTION;IV (INFUSION)

AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER

>D>	+	BAYER HLTHCARE	400MG/250ML (1.6MG/ML)	N021277	001	Nov 30, 2001	Apr	CFTG	
>A>	AP	+	400MG/250ML (1.6MG/ML)	N021277	001	Nov 30, 2001	Apr	CFTG	
>A>			MOXIFLOXACIN HYDROCHLORIDE IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER						
>A>	AP		MYLAN LABS LTD	400MG/250ML (1.6MG/ML)	A205833	001	May 05, 2017	Apr	NEWA

TABLET;ORAL

MOXIFLOXACIN HYDROCHLORIDE

AB		NOVEL LABS INC	EQ 400MG BASE	A207285	001	Feb 13, 2017	Jan	NEWA
----	--	----------------	---------------	---------	-----	--------------	-----	------

MYCOPHENOLATE MOFETIL HYDROCHLORIDE

INJECTABLE;INJECTION

MYCOPHENOLATE MOFETIL HYDROCHLORIDE

AP		AKORN INC	500MG/VIAL	A204043	001	Feb 28, 2017	Feb	NEWA
AP		MYLAN LABS LTD	500MG/VIAL	A203859	001	Mar 31, 2017	Mar	NEWA

NABILONE

CAPSULE;ORAL

CESAMET

+	!	MYLAN SPECIALITY LP	1MG	N018677	001	Dec 26, 1985	Mar	CAHN
---	---	---------------------	-----	---------	-----	--------------	-----	------

NAFTIFINE HYDROCHLORIDE

CREAM;TOPICAL

NAFTIFINE HYDROCHLORIDE

AB		TOLMAR	2%	A206960	001	Apr 10, 2017	Mar	NEWA
----	--	--------	----	---------	-----	--------------	-----	------

NALDEMEDINE TOSYLATE

TABLET;ORAL

SYMPROIC

+	!	SHIONOGI INC	EQ 0.2MG BASE	N208854	001	Mar 23, 2017	Mar	NEWA
---	---	--------------	---------------	---------	-----	--------------	-----	------

NALOXONE HYDROCHLORIDE

INJECTABLE;INJECTION

NALOXONE

@ WEST-WARD PHARMS INT 0.4MG/ML

A070298 001 Sep 24, 1986 Jan CAHN

@ 0.4MG/ML

A070496 001 Sep 24, 1986 Jan CAHN

NALOXONE HYDROCHLORIDE

AP		AKORN	0.4MG/ML	A208871	001	Feb 28, 2017	Feb	NEWA
AP			0.4MG/ML	A208872	001	Mar 14, 2017	Feb	NEWA

SPRAY, METERED;NASAL

NARCAN

+		ADAPT	2MG/SPRAY	N208411	002	Jan 24, 2017	Jan	NEWA
---	--	-------	-----------	---------	-----	--------------	-----	------

NAPROXEN

TABLET;ORAL

NAPROXEN

AB		AUROBINDO PHARMA LTD	250MG	A200429	001	Nov 08, 2011	Jan	CAHN
AB			375MG	A200429	002	Nov 08, 2011	Jan	CAHN
AB			500MG	A200429	003	Nov 08, 2011	Jan	CAHN

NATAMYCIN

SUSPENSION;OPHTHALMIC

NATACYN

+	!	NOVARTIS PHARMS CORP	5%	N050514	001		Jan	CAHN
---	---	----------------------	----	---------	-----	--	-----	------

NELFINAVIR MESYLATE

POWDER;ORAL

VIRACEPT

@ AGOURON PHARMS EQ 50MG BASE/SCOOPFUL

N020778 001 Mar 14, 1997 Jan CAHN

TABLET;ORAL

VIRACEPT

+	!	AGOURON PHARMS	EQ 250MG BASE	N020779	001	Mar 14, 1997	Jan	CAHN
+	!		EQ 625MG BASE	N021503	001	Apr 30, 2003	Jan	CAHN

NEOMYCIN SULFATE

SOLUTION;ORAL
NEO-FRADIN
@ X GEN PHARMS

EQ 87.5MG BASE/5ML

A065010 001 May 23, 2002 Feb DISC

NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION;IRRIGATION
NEOSPORIN G.U. IRRIGANT

>D> AT ! MONARCH PHARMS EQ 40MG BASE/ML;200,000 UNITS/ML
>A> AT ! EQ 40MG BASE/ML;200,000 UNITS/ML

A060707 001 Apr CAHN
A060707 001 Apr CAHN

NEOSTIGMINE METHYLSULFATE

SOLUTION;INTRAVENOUS
NEOSTIGMINE METHYLSULFATE

>A> AP PAR STERILE PRODUCTS 5MG/10ML (0.5MG/ML)
>A> AP 10MG/10ML (1MG/ML)

A208405 001 Apr 26, 2017 Apr NEWA
A208405 002 Apr 26, 2017 Apr NEWA

NEVIRAPINE

TABLET, EXTENDED RELEASE;ORAL
NEVIRAPINE

AB AUROBINDO PHARMA LTD 400MG
AB AUROBINDO PHARMA USA 400MG

A207698 001 Feb 28, 2017 Mar CAHN
A207698 001 Feb 28, 2017 Feb NEWA

NICARDIPINE HYDROCHLORIDE

INJECTABLE;INJECTION
NICARDIPINE HYDROCHLORIDE

AP WEST-WARD PHARMS INT 25MG/10ML (2.5MG/ML)

A078714 001 Dec 28, 2009 Jan CAHN

INJECTABLE;INTRAVENOUS

NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE

EXELA PHARMA SCIENCE 20MG/200ML (0.1MG/ML)
40MG/200ML (0.2MG/ML)

N022276 002 Apr 07, 2016 Feb NEWA
N022276 003 Apr 07, 2016 Feb NEWA

NIFEDIPINE

TABLET, EXTENDED RELEASE;ORAL
NIFEDIPINE

AB2 MYLAN LABS LTD 30MG
AB2 60MG
AB2 90MG

A090602 001 Sep 13, 2010 Mar CAHN
A090602 002 Sep 13, 2010 Mar CAHN
A090602 003 Sep 13, 2010 Mar CAHN

NIRAPARIB TOSYLATE

CAPSULE;ORAL
ZEJULA

+! TESARO INC EQ 100MG BASE

N208447 001 Mar 27, 2017 Mar NEWA

NITROGLYCERIN

OINTMENT;TRANSDERMAL
NITROGLYCERIN

! FOUGERA PHARMS INC 2%

A087355 001 Jul 08, 1988 Jan CAHN

NOREPINEPHRINE BITARTRATE

INJECTABLE;INJECTION
NOREPINEPHRINE BITARTRATE

AP WEST-WARD PHARMS INT EQ 1MG BASE/ML

A040462 001 Oct 31, 2003 Jan CAHN

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE;ORAL
NORTRIPTYLINE HYDROCHLORIDE

AB TARO PHARM EQ 10MG BASE
AB EQ 25MG BASE
AB EQ 50MG BASE
AB EQ 75MG BASE

A075520 004 May 08, 2000 Mar CAHN
A075520 003 May 08, 2000 Mar CAHN
A075520 001 May 08, 2000 Mar CAHN
A075520 002 May 08, 2000 Mar CAHN

NYSTATIN

SUSPENSION;ORAL
NYSTATIN

AA FOUGERA PHARMS INC 100,000 UNITS/ML
>D> AA TARO 100,000 UNITS/ML
>A> AA TARO PHARM 100,000 UNITS/ML

A062517 001 Jun 07, 1984 Jan CAHN
A062876 001 Feb 29, 1988 Apr CAHN
A062876 001 Feb 29, 1988 Apr CAHN

NYSTATIN; TRIAMCINOLONE ACETONIDE

	CREAM; TOPICAL								
	MYCOLOG-II								
	@ MYLAN PHARMS INC	100,000 UNITS/GM;0.1%	A062606	001	May 15, 1985	Jan	CAHN		
	NYSTATIN AND TRIAMCINOLONE ACETONIDE								
AT	FOUGERA PHARMS INC	100,000 UNITS/GM;0.1%	A062599	001	Oct 08, 1985	Jan	CAHN		
	OINTMENT; TOPICAL								
	MYCOLOG-II								
	@ MYLAN PHARMS INC	100,000 UNITS/GM;0.1%	A060572	001	Jun 28, 1985	Jan	CAHN		
	NYSTATIN AND TRIAMCINOLONE ACETONIDE								
AT	DR REDDYS LABS LTD	100,000 UNITS/GM;0.1%	A207741	001	Jan 31, 2017	Jan	NEWA		
AT	FOUGERA PHARMS INC	100,000 UNITS/GM;0.1%	A062602	001	Oct 09, 1985	Jan	CAHN		

OFLOXACIN

	SOLUTION/DROPS; OPHTHALMIC								
	OFLOXACIN								
AT	SANDOZ INC	0.3%	A076231	001	May 14, 2004	Feb	CAHN		
	SOLUTION/DROPS; OTIC								
	OFLOXACIN								
AT	SANDOZ INC	0.3%	A078222	001	Mar 17, 2008	Feb	CAHN		

OLANZAPINE

	TABLET; ORAL								
	OLANZAPINE								
AB	MYLAN PHARMS INC	2.5MG	A076866	001	Apr 23, 2012	Mar	CAHN		
AB		5MG	A076866	002	Apr 23, 2012	Mar	CAHN		
AB		7.5MG	A076866	003	Apr 23, 2012	Mar	CAHN		
AB		10MG	A076866	004	Apr 23, 2012	Mar	CAHN		
AB		15MG	A076866	005	Apr 23, 2012	Mar	CAHN		
AB		20MG	A076866	006	Apr 23, 2012	Mar	CAHN		

OLAPARIB

	CAPSULE; ORAL								
	LYNPARZA								
	+! ASTRAZENECA PHARMS	50MG	N206162	001	Dec 19, 2014	Mar	CRLD		

OLMESARTAN MEDOXOMIL

	TABLET; ORAL								
	OLMESARTAN MEDOXOMIL								
>A>	AB	ACCORD HLTHCARE	5MG	A207662	001	Apr 24, 2017	Apr	NEWA	
>A>	AB		20MG	A207662	002	Apr 24, 2017	Apr	NEWA	
>A>	AB		40MG	A207662	003	Apr 24, 2017	Apr	NEWA	
>A>	AB	ALEMBIC PHARMS LTD	5MG	A203012	001	Apr 24, 2017	Apr	NEWA	
>A>	AB		20MG	A203012	002	Apr 24, 2017	Apr	NEWA	
>A>	AB		40MG	A203012	003	Apr 24, 2017	Apr	NEWA	
>A>	AB	ALKEM LABS LTD	5MG	A206763	001	Apr 24, 2017	Apr	NEWA	
>A>	AB		20MG	A206763	002	Apr 24, 2017	Apr	NEWA	
>A>	AB		40MG	A206763	003	Apr 24, 2017	Apr	NEWA	
>A>	AB	AUROBINDO PHARMA LTD	5MG	A204798	001	Apr 24, 2017	Apr	NEWA	
>A>	AB		20MG	A204798	002	Apr 24, 2017	Apr	NEWA	
>A>	AB		40MG	A204798	003	Apr 24, 2017	Apr	NEWA	
>A>	AB	JUBILANT GENERICS	5MG	A205482	001	Apr 24, 2017	Apr	NEWA	
>A>	AB		20MG	A205482	002	Apr 24, 2017	Apr	NEWA	
>A>	AB		40MG	A205482	003	Apr 24, 2017	Apr	NEWA	
>A>	AB	LUPIN LTD	5MG	A206631	001	Apr 27, 2017	Apr	NEWA	
>A>	AB		20MG	A206631	002	Apr 27, 2017	Apr	NEWA	
>A>	AB		40MG	A206631	003	Apr 27, 2017	Apr	NEWA	
>A>	AB	MACLEODS PHARMS LTD	5MG	A204814	001	Apr 24, 2017	Apr	NEWA	
>A>	AB		20MG	A204814	002	Apr 24, 2017	Apr	NEWA	
>A>	AB		40MG	A204814	003	Apr 24, 2017	Apr	NEWA	
>A>	AB	TEVA PHARMS USA	5MG	A091079	001	Apr 24, 2017	Apr	NEWA	
>A>	AB		20MG	A091079	002	Apr 24, 2017	Apr	NEWA	
>A>	AB		40MG	A091079	003	Apr 24, 2017	Apr	NEWA	
>A>	AB	TORRENT PHARMS LTD	5MG	A202375	001	Apr 24, 2017	Apr	NEWA	
>A>	AB		20MG	A202375	002	Apr 24, 2017	Apr	NEWA	
>A>	AB		40MG	A202375	003	Apr 24, 2017	Apr	NEWA	
>A>	AB	ZYDUS PHARMS USA INC	5MG	A205192	001	Apr 24, 2017	Apr	NEWA	
>A>	AB		20MG	A205192	002	Apr 24, 2017	Apr	NEWA	
>A>	AB		40MG	A205192	003	Apr 24, 2017	Apr	NEWA	

OLOPATADINE HYDROCHLORIDE

SPRAY, METERED;NASAL
OLOPATADINE HYDROCHLORIDE

AB	PERRIGO ISRAEL	0.665MG/SPRAY	A202853	001	Jan 31, 2017	Jan	NEWA
----	----------------	---------------	---------	-----	--------------	-----	------

OLSALAZINE SODIUM

CAPSULE;ORAL
DIPENTUM

	+!	MYLAN SPECIALITY LP	250MG	N019715	001	Jul 31, 1990	Mar	CAHN
--	----	---------------------	-------	---------	-----	--------------	-----	------

OMACETAXINE MEPESUCCINATE

POWDER;SUBCUTANEOUS
SYNRIBO

>D>	+!	IVAX INTL	3.5MG/VIAL	N203585	001	Oct 26, 2012	Apr	CAHN
>A>	+!	TEVA PHARMS INTL	3.5MG/VIAL	N203585	001	Oct 26, 2012	Apr	CAHN

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL
OMEPRAZOLE

AB	AUROBINDO PHARMA LTD	10MG	A203270	001	Aug 19, 2015	Jan	CAHN
AB		20MG	A203270	002	Aug 19, 2015	Jan	CAHN
AB		40MG	A203270	003	Aug 19, 2015	Jan	CAHN

OMEPRAZOLE; SODIUM BICARBONATE

FOR SUSPENSION;ORAL
OMEPRAZOLE AND SODIUM BICARBONATE

AB	AJANTA PHARMA LTD	20MG/PACKET;1.68GM/PACKET	A205545	001	Jul 27, 2016	Jan	CTEC	
AB		40MG/PACKET;1.68GM/PACKET	A205545	002	Jul 27, 2016	Jan	CTEC	
AB	PAR PHARM	20MG/PACKET;1.68GM/PACKET	A079182	001	Apr 19, 2013	Jan	CMFD	
AB		40MG/PACKET;1.68GM/PACKET	A079182	002	Apr 19, 2013	Jan	CMFD	
	ZEGERID							
AB	+	SANTARUS INC	20MG/PACKET;1.68GM/PACKET	N021636	001	Jun 15, 2004	Jan	CTEC
AB	+!		40MG/PACKET;1.68GM/PACKET	N021636	002	Dec 21, 2004	Jan	CTEC

ONDANSETRON

TABLET, ORALLY DISINTEGRATING;ORAL
ONDANSETRON

	@	CHARTWELL MOLECULES	4MG	A076506	001	Dec 26, 2006	Mar	CAHN
	@		8MG	A076506	002	Dec 26, 2006	Mar	CAHN
	@		16MG	A077406	001	Dec 26, 2006	Mar	CAHN
	@		24MG	A077406	002	Dec 26, 2006	Mar	CAHN

ONDANSETRON HYDROCHLORIDE

INJECTABLE;INJECTION
ONDANSETRON HYDROCHLORIDE

AP	SANDOZ INC	EQ 2MG BASE/ML	A077430	001	Jun 27, 2007	Mar	CAHN	
AP	WEST-WARD PHARMS INT	EQ 2MG BASE/ML	A076967	001	Dec 26, 2006	Jan	CAHN	
	ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE							
AP	SANDOZ INC	EQ 2MG BASE/ML	A077551	001	Jun 27, 2007	Mar	CAHN	
AP	WEST-WARD PHARMS INT	EQ 2MG BASE/ML	A077011	001	Dec 26, 2006	Jan	CAHN	
AP		EQ 2MG BASE/ML	A077541	001	Dec 26, 2006	Jan	CAHN	
	ZOFTRAN							
	+	@ NOVARTIS PHARMS CORP	EQ 2MG BASE/ML	N020007	001	Jan 04, 1991	Mar	CRLD
		ZOFTRAN PRESERVATIVE FREE						
	+	@ NOVARTIS PHARMS CORP	EQ 2MG BASE/ML	N020007	003	Dec 10, 1993	Mar	CRLD

ORPHENADRINE CITRATE

INJECTABLE;INJECTION
NORFLEX

>D>	@	IGI LABS INC	30MG/ML	N013055	001		Apr	CAHN
>A>	@	TELIGENT	30MG/ML	N013055	001		Apr	CAHN

OSELTAMIVIR PHOSPHATE

CAPSULE;ORAL
OSELTAMIVIR PHOSPHATE

AB	NESHER PHARMS	EQ 30MG BASE	A208578	001	Feb 24, 2017	Feb	NEWA
AB		EQ 45MG BASE	A208578	002	Feb 24, 2017	Feb	NEWA
AB		EQ 75MG BASE	A208578	003	Feb 24, 2017	Feb	NEWA

OSPEMIFENETABLET; ORAL
OSPHENA

+! DUCHESNAY 60MG N203505 001 Feb 26, 2013 Mar CAHN

OXALIPLATININJECTABLE; IV (INFUSION)
ELOXATIN

+ @ SANOFI AVENTIS US 200MG/40ML (5MG/ML) N021759 003 Nov 17, 2006 Jan CRLD

OXALIPLATIN

AP ACCORD HLTHCARE 50MG/10ML (5MG/ML) A207474 001 Mar 21, 2017 Mar NEWA

AP 100MG/20ML (5MG/ML) A207474 002 Mar 21, 2017 Mar NEWA

AP 200MG/40ML (5MG/ML) A207474 003 Mar 21, 2017 Mar NEWA

AP CIPLA LTD 50MG/10ML (5MG/ML) A208523 001 Feb 10, 2017 Jan NEWA

AP 100MG/20ML (5MG/ML) A208523 002 Feb 10, 2017 Jan NEWA

AP FRESENIUS KABI USA 50MG/10ML (5MG/ML) A090030 001 Jan 31, 2017 Jan NEWA

AP 100MG/20ML (5MG/ML) A090030 002 Jan 31, 2017 Jan NEWA

AP 200MG/40ML (5MG/ML) A090030 003 Jan 31, 2017 Jan NEWA

AP GLAND PHARMA LTD 50MG/10ML (5MG/ML) A207325 001 Feb 10, 2017 Jan NEWA

AP 100MG/20ML (5MG/ML) A207325 002 Feb 10, 2017 Jan NEWA

AP ! QILU PHARM CO LTD 200MG/40ML (5MG/ML) A204368 003 Jun 07, 2016 Jan CTEC

OXAPROZINTABLET; ORAL
OXAPROZIN

>A> AB AMNEAL PHARMS CO 600MG A208633 001 May 04, 2017 Apr NEWA

OXAZEPAMTABLET; ORAL
OXAZEPAM

@ SUN PHARM INDS 15MG A070683 001 Jan 16, 1987 Jan CAHN

OXCARBAZEPINETABLET; ORAL
OXCARBAZEPINE

>D> AB CADISTA PHARMS 150MG A090239 001 Jan 25, 2010 Apr CAHN

>D> AB 300MG A090239 002 Jan 25, 2010 Apr CAHN

>D> AB 600MG A090239 003 Jan 25, 2010 Apr CAHN

>A> AB JUBILANT CADISTA 150MG A090239 001 Jan 25, 2010 Apr CAHN

>A> AB 300MG A090239 002 Jan 25, 2010 Apr CAHN

>A> AB 600MG A090239 003 Jan 25, 2010 Apr CAHN

OXYBUTYNINGEL, METERED; TRANSDERMAL
GELNIQUE 3%

+ @ ALLERGAN SALES LLC 3% N202513 001 Dec 07, 2011 Feb DISC

OXYBUTYNIN CHLORIDESYRUP; ORAL
DITROPAN

+ @ ORTHO MCNEIL JANSSEN 5MG/5ML N018211 001 Jan CRLD

OXYCODONE HYDROCHLORIDETABLET; ORAL
ROXYBOND

>A> INSPIRION DELIVERY 5MG N209777 001 Apr 20, 2017 Apr NEWA

>A> 15MG N209777 002 Apr 20, 2017 Apr NEWA

>A> 30MG N209777 003 Apr 20, 2017 Apr NEWA

OXYMETAZOLINE HYDROCHLORIDECREAM; TOPICAL
RHOFAGE

+! ALLERGAN INC 1% N208552 001 Jan 18, 2017 Jan NEWA

OXYMETHOLONETABLET; ORAL
ANADROL-50

+! MYLAN SPECIALITY LP 50MG N016848 001 Mar CAHN

OXYMORPHONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL
OXYMORPHONE HYDROCHLORIDE

>D>	AB	ACTAVIS ELIZABETH	5MG	A079046	003	Jul 11, 2013	Apr	CAHN
>A>	AB		5MG	A079046	003	Jul 11, 2013	Apr	CAHN
>D>	AB		7.5MG	A079046	001	Dec 13, 2010	Apr	CAHN
>A>	AB		7.5MG	A079046	001	Dec 13, 2010	Apr	CAHN
>D>	AB		10MG	A079046	004	Jul 11, 2013	Apr	CAHN
>A>	AB		10MG	A079046	004	Jul 11, 2013	Apr	CAHN
>D>	AB		15MG	A079046	002	Dec 13, 2010	Apr	CAHN
>A>	AB		15MG	A079046	002	Dec 13, 2010	Apr	CAHN
>D>	AB		20MG	A079046	005	Jul 11, 2013	Apr	CAHN
>A>	AB		20MG	A079046	005	Jul 11, 2013	Apr	CAHN
>D>	AB		30MG	A079046	006	Jul 11, 2013	Apr	CAHN
>A>	AB		30MG	A079046	006	Jul 11, 2013	Apr	CAHN
>D>	AB		40MG	A079046	007	Jul 11, 2013	Apr	CAHN
>A>	AB		40MG	A079046	007	Jul 11, 2013	Apr	CAHN

PANTOPRAZOLE SODIUM

TABLET, DELAYED RELEASE;ORAL
PANTOPRAZOLE SODIUM

AB	SUN PHARM INDS LTD	EQ 20MG BASE	A077058	001	Sep 10, 2007	Mar	CAHN
AB		EQ 40MG BASE	A077058	002	Sep 10, 2007	Mar	CAHN

PARICALCITOL

SOLUTION;INTRAVENOUS
PARICALCITOL

AP	AMNEAL PHARMS CO	0.002MG/ML (0.002MG/ML)	A206699	001	Mar 09, 2017	Feb	NEWA	
AP		0.005MG/ML (0.005MG/ML)	A206699	002	Mar 09, 2017	Feb	NEWA	
AP		0.01MG/2ML (0.005MG/ML)	A206699	003	Mar 09, 2017	Feb	NEWA	
>D>	AP	SANDOZ CANADA INC	0.002MG/ML (0.002MG/ML)	A091108	001	Jul 27, 2011	Apr	CAHN
>D>	AP		0.005MG/ML (0.005MG/ML)	A091108	002	Jul 27, 2011	Apr	CAHN
>D>	AP		0.01MG/2ML (0.005MG/ML)	A091108	003	Jul 27, 2011	Apr	CAHN
>A>	AP	SANDOZ INC	0.002MG/ML (0.002MG/ML)	A091108	001	Jul 27, 2011	Apr	CAHN
>A>	AP		0.005MG/ML (0.005MG/ML)	A091108	002	Jul 27, 2011	Apr	CAHN
>A>	AP		0.01MG/2ML (0.005MG/ML)	A091108	003	Jul 27, 2011	Apr	CAHN

PAROXETINE HYDROCHLORIDE

TABLET;ORAL
PAROXETINE HYDROCHLORIDE

>D>	AB	MYLAN PHARMS INC	EQ 10MG BASE	A075716	001	Mar 08, 2004	Apr	DISC
>A>		@	EQ 10MG BASE	A075716	001	Mar 08, 2004	Apr	DISC
>D>	AB		EQ 20MG BASE	A075716	002	Mar 08, 2004	Apr	DISC
>A>		@	EQ 20MG BASE	A075716	002	Mar 08, 2004	Apr	DISC
>D>	AB		EQ 30MG BASE	A075716	003	Mar 08, 2004	Apr	DISC
>A>		@	EQ 30MG BASE	A075716	003	Mar 08, 2004	Apr	DISC
>D>	AB		EQ 40MG BASE	A075716	004	Mar 08, 2004	Apr	DISC
>A>		@	EQ 40MG BASE	A075716	004	Mar 08, 2004	Apr	DISC

TABLET, EXTENDED RELEASE;ORAL
PAROXETINE HYDROCHLORIDE

AB	LUPIN LTD	EQ 12.5MG BASE	A204134	001	Jan 20, 2017	Jan	NEWA
AB		EQ 25MG BASE	A204134	002	Jan 20, 2017	Jan	NEWA
AB		EQ 37.5MG BASE	A204134	003	Jan 20, 2017	Jan	NEWA

PENCICLOVIR

CREAM;TOPICAL
DENA VIR

+	MYLAN PHARMS INC	1%	N020629	001	Sep 24, 1996	Jan	CAHN
---	------------------	----	---------	-----	--------------	-----	------

PENICILLAMINE

TABLET;ORAL
DEPEN

+	MYLAN SPECIALITY LP	250MG	N019854	001		Mar	CAHN
---	---------------------	-------	---------	-----	--	-----	------

PENICILLIN G BENZATHINE; PENICILLIN G PROCAINE

INJECTABLE;INJECTION
BICILLIN C-R

>D>	+	KING PHARMS	150,000 UNITS/ML;150,000 UNITS/ML	N050138	002		Apr	CAHN
>D>	+		300,000 UNITS/ML;300,000 UNITS/ML	N050138	001		Apr	CAHN
>A>	+	KING PHARMS LLC	150,000 UNITS/ML;150,000 UNITS/ML	N050138	002		Apr	CAHN
>A>	+		300,000 UNITS/ML;300,000 UNITS/ML	N050138	001		Apr	CAHN

INJECTABLE; INJECTION
 BICILLIN C-R 900/300
 >D> +! KING PHARMS 900,000 UNITS/2ML; 300,000 UNITS/2ML N050138 003 Apr CAHN
 >A> +! KING PHARMS LLC 900,000 UNITS/2ML; 300,000 UNITS/2ML N050138 003 Apr CAHN

PENTOBARBITAL SODIUM

INJECTABLE; INJECTION
 PENTOBARBITAL SODIUM
 >D> AP MYLAN INSTITUTIONAL 50MG/ML A206404 001 May 23, 2016 Apr CAHN
 >A> AP SAGENT PHARMS 50MG/ML A206404 001 May 23, 2016 Apr CAHN

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE; ORAL
 TRENAL

+ @ US PHARM HOLDINGS 400MG N018631 001 Aug 30, 1984 Jan CRLD

PERMETHRIN

CREAM; TOPICAL
 ELIMITE

AB +! MYLAN PHARMS INC 5% N019855 001 Aug 25, 1989 Jan CAHN

PERPHENAZINE

TABLET; ORAL
 PERPHENAZINE

>A> AB MYLAN PHARMS INC 2MG A206691 001 Apr 14, 2017 Apr NEWA
 >A> AB 4MG A206691 002 Apr 14, 2017 Apr NEWA
 >A> AB 8MG A206691 003 Apr 14, 2017 Apr NEWA
 >A> AB 16MG A206691 004 Apr 14, 2017 Apr NEWA

PHENOXYBENZAMINE HYDROCHLORIDE

CAPSULE; ORAL
 PHENOXYBENZAMINE HYDROCHLORIDE

AB PAR PHARM INC 10MG A204522 001 Jan 24, 2017 Jan NEWA

PHENTERMINE HYDROCHLORIDE

TABLET; ORAL
 PHENTERMINE HYDROCHLORIDE

AA KVK TECH INC 8MG A203436 001 Mar 17, 2017 Mar NEWA
 AA PRINSTON INC 37.5MG A040377 001 Jan 04, 2002 Feb CAHN

PHENYLEPHRINE HYDROCHLORIDE

SOLUTION; IV (INFUSION)
 VAZCULEP

+ AVADEL LEGACY 10MG/ML (10MG/ML) N204300 001 Jun 27, 2014 Jan CAHN
 + 50MG/5ML (10MG/ML) N204300 002 Jun 27, 2014 Jan CAHN
 +! 100MG/10ML (10MG/ML) N204300 003 Jun 27, 2014 Jan CAHN

PHENYTOIN

TABLET, CHEWABLE; ORAL
 DILANTIN

AB ! PFIZER 50MG A084427 001 Feb CAHN

PHENYTOIN SODIUM

CAPSULE; ORAL
 DILANTIN

AB ! PARKE-DAVIS 30MG EXTENDED A084349 001 Feb CAHN
 AB ! 100MG EXTENDED A084349 002 Feb CAHN

INJECTABLE; INJECTION
 PHENYTOIN SODIUM

@ HOSPIRA 50MG/ML A089521 001 Mar 17, 1987 Mar DISC

PHYTONADIONE

INJECTABLE; INJECTION
 AQUAMEPHYTON

>A> + @ TELIGENT 1MG/0.5ML N012223 002 Apr CAHN
 >A> + @ 10MG/ML N012223 001 Apr CAHN
 >D> + @ TELIGENT PHARMA INC 1MG/0.5ML N012223 002 Apr CAHN
 >D> + @ 10MG/ML N012223 001 Apr CAHN

PILOCARPINE HYDROCHLORIDE

TABLET; ORAL

PILOCARPINE HYDROCHLORIDE

AB	ALLIED PHARMA INC	5MG	A076963	001	Dec 22, 2004	Mar	CAHN	
AB		7.5MG	A076963	002	Feb 27, 2007	Mar	CAHN	
>D>	AB	ELAN PHARMA INTL LTD	5MG	A076746	001	Nov 16, 2004	Apr	CAHN
>A>	AB	PERRIGO PHARMA INTL	5MG	A076746	001	Nov 16, 2004	Apr	CAHN

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE; INJECTION

PIPERACILLIN AND TAZOBACTAM

AP	APOLLO PHARMS INC	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	A207847	001	Jan 13, 2017	Jan	NEWA
AP		EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	A207847	002	Jan 13, 2017	Jan	NEWA
AP		EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL	A207848	002	Jan 13, 2017	Jan	NEWA
AP		EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A207847	003	Jan 13, 2017	Jan	NEWA
AP	WOCKHARDT BIO AG	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	A206996	001	Mar 22, 2017	Mar	NEWA
AP		EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	A206996	002	Mar 22, 2017	Mar	NEWA
AP		EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A206996	003	Mar 22, 2017	Mar	NEWA
AP		EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A207146	001	Mar 17, 2017	Mar	NEWA

PIRFENIDONE

TABLET; ORAL

ESBRIET

+	GENENTECH INC	267MG	N208780	001	Jan 11, 2017	Jan	NEWA
+	@	534MG	N208780	002	Jan 11, 2017	Jan	DISC
+	!	801MG	N208780	003	Jan 11, 2017	Jan	NEWA

PIROXICAM

CAPSULE; ORAL

PIROXICAM

>A>	AB	UNICHEM LABS LTD	10MG	A208340	001	Apr 13, 2017	Apr	NEWA
>A>	AB		20MG	A208340	002	Apr 13, 2017	Apr	NEWA

PITAVASTATIN CALCIUM

TABLET; ORAL

PITAVASTATIN CALCIUM

AB	ORIENT PHARMA CO LTD	EQ 1MG BASE	A205932	001	Feb 03, 2017	Jan	NEWA
AB		EQ 2MG BASE	A205932	002	Feb 03, 2017	Jan	NEWA
AB		EQ 4MG BASE	A205932	003	Feb 03, 2017	Jan	NEWA
AB	SAWAI USA	EQ 1MG BASE	A205955	001	Feb 03, 2017	Jan	NEWA
AB		EQ 2MG BASE	A205955	002	Feb 03, 2017	Jan	NEWA
AB		EQ 4MG BASE	A205955	003	Feb 03, 2017	Jan	NEWA

PLECANATIDE

TABLET; ORAL

TRULANCE

+	!	SYNERGY PHARMS	3MG	N208745	001	Jan 19, 2017	Jan	NEWA
---	---	----------------	-----	---------	-----	--------------	-----	------

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION; ORAL

PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE

>D>	AA	MYLAN	420GM/BOT;1.48GM/BOT;5.72GM/BOT;11 .2GM/BOT	A090409	001	Apr 02, 2010	Apr	DISC
>A>		@	420GM/BOT;1.48GM/BOT;5.72GM/BOT;11 .2GM/BOT	A090409	001	Apr 02, 2010	Apr	DISC
>D>	AA	STRIDES ARCOLAB LTD	420GM/BOT;1.48GM/BOT;5.72GM/BOT;11 .2GM/BOT	A204559	001	Apr 13, 2015	Apr	CAHN
>A>	AA	STRIDES PHARMA	420GM/BOT;1.48GM/BOT;5.72GM/BOT;11 .2GM/BOT	A204559	001	Apr 13, 2015	Apr	CAHN
AA		BRECKENRIDGE PHARM	420GM/BOT;1.48GM/BOT;5.72GM/BOT;11 .2GM/BOT	A202060	001	Mar 08, 2017	Mar	CAHN
AA		BRECKENRIDGE PHARMS	420GM/BOT;1.48GM/BOT;5.72GM/BOT;11 .2GM/BOT	A202060	001	Mar 08, 2017	Feb	NEWA
AA		TRILYTE						
AA		MYLAN PHARMS INC	420GM/BOT;1.48GM/BOT;5.72GM/BOT;	A076491	001	Feb 05, 2004	Mar	CAHN

FOR SOLUTION;ORAL
TRILYTE

11.2GM/BOT

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUSFOR SOLUTION;ORAL
COLYTE

	@ MYLAN SPECIALITY LP	120GM/PACKET;1.49GM/PACKET;3.36GM/PACKET;2.92GM/PACKET;11.36GM/PACKET	N018983	005	Oct 26, 1984	Mar	CAHN
	@	227.1GM/PACKET;2.82GM/PACKET;6.36GM/PACKET;5.53GM/PACKET;21.5GM/PACKET	N018983	004	Oct 26, 1984	Mar	CAHN
	@	227.1GM/BOT;2.82GM/BOT;6.36GM/BOT;5.53GM/BOT;21.5GM/BOT	N018983	010	Jan 31, 1989	Mar	CAHN
	@	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N018983	007	Jun 12, 1987	Mar	CAHN
	@	360GM/PACKET;4.47GM/PACKET;10.08GM/PACKET;8.76GM/PACKET;34.08GM/PACKET	N018983	006	Oct 26, 1984	Mar	CAHN
	COLYTE WITH FLAVOR PACKS						
AA	MYLAN SPECIALITY LP	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N018983	012	Oct 08, 1998	Mar	CAHN
	COLYTE-FLAVORED						
	@ MYLAN SPECIALITY LP	227.1GM/BOT;2.82GM/BOT;6.36GM/BOT;5.53GM/BOT;21.5GM/BOT	N018983	008	Nov 14, 1991	Mar	CAHN
	@	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N018983	009	Nov 14, 1991	Mar	CAHN
	PEG 3350 AND ELECTROLYTES						
>D>	AA MYLAN	236GM;2.97GM;6.74GM;5.86GM;22.74GM	A090928	001	Jan 28, 2010	Apr	DISC
>A>	@	236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT	A090928	001	Jan 28, 2010	Apr	DISC

POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE

SOLUTION/DROPS;OPHTHALMIC

TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE

AT	SANDOZ INC	10,000 UNITS/ML;EQ 1MG BASE/ML	A064211	001	Apr 13, 1998	Feb	CAHN
----	------------	--------------------------------	---------	-----	--------------	-----	------

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

POTASSIUM CHLORIDE

AB	ADARE PHARMS INC	8MEQ	A208864	001	Mar 17, 2017	Mar	NEWA
AB		10MEQ	A208864	002	Mar 17, 2017	Mar	NEWA

INJECTABLE;INJECTION

POTASSIUM CHLORIDE

>D>	AP BAXTER HLTHCARE	2MEQ/ML	A085499	001		Apr	DISC
>A>	@	2MEQ/ML	A085499	001		Apr	DISC
	POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER						
AP	+ ICU MEDCL	14.9MG/ML	N020161	005	Nov 30, 1992	Feb	CAHN
AP	+ ICU MEDCL	745MG/100ML	N020161	001	Nov 30, 1992	Feb	CAHN
	POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER						
AP	+! ICU MEDCL	29.8MG/ML	N020161	006	Aug 11, 1998	Feb	CAHN
AP	+ ICU MEDCL	1.49GM/100ML	N020161	002	Nov 30, 1992	Feb	CAHN
	POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER						
AP	+! ICU MEDCL	2.24GM/100ML	N020161	003	Aug 11, 1998	Feb	CAHN
	POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER						
AP	+! ICU MEDCL	2.98GM/100ML	N020161	004	Aug 11, 1998	Feb	CAHN

POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE;INJECTION

POTASSIUM CHLORIDE 0.149% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	ICU MEDCL	149MG/100ML;450MG/100ML	A078446	001	Sep 10, 2008	Feb	CAHN
	POTASSIUM CHLORIDE 20MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
AP	ICU MEDCL	149MG/100ML;900MG/100ML	N019686	001	Oct 17, 1988	Feb	CAHN
	POTASSIUM CHLORIDE 40MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
AP	ICU MEDCL	298MG/100ML;900MG/100ML	N019686	002	Oct 17, 1988	Feb	CAHN

POTASSIUM CITRATE

TABLET, EXTENDED RELEASE;ORAL

POTASSIUM CITRATE

AB	IMPAX LABS INC	5MEQ	A077440	001	Jun 09, 2006	Feb	CAHN
AB		10MEQ	A077440	002	Jun 09, 2006	Feb	CAHN

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET; ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

@	ACTAVIS GRP PTC	0.125MG	A091254	001	Nov 30, 2010	Jan	DISC
@		0.25MG	A091254	002	Nov 30, 2010	Jan	DISC
@		0.5MG	A091254	003	Nov 30, 2010	Jan	DISC
@		0.75MG	A091254	004	Nov 30, 2010	Jan	DISC
@		1MG	A091254	005	Nov 30, 2010	Jan	DISC
@		1.5MG	A091254	006	Nov 30, 2010	Jan	DISC
@	SANDOZ	0.125MG	A090190	001	Jul 06, 2010	Feb	DISC
@		0.25MG	A090190	002	Jul 06, 2010	Feb	DISC
@		0.5MG	A090190	003	Jul 06, 2010	Feb	DISC
@		0.75MG	A090190	006	Oct 08, 2010	Feb	DISC
@		1MG	A090190	004	Jul 06, 2010	Feb	DISC
@		1.5MG	A090190	005	Jul 06, 2010	Feb	DISC

TABLET, EXTENDED RELEASE; ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

>D>	AB	ACTAVIS ELIZABETH	2.25MG	A203615	001	Oct 14, 2016	Apr	CAHN
>A>	AB		2.25MG	A203615	001	Oct 14, 2016	Apr	CAHN
>D>	AB		3.75MG	A203615	002	Jan 03, 2017	Apr	CAHN
>A>	AB		3.75MG	A203615	002	Jan 03, 2017	Apr	CAHN
	AB	MACLEODS PHARMS LTD	3.75MG	A206156	007	Jan 23, 2017	Jan	NEWA

PRAVASTATIN SODIUM

TABLET; ORAL

PRAVASTATIN SODIUM

AB		AUROBINDO PHARMA LTD	10MG	A203367	001	Feb 02, 2017	Jan	NEWA
AB			20MG	A203367	002	Feb 02, 2017	Jan	NEWA
AB			40MG	A203367	003	Feb 02, 2017	Jan	NEWA
AB			80MG	A203367	004	Feb 02, 2017	Jan	NEWA

PREDNISOLONE

SYRUP; ORAL

PREDNISOLONE

AA		VISTAPHARM	15MG/5ML	A040323	001	May 13, 1999	Mar	CAHN
----	--	------------	----------	---------	-----	--------------	-----	------

TABLET; ORAL

PREDNISOLONE

>A>		@ CHARTWELL RX	5MG	A084542	001		Apr	CAHN
>D>		@ PERRIGO	5MG	A084542	001		Apr	CAHN

PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM

SOLUTION/DROPS; OPHTHALMIC

SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE

AT	!	BAUSCH AND LOMB	EQ 0.23% PHOSPHATE;10%	A074449	001	Dec 29, 1995	Feb	CAHN
AT		SANDOZ INC	EQ 0.23% PHOSPHATE;10%	A073630	001	May 27, 1993	Feb	CAHN

PREDNISONE

TABLET; ORAL

METICORTEN

+	@	SCHERING	1MG	N009766	002		Mar	CMS1
+	@		5MG	N009766	001		Mar	CMS1

PREDNISONE

>A>		@ CHARTWELL RX	5MG	A083059	001		Apr	CAHN
		@ CONTRACT PHARMACAL	5MG	A080209	001		Mar	DISC
AB		MYLAN PHARMS INC	5MG	A080292	001		Jan	CAHN
AB			10MG	A088832	001	Dec 04, 1985	Jan	CAHN
AB			20MG	A083677	001		Jan	CAHN
>D>		@ PERRIGO	5MG	A083059	001		Apr	CAHN

TABLET, DELAYED RELEASE; ORAL

PREDNISONE

>A>	AB	ACTAVIS LABS FL INC	1MG	A204867	001	Apr 25, 2017	Apr	NEWA
>A>	AB		2MG	A204867	002	Apr 25, 2017	Apr	NEWA
>A>	AB		5MG	A204867	003	Apr 25, 2017	Apr	NEWA

RAYOS

>D>	+	HORIZON PHARMA	1MG	N202020	001	Jul 26, 2012	Apr	CFTG
>A>	AB	+	1MG	N202020	001	Jul 26, 2012	Apr	CFTG
>D>		+	2MG	N202020	002	Jul 26, 2012	Apr	CFTG
>A>	AB	+	2MG	N202020	002	Jul 26, 2012	Apr	CFTG
>D>		+	5MG	N202020	003	Jul 26, 2012	Apr	CFTG
>A>	AB	+	5MG	N202020	003	Jul 26, 2012	Apr	CFTG

PROBENECID

TABLET; ORAL
BENEMID

+ @ MERCK 500MG N007898 004 Jan CRLD

PROCAINAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION
PROCAINAMIDE HYDROCHLORIDE

@ WEST-WARD PHARMS INT 100MG/ML A089029 001 Apr 17, 1986 Jan CAHN
@ 500MG/ML A089030 001 Apr 17, 1986 Mar CAHN

PROCARBAZINE HYDROCHLORIDE

CAPSULE; ORAL
MATULANE

+! LEADIANT BIOSCI INC EQ 50MG BASE N016785 001 Feb CAHN

PROCHLORPERAZINE EDISYLATE

INJECTABLE; INJECTION
PROCHLORPERAZINE EDISYLATE

@ ATHENEX INC EQ 5MG BASE/ML A040540 001 May 28, 2004 Mar CAHN
@ WEST-WARD PHARMS INT EQ 5MG BASE/ML A089523 001 May 03, 1988 Jan CAHN
AP EQ 5MG BASE/ML A089903 001 Aug 29, 1989 Jan CAHN

PROCYCLIDINE HYDROCHLORIDE

TABLET; ORAL
KEMADRIN

>D> @ MONARCH PHARMS 2MG N009818 005 Apr CAHN
>A> @ 2MG N009818 005 Apr CAHN
>D> @ 5MG N009818 003 Apr CAHN
>A> @ 5MG N009818 003 Apr CAHN

PROGESTERONE

CAPSULE; ORAL
PROGESTERONE

AB DR REDDYS LABS INC 100MG A208801 001 Feb 28, 2017 Feb NEWA
AB 200MG A208801 002 Feb 28, 2017 Feb NEWA

INJECTABLE; INJECTION
PROGESTERONE

AO +! ACTAVIS LABS UT INC 50MG/ML N017362 002 Feb CAHN

PROMETHAZINE HYDROCHLORIDE

SUPPOSITORY; RECTAL
PHENERGAN

+ @ MYLAN PHARMS INC 50MG N011689 001 Jan CAHN

TABLET; ORAL
PROMETHAZINE HYDROCHLORIDE

AB PRINSTON INC 12.5MG A040622 001 Jul 18, 2006 Feb CAHN
AB 25MG A040622 002 Jul 18, 2006 Feb CAHN
AB 50MG A040622 003 Jul 18, 2006 Feb CAHN

PROPIOMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION
LARGON

@ WEST-WARD PHARMS INT 20MG/ML N012382 002 Jan CAHN

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
INNOPRAN XL

BX ANI PHARMS INC 80MG N021438 001 Mar 12, 2003 Mar CAHN
BX 120MG N021438 002 Mar 12, 2003 Mar CAHN

PROPRANOLOL HYDROCHLORIDE

>D> @ UPSHER SMITH 60MG A078311 001 Mar 06, 2009 Apr CMFD
>A> BX 60MG A078311 001 Mar 06, 2009 Apr CMFD
@ 60MG A078311 001 Mar 06, 2009 Feb DISC
>D> @ 80MG A078311 002 Mar 06, 2009 Apr CMFD
>A> BX 80MG A078311 002 Mar 06, 2009 Apr CMFD
@ 80MG A078311 002 Mar 06, 2009 Feb DISC
>D> @ 120MG A078311 003 Mar 06, 2009 Apr CMFD
>A> BX 120MG A078311 003 Mar 06, 2009 Apr CMFD
@ 120MG A078311 003 Mar 06, 2009 Feb DISC
>D> @ 160MG A078311 004 Mar 06, 2009 Apr CMFD

CAPSULE, EXTENDED RELEASE;ORAL
PROPRANOLOL HYDROCHLORIDE

>A> BX		160MG	A078311	004	Mar 06, 2009	Apr	CMFD
	@	160MG	A078311	004	Mar 06, 2009	Feb	DISC

INJECTABLE;INJECTION
PROPRANOLOL HYDROCHLORIDE

AP	ATHENEX INC	1MG/ML	A075792	001	Aug 29, 2000	Mar	CAHN
	@ SANDOZ INC	1MG/ML	A076400	001	Feb 26, 2003	Mar	CAHN

TABLET;ORAL
INDERAL

+	@ WYETH PHARMS INC	40MG	N016418	002		Jan	CRLD
---	--------------------	------	---------	-----	--	-----	------

PROPYLTHIOURACILTABLET;ORAL
PROPYLTHIOURACIL

>A>	@ CHARTWELL RX	50MG	A084543	001		Apr	CAHN
>D>	@ PERRIGO	50MG	A084543	001		Apr	CAHN

PROTAMINE SULFATEINJECTABLE;INJECTION
PROTAMINE SULFATE

@	WEST-WARD PHARMS INT	10MG/ML	A089474	001	Nov 05, 1986	Mar	CAHN
@		10MG/ML	A089475	001	Nov 05, 1986	Jan	CAHN

PYRIDOSTIGMINE BROMIDETABLET;ORAL
PYRIDOSTIGMINE BROMIDE

@	IMPAX LABS INC	60MG	A040457	001	Dec 26, 2002	Feb	CAHN
---	----------------	------	---------	-----	--------------	-----	------

QUETIAPINE FUMARATETABLET, EXTENDED RELEASE;ORAL
QUETIAPINE FUMARATE

>A> AB	ACCORD HLTHCARE	EQ 150MG BASE	A090681	001	May 09, 2017	Apr	NEWA
>A> AB		EQ 200MG BASE	A090681	002	May 09, 2017	Apr	NEWA
>A> AB		EQ 300MG BASE	A090681	003	May 09, 2017	Apr	NEWA
>A> AB		EQ 400MG BASE	A090681	004	Nov 01, 2016	Mar	CAHN
>A> AB	INTELLIPHARMACEUTICS	EQ 50MG BASE	A202939	001	May 09, 2017	Apr	NEWA
>A> AB		EQ 50MG BASE	A202939	001	May 01, 2017	Apr	NEWA
>A> AB		EQ 150MG BASE	A202939	002	May 09, 2017	Apr	NEWA
>A> AB		EQ 150MG BASE	A202939	002	May 01, 2017	Apr	NEWA
>A> AB		EQ 200MG BASE	A202939	003	May 09, 2017	Apr	NEWA
>A> AB		EQ 200MG BASE	A202939	003	May 01, 2017	Apr	NEWA
>A> AB		EQ 300MG BASE	A202939	004	May 09, 2017	Apr	NEWA
>A> AB		EQ 300MG BASE	A202939	004	May 01, 2017	Apr	NEWA
>A> AB		EQ 400MG BASE	A202939	005	May 09, 2017	Apr	NEWA
>A> AB		EQ 400MG BASE	A202939	005	May 01, 2017	Apr	NEWA
>A> AB	PAR PHARM	EQ 50MG BASE	A090482	001	May 09, 2017	Apr	NEWA
>A> AB		EQ 150MG BASE	A090482	002	May 09, 2017	Apr	NEWA
>A> AB		EQ 200MG BASE	A090482	003	May 09, 2017	Apr	NEWA
>A> AB		EQ 300MG BASE	A090482	004	May 09, 2017	Apr	NEWA
>A> AB		EQ 400MG BASE	A090482	005	May 09, 2017	Apr	NEWA
>A> AB	PHARMADAX INC	EQ 50MG BASE	A206260	001	May 09, 2017	Apr	NEWA
>A> AB		EQ 150MG BASE	A206260	002	May 09, 2017	Apr	NEWA
>A> AB		EQ 200MG BASE	A206260	003	May 09, 2017	Apr	NEWA
>A> AB		EQ 300MG BASE	A206260	004	May 09, 2017	Apr	NEWA
>A> AB		EQ 400MG BASE	A206260	005	May 09, 2017	Apr	NEWA
	SEROQUEL XR						
>D>	+ ASTRAZENECA	EQ 50MG BASE	N022047	001	May 17, 2007	Apr	CTEC
>A> AB	+	EQ 50MG BASE	N022047	001	May 17, 2007	Apr	CTEC
>D>	+	EQ 150MG BASE	N022047	005	Aug 11, 2008	Apr	CTEC
>A> AB	+	EQ 150MG BASE	N022047	005	Aug 11, 2008	Apr	CTEC
>D>	+!	EQ 200MG BASE	N022047	002	May 17, 2007	Apr	CTEC
>A> AB	+!	EQ 200MG BASE	N022047	002	May 17, 2007	Apr	CTEC
>D>	+	EQ 300MG BASE	N022047	003	May 17, 2007	Apr	CTEC
>A> AB	+	EQ 300MG BASE	N022047	003	May 17, 2007	Apr	CTEC

RABEPRAZOLE SODIUMTABLET, DELAYED RELEASE;ORAL
RABEPRAZOLE SODIUM

AB	AUROBINDO PHARMA LTD	20MG	A205761	001	Feb 17, 2017	Feb	NEWA
AB	KREMERS URBAN PHARMS	20MG	A090678	001	Nov 08, 2013	Jan	CAHN

RAMIPRIL

CAPSULE;ORAL

RAMIPRIL

AB		ACCORD HLTHCARE	1.25MG	A202392	001	Apr 15, 2014	Mar	CAHN
AB			2.5MG	A202392	002	Apr 15, 2014	Mar	CAHN
AB			5MG	A202392	003	Apr 15, 2014	Mar	CAHN
AB			10MG	A202392	004	Apr 15, 2014	Mar	CAHN

RANITIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

ZANTAC

>A>	AP	+	TELIGENT	EQ 25MG BASE/ML	N019090	001	Oct 19, 1984	Apr	CAHN
>D>	AP	+	TELIGENT PHARMA INC	EQ 25MG BASE/ML	N019090	001	Oct 19, 1984	Apr	CAHN
	AP	+		EQ 25MG BASE/ML	N019090	001	Oct 19, 1984	Jan	CAHN

SYRUP;ORAL

RANITIDINE HYDROCHLORIDE

AA		AUROBINDO PHARMA LTD	EQ 15MG BASE/ML	A090623	001	Jul 28, 2010	Jan	CAHN
----	--	----------------------	-----------------	---------	-----	--------------	-----	------

RANOLAZINE

TABLET, EXTENDED RELEASE;ORAL

RANEXA

+	GILEAD	500MG	N021526	002	Jan 27, 2006	Feb	CTEC
+	!	1GM	N021526	001	Feb 12, 2007	Feb	CTEC

RANOLAZINE

@	LUPIN LTD	500MG	A201046	001	Jul 29, 2013	Feb	DISC
@		1GM	A201046	002	Jul 29, 2013	Feb	DISC

REPAGLINIDE

TABLET;ORAL

PRANDIN

AB	+	GEMINI LABS LLC	0.5MG	N020741	001	Dec 22, 1997	Feb	CAHN
AB	+		1MG	N020741	002	Dec 22, 1997	Feb	CAHN
AB	+	!	2MG	N020741	003	Dec 22, 1997	Feb	CAHN

RESERPINE

TABLET;ORAL

RESERPINE

>D>	BP	+	SANDOZ	0.1MG	N009838	001		Apr	DISC
>A>		+	@	0.1MG	N009838	001		Apr	DISC
>D>	BP	+	!	0.25MG	N009838	002		Apr	DISC
>A>		+	@	0.25MG	N009838	002		Apr	DISC

RIBAVIRIN

CAPSULE;ORAL

RIBASPHERE

AB		KADMON PHARMS LLC	200MG	A076203	001	Apr 06, 2004	Jan	CAHN
----	--	-------------------	-------	---------	-----	--------------	-----	------

TABLET;ORAL

RIBAVIRIN

AB		KADMON PHARMS LLC	200MG	A077456	001	Dec 05, 2005	Jan	CAHN
AB			400MG	A077456	002	Dec 05, 2005	Jan	CAHN
AB	!		600MG	A077456	003	Dec 05, 2005	Jan	CAHN

RIBOCICLIB SUCCINATE

TABLET;ORAL

KISQALI

+	NOVARTIS PHARMS CORP	EQ 200MG BASE	N209092	001	Mar 13, 2017	Mar	NEWA
---	----------------------	---------------	---------	-----	--------------	-----	------

RIFAMPIN

INJECTABLE; INJECTION

RIFAMPIN

AP		WATSON PHARMS TEVA	600MG/VIAL	A206736	001	Jan 19, 2016	Feb	CAHN
AP		WEST-WARD PHARMS INT	600MG/VIAL	A064217	001	Oct 29, 1999	Jan	CAHN

RIMANTADINE HYDROCHLORIDE

TABLET;ORAL

RIMANTADINE HYDROCHLORIDE

@	IMPAX LABS INC	100MG	A075916	001	Nov 02, 2001	Feb	CAHN
---	----------------	-------	---------	-----	--------------	-----	------

RISPERIDONE

TABLET;ORAL

RISPERIDONE

>D>	@	CADISTA PHARMS	0.25MG	A 078828	001	Mar 23, 2009	Apr	CAHN
>D>	@		0.5MG	A 078828	002	Mar 23, 2009	Apr	CAHN
>D>	@		1MG	A 078828	003	Mar 23, 2009	Apr	CAHN
>D>	@		2MG	A 078828	004	Mar 23, 2009	Apr	CAHN
>D>	@		3MG	A 078828	005	Mar 23, 2009	Apr	CAHN
>D>	@		4MG	A 078828	006	Mar 23, 2009	Apr	CAHN
>A>	@	JUBILANT CADISTA	0.25MG	A 078828	001	Mar 23, 2009	Apr	CAHN
>A>	@		0.5MG	A 078828	002	Mar 23, 2009	Apr	CAHN
>A>	@		1MG	A 078828	003	Mar 23, 2009	Apr	CAHN
>A>	@		2MG	A 078828	004	Mar 23, 2009	Apr	CAHN
>A>	@		3MG	A 078828	005	Mar 23, 2009	Apr	CAHN
>A>	@		4MG	A 078828	006	Mar 23, 2009	Apr	CAHN
AB		PRINSTON INC	0.25MG	A 078707	001	Dec 29, 2008	Feb	CAHN
AB			0.5MG	A 078707	002	Dec 29, 2008	Feb	CAHN
AB			1MG	A 078707	003	Dec 29, 2008	Feb	CAHN
AB			2MG	A 078707	004	Dec 29, 2008	Feb	CAHN
AB			3MG	A 078707	005	Dec 29, 2008	Feb	CAHN
AB			4MG	A 078707	006	Dec 29, 2008	Feb	CAHN

RIVASTIGMINE TARTRATE

CAPSULE;ORAL

RIVASTIGMINE TARTRATE

AB		CADILA PHARMS LTD	EQ 1.5MG BASE	A 203844	001	Feb 13, 2017	Jan	NEWA
AB			EQ 3MG BASE	A 203844	002	Feb 13, 2017	Jan	NEWA
AB			EQ 4.5MG BASE	A 203844	003	Feb 13, 2017	Jan	NEWA
AB			EQ 6MG BASE	A 203844	004	Feb 13, 2017	Jan	NEWA
AB		SUN PHARM INDS LTD	EQ 1.5MG BASE	A 077131	001	Oct 22, 2007	Mar	CAHN
AB			EQ 3MG BASE	A 077131	002	Oct 22, 2007	Mar	CAHN
AB			EQ 4.5MG BASE	A 077131	003	Oct 22, 2007	Mar	CAHN
AB			EQ 6MG BASE	A 077131	004	Oct 22, 2007	Mar	CAHN

RIZATRIPTAN BENZOATE

TABLET;ORAL

RIZATRIPTAN BENZOATE

AB		ECI PHARMS LLC	EQ 5MG BASE	A 202047	001	Dec 31, 2012	Mar	CAHN
AB			EQ 10MG BASE	A 202047	002	Dec 31, 2012	Mar	CAHN
AB		UNICHEM LABS LTD	EQ 5MG BASE	A 207836	001	Mar 07, 2017	Feb	NEWA
AB			EQ 10MG BASE	A 207836	002	Mar 07, 2017	Feb	NEWA

TABLET, ORALLY DISINTEGRATING;ORAL

RIZATRIPTAN BENZOATE

AB		PANACEA BIOTEC LTD	EQ 5MG BASE	A 204722	001	Jan 11, 2017	Jan	NEWA
AB			EQ 10MG BASE	A 204722	002	Jan 11, 2017	Jan	NEWA
AB		UNICHEM LABS LTD	EQ 5MG BASE	A 207835	001	Mar 07, 2017	Feb	NEWA
AB			EQ 10MG BASE	A 207835	002	Mar 07, 2017	Feb	NEWA

ROCURONIUM BROMIDE

INJECTABLE;INJECTION

ROCURONIUM BROMIDE

AP		AUROBINDO PHARMA LTD	50MG/5ML (10MG/ML)	A 206206	001	Apr 12, 2017	Mar	NEWA
AP			100MG/10ML (10MG/ML)	A 206206	002	Apr 12, 2017	Mar	NEWA
AP	!	SANDOZ INC	50MG/5ML (10MG/ML)	A 079195	001	Dec 05, 2008	Mar	CAHN
AP	!		100MG/10ML (10MG/ML)	A 079195	002	Dec 05, 2008	Mar	CAHN
AP		WEST WARD PHARM CORP	50MG/5ML (10MG/ML)	A 204679	001	Feb 28, 2017	Feb	NEWA
AP			100MG/10ML (10MG/ML)	A 204679	002	Feb 28, 2017	Feb	NEWA

ROPINIROLE HYDROCHLORIDE

TABLET;ORAL

ROPINIROLE HYDROCHLORIDE

>A>	AB	ACCORD HLTHCARE	EQ 0.25MG BASE	A 204022	001	Feb 28, 2017	Apr	CAHN
>A>	AB		EQ 0.5MG BASE	A 204022	002	Feb 28, 2017	Apr	CAHN
>A>	AB		EQ 1MG BASE	A 204022	003	Feb 28, 2017	Apr	CAHN
>A>	AB		EQ 2MG BASE	A 204022	004	Feb 28, 2017	Apr	CAHN
>A>	AB		EQ 3MG BASE	A 204022	005	Feb 28, 2017	Apr	CAHN
>A>	AB		EQ 4MG BASE	A 204022	006	Feb 28, 2017	Apr	CAHN
>A>	AB		EQ 5MG BASE	A 204022	007	Feb 28, 2017	Apr	CAHN
>D>	AB	ACCORD HLTHCARE INC	EQ 0.25MG BASE	A 204022	001	Feb 28, 2017	Apr	CAHN
	AB		EQ 0.25MG BASE	A 204022	001	Feb 28, 2017	Feb	NEWA
>D>	AB		EQ 0.5MG BASE	A 204022	002	Feb 28, 2017	Apr	CAHN
	AB		EQ 0.5MG BASE	A 204022	002	Feb 28, 2017	Feb	NEWA

TABLET;ORAL

ROPINIROLE HYDROCHLORIDE

>D>	AB		EQ 1MG BASE	A204022	003	Feb 28, 2017	Apr	CAHN
	AB		EQ 1MG BASE	A204022	003	Feb 28, 2017	Feb	NEWA
>D>	AB		EQ 2MG BASE	A204022	004	Feb 28, 2017	Apr	CAHN
	AB		EQ 2MG BASE	A204022	004	Feb 28, 2017	Feb	NEWA
>D>	AB		EQ 3MG BASE	A204022	005	Feb 28, 2017	Apr	CAHN
	AB		EQ 3MG BASE	A204022	005	Feb 28, 2017	Feb	NEWA
>D>	AB		EQ 4MG BASE	A204022	006	Feb 28, 2017	Apr	CAHN
	AB		EQ 4MG BASE	A204022	006	Feb 28, 2017	Feb	NEWA
>D>	AB		EQ 5MG BASE	A204022	007	Feb 28, 2017	Apr	CAHN
	AB		EQ 5MG BASE	A204022	007	Feb 28, 2017	Feb	NEWA

TABLET, EXTENDED RELEASE;ORAL

ROPINIROLE HYDROCHLORIDE

>D>		MYLAN PHARMS INC	EQ 3MG BASE	A200462	002	Oct 15, 2012	Apr	DISC
>A>	@		EQ 3MG BASE	A200462	002	Oct 15, 2012	Apr	DISC

ROSUVASTATIN CALCIUM

TABLET;ORAL

ROSUVASTATIN CALCIUM

	AB	ACCORD HLTHCARE	5MG	A206434	001	Oct 31, 2016	Mar	CAHN
	AB		10MG	A206434	002	Oct 31, 2016	Mar	CAHN
	AB		20MG	A206434	003	Oct 31, 2016	Mar	CAHN
	AB		40MG	A206434	004	Oct 31, 2016	Mar	CAHN
	AB	ALKEM LABS LTD	5MG	A206465	001	Mar 21, 2017	Mar	NEWA
	AB		10MG	A206465	002	Mar 21, 2017	Mar	NEWA
	AB		20MG	A206465	003	Mar 21, 2017	Mar	NEWA
	AB		40MG	A206465	004	Mar 21, 2017	Mar	NEWA
>D>	AB	TORRENT PHARMS LLC	5MG	A201619	001	Oct 31, 2016	Apr	CAHN
>D>	AB		10MG	A201619	002	Oct 31, 2016	Apr	CAHN
>D>	AB		20MG	A201619	003	Oct 31, 2016	Apr	CAHN
>D>	AB		40MG	A201619	004	Oct 31, 2016	Apr	CAHN
>A>	AB	TORRENT PHARMS LTD	5MG	A201619	001	Oct 31, 2016	Apr	CAHN
>A>	AB		10MG	A201619	002	Oct 31, 2016	Apr	CAHN
>A>	AB		20MG	A201619	003	Oct 31, 2016	Apr	CAHN
>A>	AB		40MG	A201619	004	Oct 31, 2016	Apr	CAHN

SAFINAMIDE MESYLATE

TABLET;ORAL

XADAGO

>D>	+	NEWRON PHARMS US INC	50MG	N207145	001	Mar 21, 2017	Apr	CAHN
	+		50MG	N207145	001	Mar 21, 2017	Mar	NEWA
>D>	+		100MG	N207145	002	Mar 21, 2017	Apr	CAHN
	+		100MG	N207145	002	Mar 21, 2017	Mar	NEWA
>A>	+	US WORLDMEDS LLC	50MG	N207145	001	Mar 21, 2017	Apr	CAHN
>A>	+		100MG	N207145	002	Mar 21, 2017	Apr	CAHN

SELEGILINE HYDROCHLORIDE

TABLET;ORAL

SELEGILINE HYDROCHLORIDE

@ CHARTWELL MOLECULES

@

		5MG	A074565	001	Aug 02, 1996	Jan	CAHN
		5MG	A074641	001	Aug 02, 1996	Jan	CAHN

SERTRALINE HYDROCHLORIDE

CONCENTRATE;ORAL

SERTRALINE HYDROCHLORIDE

@ ALLIED PHARMA INC

		EQ 20MG BASE/ML	A076934	001	Jun 30, 2006	Mar	CAHN
--	--	-----------------	---------	-----	--------------	-----	------

TABLET;ORAL

SERTRALINE HYDROCHLORIDE

@ ALLIED PHARMA INC

@

@

@ MYLAN

@

@

		EQ 25MG BASE	A076881	001	Feb 06, 2007	Mar	CAHN
		EQ 50MG BASE	A076881	002	Feb 06, 2007	Mar	CAHN
		EQ 100MG BASE	A076881	003	Feb 06, 2007	Mar	CAHN
		EQ 25MG BASE	A076671	001	Feb 06, 2007	Mar	DISC
		EQ 50MG BASE	A076671	002	Feb 06, 2007	Mar	DISC
		EQ 100MG BASE	A076671	003	Feb 06, 2007	Mar	DISC

SILODOSIN

CAPSULE;ORAL

RAPAFLO

AB	+	ALLERGAN SALES LLC	4MG	N022206	001	Oct 08, 2008	Mar	CFTG
AB	+		8MG	N022206	002	Oct 08, 2008	Mar	CFTG

		CAPSULE;ORAL							
		SILODOSIN							
AB		SANDOZ INC	4MG	A204726	001	Mar 31, 2017	Mar	NEWA	
AB			8MG	A204726	002	Mar 31, 2017	Mar	NEWA	
		<u>SIMVASTATIN</u>							
		SUSPENSION;ORAL							
		SIMVASTATIN							
	+	TCG FLUENT PHARMA	20MG/5ML	N206679	001	Apr 21, 2016	Jan	CAHN	
	+	!	40MG/5ML	N206679	002	Apr 21, 2016	Jan	CAHN	
		<u>SODIUM BENZOATE; SODIUM PHENYLACETATE</u>							
		SOLUTION;IV (INFUSION)							
		SODIUM PHENYLACETATE AND SODIUM BENZOATE							
>A>	AP	MAIA PHARMS INC	10%;10% (5GM/50ML; 5GM/50ML)	A208521	001	May 08, 2017	Apr	NEWA	
		<u>SODIUM BICARBONATE</u>							
		INJECTABLE;INJECTION							
		SODIUM BICARBONATE							
AP	!	HOSPIRA	0.9MEQ/ML	A077394	001	Nov 09, 2005	Feb	CTEC	
AP	!		1MEQ/ML	A077394	002	Nov 09, 2005	Feb	CTEC	
		HOSPIRA INC	0.5MEQ/ML	A202679	001	Mar 07, 2017	Feb	NEWA	
AP			0.9MEQ/ML	A202494	001	Mar 06, 2017	Feb	NEWA	
			1MEQ/ML	A202495	001	Mar 06, 2017	Feb	NEWA	
AP			1MEQ/ML	A202494	002	Mar 06, 2017	Feb	NEWA	
		<u>SODIUM CHLORIDE</u>							
		INJECTABLE;INJECTION							
		SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER							
AP	+	! ICU MEDCL	450MG/100ML	N018090	001		Feb	CAHN	
		SODIUM CHLORIDE 0.9%							
AP		WEST-WARD PHARMS INT	9MG/ML	A201850	001	Jan 20, 2012	Jan	CAHN	
		SODIUM CHLORIDE 0.9%							
		WEST-WARD PHARMS INT	9MG/ML	A201833	001	Sep 24, 2013	Jan	CAHN	
		SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER							
AP	+	! ICU MEDCL	900MG/100ML	N016366	001		Feb	CAHN	
>A>	AP	!	TARO	A077407	001	Aug 11, 2006	Apr	CAHN	
>D>	AP	!	TARO PHARMS IRELAND	A077407	001	Aug 11, 2006	Apr	CAHN	
		SODIUM CHLORIDE 23.4% IN PLASTIC CONTAINER							
	+	@ ABRAXIS PHARM	234MG/ML	N019329	001	Apr 22, 1987	Jan	CRLD	
		SODIUM CHLORIDE IN PLASTIC CONTAINER							
	+	HOSPIRA	2.5MEQ/ML	N018897	001	Jul 20, 1984	Mar	CRLD	
		SOLUTION;IRRIGATION							
		SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER							
AT		ICU MEDCL	900MG/100ML	N017514	001		Feb	CAHN	
AT			900MG/100ML	N018314	001		Feb	CAHN	
		<u>SODIUM NITROPRUSSIDE</u>							
		INJECTABLE;INJECTION							
		SODIUM NITROPRUSSIDE							
>A>	AP	AKORN	25MG/ML	A208635	001	May 04, 2017	Apr	NEWA	
		SOLUTION;IV (INFUSION)							
		NIPRIDE RTU IN SODIUM CHLORIDE 0.9%							
	+	! EXELA PHARMA SCS LLC	50MG/100ML (0.5MG/ML)	N209387	001	Mar 08, 2017	Mar	NEWA	
		<u>SODIUM OXYBATE</u>							
		SOLUTION;ORAL							
		SODIUM OXYBATE							
AA		WEST-WARD PHARMS INT	500MG/ML	A202090	001	Jan 17, 2017	Jan	NEWA	
		XYREM							
AA	+	! JAZZ PHARMS	500MG/ML	N021196	001	Jul 17, 2002	Jan	CFTG	
		<u>SODIUM PHENYLBUTYRATE</u>							
		TABLET;ORAL							
		SODIUM PHENYLBUTYRATE							
>A>	AB	ALVOGEN MALTA	500MG	A090910	001	Nov 18, 2011	Apr	CAHN	
>D>	AB	FERA PHARMS LLC	500MG	A090910	001	Nov 18, 2011	Apr	CAHN	

SODIUM POLYSTYRENE SULFONATE

POWDER;ORAL, RECTAL

SODIUM POLYSTYRENE SULFONATE

>D>	AA	CAROLINA MEDCL	454GM/BOT	A089910	001	Jan 19, 1989	Apr	CAHN
>A>	AA	CMP PHARMA INC	454GM/BOT	A089910	001	Jan 19, 1989	Apr	CAHN
	AA	ECI PHARMS LLC	453.6GM/BOT	A090313	001	Dec 21, 2011	Mar	CAHN

SUSPENSION;ORAL, RECTAL

SPS

>D>	AA	! CAROLINA MEDCL	15GM/60ML	A087859	001	Dec 08, 1982	Apr	CAHN
>A>	AA	! CMP PHARMA INC	15GM/60ML	A087859	001	Dec 08, 1982	Apr	CAHN

SONIDEGIB PHOSPHATE

CAPSULE;ORAL

ODOMZO

	+!	SUN PHARM INDS INC	EQ 200MG BASE	N205266	001	Jul 24, 2015	Mar	CAHN
--	----	--------------------	---------------	---------	-----	--------------	-----	------

SOTALOL HYDROCHLORIDE

TABLET;ORAL

SOTALOL HYDROCHLORIDE

>D>	AB2	TEVA	80MG	A076883	001	Jul 26, 2004	Apr	DISC
>A>		@	80MG	A076883	001	Jul 26, 2004	Apr	DISC
>D>	AB2		120MG	A076883	002	Jul 26, 2004	Apr	DISC
>A>		@	120MG	A076883	002	Jul 26, 2004	Apr	DISC
>D>	AB2		160MG	A076883	003	Jul 26, 2004	Apr	DISC
>A>		@	160MG	A076883	003	Jul 26, 2004	Apr	DISC

SPIRONOLACTONE

TABLET;ORAL

SPIRONOLACTONE

AB		ACCORD HLTHCARE	25MG	A203512	001	Sep 19, 2016	Mar	CAHN
AB			50MG	A203512	002	Sep 19, 2016	Mar	CAHN
AB			100MG	A203512	003	Sep 19, 2016	Mar	CAHN

STAVUDINE

CAPSULE;ORAL

STAVUDINE

AB		MYLAN LABS LTD	30MG	A078775	001	Jan 05, 2009	Mar	CAHN
AB			40MG	A078775	002	Jan 05, 2009	Mar	CAHN

STERILE WATER FOR INJECTION

LIQUID;N/A

STERILE WATER FOR INJECTION

AP		WEST-WARD PHARMS INT	100%	A206369	001	Sep 02, 2015	Jan	CAHN
----	--	----------------------	------	---------	-----	--------------	-----	------

STERILE WATER FOR INJECTION IN PLASTIC CONTAINER

>D>	AP	+!	HOSPIRA	100%	N019869	001	Dec 26, 1989	Apr	CAHN
	AP	+!	ICU MEDCL	100%	N018233	001		Feb	CAHN
>A>	AP	+!		100%	N019869	001	Dec 26, 1989	Apr	CAHN
>A>	AP		TARO	100%	A077393	001	Aug 11, 2006	Apr	CAHN
>D>	AP		TARO PHARMS IRELAND	100%	A077393	001	Aug 11, 2006	Apr	CAHN

STERILE WATER FOR IRRIGATION

LIQUID;IRRIGATION

STERILE WATER IN PLASTIC CONTAINER

AT		ICU MEDCL	100%	N017513	001		Feb	CAHN
AT			100%	N018313	001		Feb	CAHN

SULFACETAMIDE SODIUM

SOLUTION/DROPS;OPHTHALMIC

SULFACETAMIDE SODIUM

AT		SANDOZ INC	10%	A089560	001	Oct 18, 1988	Feb	CAHN
----	--	------------	-----	---------	-----	--------------	-----	------

SULFAMETHOXAZOLE; TRIMETHOPRIM

TABLET;ORAL

SULFAMETHOXAZOLE AND TRIMETHOPRIM

AB		CHARTWELL MOLECULES	400MG;80MG	A078060	002	Jan 25, 2007	Mar	CAHN
AB			800MG;160MG	A078060	001	Jan 25, 2007	Mar	CAHN
AB		CHARTWELL PHARMS LLC	400MG;80MG	A078060	002	Jan 25, 2007	Jan	CAHN
AB			800MG;160MG	A078060	001	Jan 25, 2007	Jan	CAHN

SULFANILAMIDE

CREAM;VAGINAL
AVC

+! MYLAN SPECIALITY LP 15% N006530 003 Jan 27, 1987 Mar CAHN
SUPPOSITORY;VAGINAL

AVC
@ MYLAN SPECIALITY LP 1.05GM N006530 004 Jan 27, 1987 Mar CAHN

SUMATRIPTAN SUCCINATE

INJECTABLE;SUBCUTANEOUS
SUMATRIPTAN SUCCINATE

@ SANDOZ INC EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML) A078067 002 Feb 06, 2009 Mar CAHN

@ EQ 6MG BASE/0.5ML (EQ 12MG
BASE/ML) A078067 001 Feb 06, 2009 Mar CAHN

AP WEST-WARD PHARMS INT EQ 6MG BASE/0.5ML (EQ 12MG
BASE/ML) A079123 001 Feb 06, 2009 Jan CAHN

SYSTEM;IONTOPHORESIS
ZECUITY

+ @ TEVA BRANDED PHARM EQ 6.5MG BASE/4HR N202278 001 Jan 17, 2013 Jan DISC

SUNITINIB MALATE

CAPSULE;ORAL
SUTENT

+ CPPI CV EQ 12.5MG BASE N021938 001 Jan 26, 2006 Mar CTEC

+ EQ 25MG BASE N021938 002 Jan 26, 2006 Mar CTEC

+ EQ 37.5MG BASE N021938 004 Mar 31, 2009 Mar CTEC

+! EQ 50MG BASE N021938 003 Jan 26, 2006 Mar CTEC

TALC

POWDER;INTRAPLEURAL
STERITALC

>A> + NOVATECH SA 2GM/VIAL N205555 001 May 01, 2017 Apr NEWA

>A> + 3GM/VIAL N205555 002 May 01, 2017 Apr NEWA

>A> +! 4GM/VIAL N205555 003 May 01, 2017 Apr NEWA

TAMSULOSIN HYDROCHLORIDE

CAPSULE;ORAL
TAMSULOSIN HYDROCHLORIDE

AB MACLEODS PHARMS LTD 0.4MG A204645 001 Jan 20, 2017 Jan NEWA

TAZAROTENE

AEROSOL, FOAM;TOPICAL
FABIOR

+! MAYNE PHARMA 0.1% N202428 001 May 11, 2012 Jan CAHN

CREAM;TOPICAL
AVAGE

AB +! ALLERGAN 0.1% N021184 003 Sep 30, 2002 Mar CFTG

TAZAROTENE

AB TARO 0.1% A208258 001 Apr 03, 2017 Mar NEWA

TAZORAC

AB +! ALLERGAN 0.1% N021184 002 Sep 29, 2000 Mar CFTG

TECHNETIUM TC-99M MEDRONATE KIT

INJECTABLE;INJECTION
MDP-BRACCO

>D> AP BRACCO N/A N018107 001 Apr CAHN

>A> AP CARDINAL HEALTH 414 N/A N018107 001 Apr CAHN

TECHNETIUM TC-99M TILMANOCEPT

INJECTABLE;INJECTION
LYMPHOSEEK KIT

+! CARDINAL HLTH 414 N/A N202207 001 Mar 13, 2013 Mar CAHN

TELMISARTAN

TABLET;ORAL
TELMISARTAN

>A> AB PRINSTON INC 20MG A207882 001 May 03, 2017 Apr NEWA

>A> AB 40MG A207882 002 May 03, 2017 Apr NEWA

>A> AB 80MG A207882 003 May 03, 2017 Apr NEWA

TELOTRISTAT ETIPRATE

TABLET; ORAL

XERMELO

+! LEXICON PHARMS INC EQ 250MG BASE N208794 001 Feb 28, 2017 Feb NEWA

TEMAZEPAM

CAPSULE; ORAL

TEMAZEPAM

AB	PRINSTON INC	7.5MG	A201781	001	Jun 04, 2015	Feb CAHN
AB		15MG	A201781	002	Jun 04, 2015	Feb CAHN
AB		22.5MG	A201781	003	Jun 04, 2015	Feb CAHN
AB		30MG	A201781	004	Jun 04, 2015	Feb CAHN

TEMOZOLOMIDE

CAPSULE; ORAL

TEMOZOLOMIDE

AB	ACCORD HLTHCARE	5MG	A201528	001	Feb 27, 2017	Feb NEWA	
AB		20MG	A201528	002	Feb 27, 2017	Feb NEWA	
AB		100MG	A201528	003	Feb 27, 2017	Feb NEWA	
AB		140MG	A201528	004	Feb 27, 2017	Feb NEWA	
AB		180MG	A201528	005	Feb 27, 2017	Feb NEWA	
AB		250MG	A201528	006	Feb 27, 2017	Feb NEWA	
>A>	AB	DEVA HOLDING AS	5MG	A207658	001	Apr 26, 2017	Apr NEWA
>A>	AB		20MG	A207658	002	Apr 26, 2017	Apr NEWA
>A>	AB		100MG	A207658	003	Apr 26, 2017	Apr NEWA
>A>	AB		140MG	A207658	004	Apr 26, 2017	Apr NEWA
>A>	AB		180MG	A207658	005	Apr 26, 2017	Apr NEWA
>A>	AB		250MG	A207658	006	Apr 26, 2017	Apr NEWA
>A>	AB	WATSON LABS TEVA	5MG	A203959	001	Apr 18, 2017	Apr NEWA
>A>	AB		20MG	A203959	002	Apr 18, 2017	Apr NEWA
>A>	AB		100MG	A203959	003	Apr 18, 2017	Apr NEWA
>A>	AB		140MG	A203959	004	Apr 18, 2017	Apr NEWA
>A>	AB		250MG	A203959	005	Apr 18, 2017	Apr NEWA

TERAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

TERAZOSIN HYDROCHLORIDE

AB	MYLAN PHARMS INC	EQ 1MG BASE	A075140	002	Feb 11, 2000	Mar CAHN
AB		EQ 2MG BASE	A075140	003	Feb 11, 2000	Mar CAHN
AB		EQ 5MG BASE	A075140	001	Feb 11, 2000	Mar CAHN
AB		EQ 10MG BASE	A075140	004	Feb 11, 2000	Mar CAHN

TERBUTALINE SULFATE

INJECTABLE; INJECTION

TERBUTALINE SULFATE

AP ! ATHENEX INC 1MG/ML A076770 001 Apr 23, 2004 Mar CAHN

TABLET; ORAL

BRETHINE

+ @ ANI PHARMS INC 2.5MG N017849 001 Feb CAHN

+ @ 5MG N017849 002 Feb CAHN

TERBUTALINE SULFATE

! LANNETT 5MG A077152 002 Mar 25, 2005 Jan CHRS

TESTOSTERONE

GEL, METERED; TRANSDERMAL

TESTOSTERONE

AB ACTAVIS LABS UT INC 10MG/0.5GM ACTUATION A204571 001 Aug 05, 2015 Mar CAHN

SOLUTION, METERED; TRANSDERMAL

AXIRON

AT +! ELI LILLY AND CO 30MG/1.5ML ACTUATION N022504 001 Nov 23, 2010 Feb CFTG

TESTOSTERONE

AT PERRIGO ISRAEL 30MG/1.5ML ACTUATION A204255 001 Feb 28, 2017 Feb NEWA

TESTOSTERONE CYPIONATE

INJECTABLE; INJECTION

TESTOSTERONE CYPIONATE

AO	SANDOZ INC	100MG/ML	A040615	001	Aug 10, 2006	Mar CAHN
AO		200MG/ML	A040615	002	Aug 10, 2006	Mar CAHN
AO	WATSON PHARMS INC	200MG/ML	A086030	001		Feb CAHN
AO	WEST-WARD PHARMS INT	100MG/ML	A090387	001	Jul 15, 2010	Jan CAHN
AO		200MG/ML	A090387	002	Jul 15, 2010	Jan CAHN

TESTOSTERONE ENANTHATE

INJECTABLE; INJECTION
 TESTOSTERONE ENANTHATE
 AO WATSON PHARMS INC 200MG/ML A 085598 001 Feb CAHN

TETRABENAZINE

TABLET; ORAL
 TETRABENAZINE
 AB APICORE US 12.5MG A 207682 001 Jan 31, 2017 Jan NEWA
 AB 25MG A 207682 002 Jan 31, 2017 Jan NEWA

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL
 ACHROMYCIN V
 AB + HERITAGE PHARMA 250MG N 050278 003 Jan CAHN
 AB +! 500MG N 050278 001 Jan CAHN
 TETRACYCLINE HYDROCHLORIDE
 >D> AB CHARTWELL CIENCA 250MG A 062752 001 Aug 12, 1988 Apr CAHN
 >D> AB 500MG A 062752 002 Aug 12, 1988 Apr CAHN
 >A> AB CHARTWELL TETRA 250MG A 062752 001 Aug 12, 1988 Apr CAHN
 >A> AB 500MG A 062752 002 Aug 12, 1988 Apr CAHN

THEOPHYLLINE

ELIXIR; ORAL
 THEOPHYLLINE
 >A> @ CHARTWELL RX 80MG/15ML A 085952 001 Apr CAHN
 >D> @ PERRIGO 80MG/15ML A 085952 001 Apr CAHN
 TABLET, EXTENDED RELEASE; ORAL
 THEOPHYLLINE
 >D> AB ALEMBIC LTD 450MG A 090430 002 Oct 27, 2010 Apr CHRS
 >A> ! 450MG A 090430 002 Oct 27, 2010 Apr CHRS

THIAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
 THIAMINE HYDROCHLORIDE
 @ WEST-WARD PHARMS INT 100MG/ML A 080575 001 Jan CAHN

THIORIDAZINE HYDROCHLORIDE

CONCENTRATE; ORAL
 THIORIDAZINE HYDROCHLORIDE
 @ ANI PHARMS INC 30MG/ML A 089602 001 Nov 09, 1987 Jan CAHN

THIOTEPA

POWDER; IV (INFUSION)
 TEPADINA
 +! ADIENNE SA 15MG/VIAL N 208264 001 Jan 26, 2017 Jan NEWA
 +! 100MG/VIAL N 208264 002 Jan 26, 2017 Jan NEWA

TICAGRELOR

TABLET; ORAL
 BRILINTA
 + ASTRAZENECA PHARMS 60MG N 022433 002 Sep 03, 2015 Jan CAHN
 +! 90MG N 022433 001 Jul 20, 2011 Jan CAHN

TIGECYCLINE

POWDER; IV (INFUSION)
 TIGECYCLINE
 AP SANDOZ INC 50MG/VIAL A 091620 001 May 27, 2015 Feb CDFR
 TYGACIL
 AP +! PF PRISM CV 50MG/VIAL N 021821 001 Jun 15, 2005 Feb CDFR

TIMOLOL MALEATE

SOLUTION, GEL FORMING/DROPS; OPHTHALMIC
 TIMOLOL MALEATE
 AB SANDOZ INC EQ 0.25% BASE N 020963 001 Oct 21, 1998 Feb CAHN
 AB EQ 0.5% BASE N 020963 002 Oct 21, 1998 Feb CAHN
 SOLUTION/DROPS; OPHTHALMIC
 TIMOLOL MALEATE
 AT ! ALCON RES LTD EQ 0.25% BASE A 074261 001 Apr 28, 1995 Jan CHRS
 AT1 ! EQ 0.5% BASE A 074262 001 Apr 28, 1995 Jan CHRS

SOLUTION/DROPS;OPHTHALMIC
TIMOLOL MALEATE

AT	!	SANDOZ INC	EQ 0.25% BASE	A074261	001	Apr 28, 1995	Feb CAHN
AT1	!		EQ 0.5% BASE	A074262	001	Apr 28, 1995	Feb CAHN
		TIMOPTIC					
	+	@ ATON	EQ 0.25% BASE	N018086	001		Jan DISC
	+	@	EQ 0.5% BASE	N018086	002		Jan DISC

TINIDAZOLE

TABLET;ORAL
TINIDAZOLE

AB		UNIQUE PHARM LABS	250MG	A202489	001	Oct 09, 2013	Jan CTEC
AB			500MG	A202489	002	Oct 09, 2013	Jan CTEC

TIZANIDINE HYDROCHLORIDE

CAPSULE;ORAL
TIZANIDINE HYDROCHLORIDE

AB		PAR PHARM INC	EQ 2MG BASE	A207199	001	Mar 14, 2017	Feb NEWA
AB			EQ 4MG BASE	A207199	002	Mar 14, 2017	Feb NEWA
AB			EQ 6MG BASE	A207199	003	Mar 14, 2017	Feb NEWA
AB		ZYDUS PHARMS USA INC	EQ 2MG BASE	A208622	001	Mar 03, 2017	Feb NEWA
AB			EQ 4MG BASE	A208622	002	Mar 03, 2017	Feb NEWA
AB			EQ 6MG BASE	A208622	003	Mar 03, 2017	Feb NEWA

TABLET;ORAL
TIZANIDINE HYDROCHLORIDE

AB		PAR PHARM INC	EQ 2MG BASE	A207170	001	Jan 26, 2017	Jan NEWA
AB			EQ 4MG BASE	A207170	002	Jan 26, 2017	Jan NEWA

TOBRAMYCIN

SOLUTION;INHALATION
TOBRAMYCIN

AN		LUPIN ATLANTIS	300MG/5ML	A208964	001	Mar 22, 2017	Mar NEWA
----	--	----------------	-----------	---------	-----	--------------	----------

SOLUTION/DROPS;OPHTHALMIC
TOBREX

AT		SANDOZ INC	0.3%	A062535	001	Dec 13, 1984	Feb CAHN
----	--	------------	------	---------	-----	--------------	----------

TOLMETIN SODIUM

TABLET;ORAL
TOLMETIN SODIUM

>D>	AB	SUN PHARM INDS	EQ 200MG BASE	A073310	001	Nov 27, 1991	Apr DISC
>A>		@	EQ 200MG BASE	A073310	001	Nov 27, 1991	Apr DISC

TOREMIFENE CITRATE

TABLET;ORAL
FARESTON

	+	!	KYOWA KIRIN	EQ 60MG BASE	N020497	001	May 29, 1997	Jan CAHN
--	---	---	-------------	--------------	---------	-----	--------------	----------

TORSEMIDE

TABLET;ORAL
DEMADEX

AB	+	MYLAN SPECIALITY LP	5MG	N020136	001	Aug 23, 1993	Mar CAHN
AB	+		10MG	N020136	002	Aug 23, 1993	Mar CAHN
AB	+	!	20MG	N020136	003	Aug 23, 1993	Mar CAHN
AB	+		100MG	N020136	004	Aug 23, 1993	Mar CAHN

TRAMADOL HYDROCHLORIDE

TABLET;ORAL
TRAMADOL HYDROCHLORIDE

AB		ACCORD HLTHCARE	50MG	A202390	001	May 16, 2013	Mar CAHN
----	--	-----------------	------	---------	-----	--------------	----------

TABLET, EXTENDED RELEASE;ORAL
ULTRAM ER

	+	@	VALEANT PHARMS	100MG	N021692	001	Sep 08, 2005	Mar CRLD
	+	@		200MG	N021692	002	Sep 08, 2005	Mar CRLD
	+	@		300MG	N021692	003	Sep 08, 2005	Mar CRLD

TRANDOLAPRIL

TABLET;ORAL
TRANDOLAPRIL

>D>	AB	INVAGEN PHARMS	1MG	A078320	001	Jun 12, 2007	Apr CTEC
>A>	BX		1MG	A078320	001	Jun 12, 2007	Apr CTEC
>D>	AB		2MG	A078320	002	Jun 12, 2007	Apr CTEC
>A>	BX		2MG	A078320	002	Jun 12, 2007	Apr CTEC

TABLET;ORAL

TRANDOLAPRIL

>D>	AB		4MG	A078320	003	Jun 12, 2007	Apr CTEC
>A>	BX		4MG	A078320	003	Jun 12, 2007	Apr CTEC

TRANEXAMIC ACID

INJECTABLE;INJECTION

TRANEXAMIC ACID

AP		AMNEAL PHARMS CO	100MG/ML	A208840	001	Feb 28, 2017	Feb NEWA
AP		GLAND PHARMA LTD	100MG/ML	A207239	001	Feb 13, 2017	Jan NEWA

TRETINOIN

CREAM;TOPICAL

TRETINOIN

		@ ALLERGAN SALES LLC	0.0375%	A090098	001	Mar 22, 2010	Feb DISC
		@	0.075%	A202209	001	Oct 11, 2012	Feb DISC
AB2		ZO SKIN HEALTH	0.05%	A076498	001	Sep 15, 2005	Feb CAHN

TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL

TRIAMCINOLONE ACETONIDE

AT		LUPIN ATLANTIS	0.025%	A208763	001	Feb 01, 2017	Jan NEWA
AT			0.1%	A208763	002	Feb 01, 2017	Jan NEWA
AT			0.5%	A208763	003	Feb 01, 2017	Jan NEWA
AT	+	MYLAN PHARMS INC	0.025%	N011601	003		Jan CAHN
AT	+		0.1%	N011601	006		Jan CAHN
>D>		@ TARO	0.025%	A040038	001	Oct 26, 1994	Apr CAHN
>A>		@	0.025%	A040038	001	Oct 26, 1994	Apr CAHN
>D>	AT		0.1%	A040039	001	Nov 26, 1997	Apr CAHN
>A>	AT		0.1%	A040039	001	Nov 26, 1997	Apr CAHN
	AT		0.1%	A040039	001	Nov 26, 1997	Mar CAHN

INJECTABLE;INJECTION

TRIAMCINOLONE ACETONIDE

>D>		@ SANDOZ	10MG/ML	A090166	001	May 27, 2009	Apr CAHN
>D>		@ SANDOZ CANADA INC	40MG/ML	A090164	001	Jun 01, 2009	Apr CAHN
>A>		@ SANDOZ INC	10MG/ML	A090166	001	May 27, 2009	Apr CAHN
>A>		@	40MG/ML	A090164	001	Jun 01, 2009	Apr CAHN

OINTMENT;TOPICAL

KENALOG

AT		MYLAN PHARMS INC	0.025%	N011600	003		Jan CAHN
AT			0.1%	N011600	001		Jan CAHN

TRIAMCINOLONE ACETONIDE

>D>		@ TARO	0.025%	A040040	001	Sep 30, 1994	Apr CAHN
>A>		@	0.025%	A040040	001	Sep 30, 1994	Apr CAHN
>D>	AT		0.1%	A040037	001	Sep 30, 1994	Apr CAHN
>A>	AT		0.1%	A040037	001	Sep 30, 1994	Apr CAHN
	AT	TELIGENT PHARMA INC	0.5%	A208590	001	Mar 03, 2017	Feb NEWA

TRIAMCINOLONE ACETONIDE IN ABSORBABLE

>D>	!	CAROLINA MEDCL	0.05%	A089595	001	Mar 23, 1995	Apr CAHN
>A>	!	CMP PHARMA INC	0.05%	A089595	001	Mar 23, 1995	Apr CAHN

PASTE;DENTAL

TRIAMCINOLONE ACETONIDE

AT		G AND W LABS INC	0.1%	A205592	001	Jan 12, 2017	Jan NEWA
----	--	------------------	------	---------	-----	--------------	----------

SPRAY, METERED;NASAL

TRIAMCINOLONE ACETONIDE

		@ PERRIGO ISRAEL	0.055MG/SPRAY	A078104	001	Jul 30, 2009	Jan CAHN
--	--	------------------	---------------	---------	-----	--------------	----------

TRIFLURIDINE

SOLUTION/DROPS;OPHTHALMIC

TRIFLURIDINE

AT		SANDOZ INC	1%	A074311	001	Oct 06, 1995	Feb CAHN
AT	+	MONARCH PHARMS	1%	N018299	001		Feb CAHN

TRIHENXYPHENIDYL HYDROCHLORIDE

TABLET;ORAL

TRIHENXYPHENIDYL HYDROCHLORIDE

AA		VINTAGE PHARMS LLC	2MG	A040254	001	Dec 24, 1998	Mar CAHN
AA			5MG	A040254	002	Dec 24, 1998	Mar CAHN

TROPICAMIDESOLUTION/DROPS;OPHTHALMIC
MYDRIACYL

AT	!	SANDOZ INC	0.5%	A084305	001		Feb	CAHN
----	---	------------	------	---------	-----	--	-----	------

ULIPRISTAL ACETATETABLET;ORAL
ELLA

AB	+	LAB HRA PHARMA	30MG	N022474	001	Aug 13, 2010	Jan	CFTG
----	---	----------------	------	---------	-----	--------------	-----	------

AB		TEVA PHARMS USA	30MG	A207952	001	Feb 13, 2017	Jan	NEWA
----	--	-----------------	------	---------	-----	--------------	-----	------

URSODIOLCAPSULE;ORAL
URSODIOL

>D>	AB	IMPAX LABS INC	300MG	A077895	001	Jul 27, 2006	Apr	CTEC
-----	----	----------------	-------	---------	-----	--------------	-----	------

>A>	BX		300MG	A077895	001	Jul 27, 2006	Apr	CTEC
-----	----	--	-------	---------	-----	--------------	-----	------

AB			300MG	A077895	001	Jul 27, 2006	Feb	CAHN
----	--	--	-------	---------	-----	--------------	-----	------

>A> VALBENZAZINE TOSYLATE

>A> CAPSULE;ORAL

>A> INGREZZA

>A>	+	NEUROCRINE	40MG	N209241	001	Apr 11, 2017	Apr	NEWA
-----	---	------------	------	---------	-----	--------------	-----	------

VALPROATE SODIUMINJECTABLE;INJECTION
VALPROATE SODIUM

AP		ATHENEX INC	EQ 100MG BASE/ML	A076295	001	Nov 14, 2002	Mar	CAHN
----	--	-------------	------------------	---------	-----	--------------	-----	------

VALPROIC ACIDSYRUP;ORAL
VALPROIC ACID

AA		ECI PHARMS LLC	250MG/5ML	A090517	001	May 28, 2010	Mar	CAHN
----	--	----------------	-----------	---------	-----	--------------	-----	------

AA		VISTAPHARM	250MG/5ML	A075782	001	Dec 22, 2000	Feb	CAHN
----	--	------------	-----------	---------	-----	--------------	-----	------

VALSARTANTABLET;ORAL
VALSARTAN

AB		MYLAN PHARMS INC	40MG	A090866	001	Jan 05, 2015	Feb	CAHN
----	--	------------------	------	---------	-----	--------------	-----	------

AB			80MG	A090866	002	Jan 05, 2015	Feb	CAHN
----	--	--	------	---------	-----	--------------	-----	------

AB			160MG	A090866	003	Jan 05, 2015	Feb	CAHN
----	--	--	-------	---------	-----	--------------	-----	------

AB			320MG	A090866	004	Jan 05, 2015	Feb	CAHN
----	--	--	-------	---------	-----	--------------	-----	------

VASOPRESSINSOLUTION;IV (INFUSION)
VASOSTRICT

>D>	+	PAR STERILE PRODUCTS	20UNITS/ML (20UNITS/ML)	N204485	001	Apr 17, 2014	Apr	DISC
-----	---	----------------------	-------------------------	---------	-----	--------------	-----	------

>A>	+	@	20UNITS/ML (20UNITS/ML)	N204485	001	Apr 17, 2014	Apr	DISC
-----	---	---	-------------------------	---------	-----	--------------	-----	------

>A>	+	!	20UNITS/ML (20UNITS/ML)	N204485	002	Mar 18, 2016	Apr	NEWA
-----	---	---	-------------------------	---------	-----	--------------	-----	------

VECURONIUM BROMIDEINJECTABLE;INJECTION
VECURONIUM BROMIDE

AP	@	WEST-WARD PHARMS INT	10MG/VIAL	A075218	001	Aug 23, 1999	Mar	CAHN
----	---	----------------------	-----------	---------	-----	--------------	-----	------

AP			10MG/VIAL	A075549	001	Jun 13, 2000	Jan	CAHN
----	--	--	-----------	---------	-----	--------------	-----	------

AP	@		20MG/VIAL	A075218	002	Aug 23, 1999	Mar	CAHN
----	---	--	-----------	---------	-----	--------------	-----	------

AP			20MG/VIAL	A075549	002	Jun 13, 2000	Jan	CAHN
----	--	--	-----------	---------	-----	--------------	-----	------

VENLAFAXINE HYDROCHLORIDETABLET;ORAL
VENLAFAXINE HYDROCHLORIDE

AB		PRINSTON INC	EQ 25MG BASE	A090027	001	Aug 04, 2010	Feb	CAHN
----	--	--------------	--------------	---------	-----	--------------	-----	------

AB			EQ 37.5MG BASE	A090027	002	Aug 04, 2010	Feb	CAHN
----	--	--	----------------	---------	-----	--------------	-----	------

AB			EQ 50MG BASE	A090027	003	Aug 04, 2010	Feb	CAHN
----	--	--	--------------	---------	-----	--------------	-----	------

AB			EQ 75MG BASE	A090027	004	Aug 04, 2010	Feb	CAHN
----	--	--	--------------	---------	-----	--------------	-----	------

AB			EQ 100MG BASE	A090027	005	Aug 04, 2010	Feb	CAHN
----	--	--	---------------	---------	-----	--------------	-----	------

TABLET, EXTENDED RELEASE;ORAL
VENLAFAXINE HYDROCHLORIDE

AB		NOSTRUM LABS INC	EQ 150MG BASE	A205468	002	Mar 24, 2017	Mar	NEWA
----	--	------------------	---------------	---------	-----	--------------	-----	------

AB			EQ 225MG BASE	A205468	003	Mar 24, 2017	Mar	NEWA
----	--	--	---------------	---------	-----	--------------	-----	------

AB	+	OSMOTICA PHARM	EQ 225MG BASE	N022104	004	May 20, 2008	Mar	CFTG
----	---	----------------	---------------	---------	-----	--------------	-----	------

VERAPAMIL HYDROCHLORIDE

INJECTABLE; INJECTION
ISOPTIN

>D>	@ MT ADAMS	2.5MG/ML	N018485	001		Apr	CRLD
>A>	+ @	2.5MG/ML	N018485	001		Apr	CRLD
	TABLET, EXTENDED RELEASE; ORAL						
	CALAN SR						
	+ @ PFIZER	180MG	N019152	002	Dec 15, 1989	Jan	CRLD
	COVERA-HS						
	@ GD SEARLE LLC	180MG	N020552	001	Feb 26, 1996	Jan	DISC
	@	240MG	N020552	002	Feb 26, 1996	Jan	DISC
	VERAPAMIL HYDROCHLORIDE						
>A>	AB CADILA PHARMS LTD	180MG	A206173	001	May 05, 2017	Apr	NEWA
>A>	AB	240MG	A206173	002	May 05, 2017	Apr	NEWA

VIGABATRIN

FOR SOLUTION; ORAL
SABRIL

>D>	+! LUNDBECK PHARMS LLC	500MG/PACKET	N022006	001	Aug 21, 2009	Apr	CFTG
>A>	AA +!	500MG/PACKET	N022006	001	Aug 21, 2009	Apr	CFTG
	+!	500MG/PACKET	N022006	001	Aug 21, 2009	Jan	CAHN
>A>	VIGABATRIN						
>A>	AA PAR PHARM INC	500MG/PACKET	A208218	001	Apr 27, 2017	Apr	NEWA
	TABLET; ORAL						
	SABRIL						
	+! LUNDBECK PHARMS LLC	500MG	N020427	001	Aug 21, 2009	Jan	CAHN

VINORELBINE TARTRATE

INJECTABLE; INJECTION
VINORELBINE TARTRATE

AP	WEST-WARD PHARMS INT	EQ 10MG BASE/ML	A075992	001	Jun 10, 2003	Mar	CAHN
AP		EQ 10MG BASE/ML	A076461	001	Dec 11, 2003	Jan	CAHN

VORICONAZOLE

POWDER; IV (INFUSION)
VORICONAZOLE

	XELLIA PHARMS APS	200MG/VIAL	N208562	001	Mar 09, 2017	Mar	NEWA
--	-------------------	------------	---------	-----	--------------	-----	------

VORTIOXETINE HYDROBROMIDE

TABLET; ORAL
TRINTELLIX

	+ @ TAKEDA PHARMS USA	EQ 15MG BASE	N204447	003	Sep 30, 2013	Mar	DISC
--	-----------------------	--------------	---------	-----	--------------	-----	------

WARFARIN SODIUM

TABLET; ORAL
WARFARIN SODIUM

>D>	AB MYLAN	1MG	A040415	001	Sep 27, 2004	Apr	DISC
>A>	@	1MG	A040415	001	Sep 27, 2004	Apr	DISC
>D>	AB	2MG	A040415	002	Sep 27, 2004	Apr	DISC
>A>	@	2MG	A040415	002	Sep 27, 2004	Apr	DISC
>D>	AB	2.5MG	A040415	003	Sep 29, 2004	Apr	DISC
>A>	@	2.5MG	A040415	003	Sep 29, 2004	Apr	DISC
>D>	AB	3MG	A040415	004	Sep 27, 2004	Apr	DISC
>A>	@	3MG	A040415	004	Sep 27, 2004	Apr	DISC
>D>	AB	4MG	A040415	005	Sep 27, 2004	Apr	DISC
>A>	@	4MG	A040415	005	Sep 27, 2004	Apr	DISC
>D>	AB	5MG	A040415	006	Sep 27, 2004	Apr	DISC
>A>	@	5MG	A040415	006	Sep 27, 2004	Apr	DISC
>D>	AB	6MG	A040415	007	Sep 27, 2004	Apr	DISC
>A>	@	6MG	A040415	007	Sep 27, 2004	Apr	DISC
>D>	AB	7.5MG	A040415	008	Sep 27, 2004	Apr	DISC
>A>	@	7.5MG	A040415	008	Sep 27, 2004	Apr	DISC
>D>	AB	10MG	A040415	009	Sep 27, 2004	Apr	DISC
>A>	@	10MG	A040415	009	Sep 27, 2004	Apr	DISC
	AB TARO PHARM	1MG	A040301	002	Jul 15, 1999	Mar	CAHN
	AB	2MG	A040301	003	Jul 15, 1999	Mar	CAHN
	AB	2.5MG	A040301	004	Jul 15, 1999	Mar	CAHN
	AB	3MG	A040301	005	Jul 15, 1999	Mar	CAHN
	AB	4MG	A040301	006	Jul 15, 1999	Mar	CAHN
	AB	5MG	A040301	007	Jul 15, 1999	Mar	CAHN
	AB	6MG	A040301	008	Jul 15, 1999	Mar	CAHN

TABLET;ORAL

WARFARIN SODIUM

AB		7.5MG	A040301	009	Jul 15, 1999	Mar	CAHN
AB		10MG	A040301	001	Jul 15, 1999	Mar	CAHN

ZILEUTON

TABLET, EXTENDED RELEASE;ORAL

ZILEUTON

AB	PACK PHARMS LLC	600MG	A204929	001	Mar 17, 2017	Mar	NEWA
AB	RISING PHARMS INC	600MG	A204929	001	Mar 17, 2017	Mar	CAHN
ZYFLO CR							
AB	+! CHIESI USA INC	600MG	N022052	001	May 30, 2007	Mar	CFTG

ZIPRASIDONE HYDROCHLORIDE

CAPSULE;ORAL

ZIPRASIDONE HYDROCHLORIDE

AB	MACLEODS PHARMS LTD	EQ 20MG BASE	A204375	001	Feb 17, 2017	Feb	NEWA
AB		EQ 40MG BASE	A204375	002	Feb 17, 2017	Feb	NEWA
AB		EQ 60MG BASE	A204375	003	Feb 17, 2017	Feb	NEWA
AB		EQ 80MG BASE	A204375	004	Feb 17, 2017	Feb	NEWA

ZOLEDRONIC ACID

INJECTABLE;IV (INFUSION)

ZOLEDRONIC ACID

AP	MYLAN LABS LTD	EQ 5MG BASE/100ML	A203841	001	Feb 14, 2017	Jan	NEWA
----	----------------	-------------------	---------	-----	--------------	-----	------

ZOLMITRIPTAN

TABLET;ORAL

ZOLMITRIPTAN

AB	PLD ACQUISITIONS LLC	2.5MG	A207867	001	Feb 27, 2017	Feb	NEWA
AB		5MG	A207867	002	Feb 27, 2017	Feb	NEWA

ZOLPIDEM TARTRATE

TABLET;ORAL

ZOLPIDEM TARTRATE

AB	ALLIED PHARMA INC	5MG	A077214	001	Apr 23, 2007	Mar	CAHN
AB		10MG	A077214	002	Apr 23, 2007	Mar	CAHN

TABLET;SUBLINGUAL

EDLUAR

AB	+ MYLAN SPECIALITY LP	5MG	N021997	001	Mar 13, 2009	Mar	CAHN
AB	+!	10MG	N021997	002	Mar 13, 2009	Mar	CAHN

TABLET, EXTENDED RELEASE;ORAL

ZOLPIDEM TARTRATE

AB	SUN PHARMA GLOBAL	6.25MG	A204170	001	Jan 24, 2017	Jan	NEWA
AB		12.5MG	A204170	002	Jan 24, 2017	Jan	NEWA
>D> AB	SYNTHON PHARMS	6.25MG	A078483	001	Apr 12, 2011	Apr	DISC
>A>	@	6.25MG	A078483	001	Apr 12, 2011	Apr	DISC
>D> AB		12.5MG	A078483	002	Jun 06, 2011	Apr	DISC
>A>	@	12.5MG	A078483	002	Jun 06, 2011	Apr	DISC

CETIRIZINE HYDROCHLORIDE

SYRUP;ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

>A>	ALLIED PHARMA INC	5MG/5ML	A 091327	001	Oct 17, 2011	Apr	CAHN
>D>	NOSTRUM LABS INC	5MG/5ML	A 091327	001	Oct 17, 2011	Apr	CAHN
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF							
>A>	ALLIED PHARMA INC	5MG/5ML	A 091327	002	Oct 17, 2011	Apr	CAHN
>D>	NOSTRUM LABS INC	5MG/5ML	A 091327	002	Oct 17, 2011	Apr	CAHN

TABLET;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

>D>	CADISTA PHARMS	5MG	A 078933	001	Jun 15, 2010	Apr	CAHN
>D>		10MG	A 078933	002	Jun 15, 2010	Apr	CAHN
>A>	JUBILANT CADISTA	5MG	A 078933	001	Jun 15, 2010	Apr	CAHN
>A>		10MG	A 078933	002	Jun 15, 2010	Apr	CAHN
CETIRIZINE HYDROCHLORIDE HIVES							
>D>	CADISTA PHARMS	5MG	A 078933	003	Jun 15, 2010	Apr	CAHN
>D>		10MG	A 078933	004	Jun 15, 2010	Apr	CAHN
>A>	JUBILANT CADISTA	5MG	A 078933	003	Jun 15, 2010	Apr	CAHN
>A>		10MG	A 078933	004	Jun 15, 2010	Apr	CAHN

CHLORPHENIRAMINE MALEATE; IBUPROFEN; PHENYLEPHRINE HYDROCHLORIDE

TABLET;ORAL

ADVIL MULTI-SYMPOM COLD & FLU

>A>	+	PFIZER	4MG;200MG;10MG	N 022113	002	Apr 28, 2017	Apr	NEWA
-----	---	--------	----------------	----------	-----	--------------	-----	------

CIMETIDINE

TABLET;ORAL

CIMETIDINE

>A>	L PERRIGO CO	200MG	A 075285	001	Oct 29, 1998	Apr	CAHN
>D>	PERRIGO	200MG	A 075285	001	Oct 29, 1998	Apr	CAHN
	@ SANDOZ INC	100MG	A 075122	001	Jun 19, 1998	Mar	CAHN
	@	200MG	A 075122	002	Jun 19, 1998	Mar	CAHN

CLEMASTINE FUMARATE

TABLET;ORAL

CLEMASTINE FUMARATE

>A>	L PERRIGO CO	1.34MG	A 074512	001	Nov 22, 1995	Apr	CAHN	
>D>	PERRIGO	1.34MG	A 074512	001	Nov 22, 1995	Apr	CAHN	
TAVIST-1								
>A>	+	GLAXOSMITHKLINE CONS	1.34MG	N 020925	001	Aug 21, 1992	Apr	CAHN
>D>	+	NOVARTIS	1.34MG	N 020925	001	Aug 21, 1992	Apr	CAHN

CLOTRIMAZOLE

CREAM;VAGINAL

CLOTRIMAZOLE

>D>	TARO	1%	A 072641	001	Dec 04, 1995	Apr	CAHN
>A>		1%	A 072641	001	Dec 04, 1995	Apr	CAHN

DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN

TABLET, EXTENDED RELEASE;ORAL

GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE

	ACTAVIS LABS FL	30MG;600MG	A 091070	001	Aug 31, 2015	Mar	CAHN
		60MG;1.2GM	A 091070	002	Aug 31, 2015	Mar	CAHN
	AUROBINDO PHARMA LTD	30MG;600MG	A 206941	001	Mar 17, 2017	Mar	NEWA
		60MG;1.2GM	A 206941	002	Mar 17, 2017	Mar	NEWA

FAMOTIDINE

TABLET;ORAL

FAMOTIDINE

>D>	PERRIGO	20MG	A 077351	001	Sep 25, 2006	Apr	CAHN
>A>	PERRIGO R AND D	20MG	A 077351	001	Sep 25, 2006	Apr	CAHN

GUAIFENESIN

TABLET, EXTENDED RELEASE;ORAL

GUAIFENESIN

	ACTAVIS LABS FL	1.2GM	A 091009	002	Sep 03, 2015	Mar	CAHN
--	-----------------	-------	----------	-----	--------------	-----	------

GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE

ACTAVIS LABS FL 600MG;60MG
1.2GM;120MGA 091071 001 May 27, 2015 Mar CAHN
A 091071 002 May 27, 2015 Mar CAHNIBUPROFEN

SUSPENSION/DROPS;ORAL

IBUPROFEN

>A> L PERRIGO CO 40MG/ML
>D> PERRIGO 40MG/MLA 075217 001 Dec 16, 1998 Apr CAHN
A 075217 001 Dec 16, 1998 Apr CAHN

TABLET;ORAL

IBUPROFEN

>A> AIPING PHARM INC 200MG
>D> AMNEAL PHARMS 200MG
>A> 200MGA 207095 001 May 05, 2017 Apr NEWA
A 079233 001 Mar 18, 2014 Apr CAHN
A 079233 001 Mar 18, 2014 Apr CAHN

JUNIOR STRENGTH IBUPROFEN

>A> L PERRIGO CO 100MG
>D> PERRIGO 100MGA 075367 001 Apr 22, 1999 Apr CAHN
A 075367 001 Apr 22, 1999 Apr CAHNLEVOCETIRIZINE DIHYDROCHLORIDE

SOLUTION;ORAL

XYZAL ALLERGY 24HR

+ SANOFI-AVENTIS US 2.5MG/5ML (0.5MG/ML)
+ UCB INC 2.5MG/5ML (0.5MG/ML)N 209090 001 Jan 31, 2017 Feb CAHN
N 209090 001 Jan 31, 2017 Jan NEWA

TABLET;ORAL

XYZAL ALLERGY 24HR

+ SANOFI-AVENTIS US 5MG
+ UCB INC 5MGN 209089 001 Jan 31, 2017 Feb CAHN
N 209089 001 Jan 31, 2017 Jan NEWALEVONORGESTREL

TABLET;ORAL

LEVONORGESTREL

>D> LOTUS PHARM CO LTD 1.5MG
>A> RECKITT BENCKISER 1.5MGA 202246 001 Jun 05, 2015 Apr CAHN
A 202246 001 Jun 05, 2015 Apr CAHNLOPERAMIDE HYDROCHLORIDE

SOLUTION;ORAL

LOPERAMIDE HYDROCHLORIDE

ALLIED PHARMA INC 1MG/5ML

A 073079 001 Apr 30, 1992 Mar CAHN

TABLET;ORAL

LOPERAMIDE HYDROCHLORIDE

>A> L PERRIGO CO 2MG
>D> PERRIGO 2MGA 075232 001 Jan 06, 2000 Apr CAHN
A 075232 001 Jan 06, 2000 Apr CAHN

TABLET, CHEWABLE;ORAL

IMODIUM A-D EZ CHEWS

+ @ J AND J CONSUMER INC 2MG

N 020448 001 Jul 24, 1997 Jan DISC

LOPERAMIDE HYDROCHLORIDE; SIMETHICONE

TABLET, CHEWABLE;ORAL

IMODIUM MULTI-SYMPTOM RELIEF

+ @ J AND J CONSUMER INC 2MG;125MG

N 020606 001 Jun 26, 1996 Jan DISC

LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE

! PERRIGO 2MG;125MG

A 076029 001 Aug 30, 2002 Jan CHRS

LORATADINE

SYRUP;ORAL

LORATADINE

TARO PHARM 1MG/ML

A 201865 001 Jul 31, 2015 Mar CAHN

MICONAZOLE NITRATE

CREAM;VAGINAL

MICONAZOLE NITRATE

>D> TARO 2%
>A> 2%A 074444 001 Jan 13, 1997 Apr CAHN
A 074444 001 Jan 13, 1997 Apr CAHN

MINOXIDIL

	AEROSOL, FOAM;TOPICAL						
	MINOXIDIL (FOR MEN)						
	WATSON LABS INC	5%	A208092	001	Feb 17, 2017	Feb	NEWA
	SOLUTION;TOPICAL						
	MINOXIDIL (FOR MEN)						
>A>	L PERRIGO CO	2%	A075357	001	Jul 30, 1999	Apr	CAHN
>D>	PERRIGO	2%	A075357	001	Jul 30, 1999	Apr	CAHN
	MINOXIDIL (FOR WOMEN)						
>A>	L PERRIGO CO	2%	A075357	002	Jul 30, 1999	Apr	CAHN
>D>	PERRIGO	2%	A075357	002	Jul 30, 1999	Apr	CAHN

NAPROXEN SODIUM

	TABLET;ORAL						
	NAPROXEN SODIUM						
	LNK INTL INC	EQ 200MG BASE	A204872	001	Jan 23, 2017	Jan	NEWA

NICOTINE POLACRILEX

	GUM, CHEWING;BUCCAL						
	NICOTINE POLACRILEX						
>A>	L PERRIGO CO	EQ 2MG BASE	A076775	001	Sep 16, 2004	Apr	CAHN
>A>		EQ 2MG BASE	A076776	001	Sep 16, 2004	Apr	CAHN
>A>		EQ 2MG BASE	A076777	001	Sep 16, 2004	Apr	CAHN
>A>		EQ 4MG BASE	A076778	001	Sep 16, 2004	Apr	CAHN
>A>		EQ 4MG BASE	A076779	001	Sep 16, 2004	Apr	CAHN
>A>		EQ 4MG BASE	A076789	001	Sep 16, 2004	Apr	CAHN
>D>	PERRIGO	EQ 2MG BASE	A076775	001	Sep 16, 2004	Apr	CAHN
>D>		EQ 2MG BASE	A076776	001	Sep 16, 2004	Apr	CAHN
>D>		EQ 2MG BASE	A076777	001	Sep 16, 2004	Apr	CAHN
>D>		EQ 4MG BASE	A076778	001	Sep 16, 2004	Apr	CAHN
>D>		EQ 4MG BASE	A076779	001	Sep 16, 2004	Apr	CAHN
>D>		EQ 4MG BASE	A076789	001	Sep 16, 2004	Apr	CAHN

PSEUDOEPHEDRINE HYDROCHLORIDE

	TABLET, EXTENDED RELEASE;ORAL						
	PSEUDOEPHEDRINE HYDROCHLORIDE						
>A>	L PERRIGO CO	120MG	A075153	001	Feb 26, 1999	Apr	CAHN
>D>	PERRIGO	120MG	A075153	001	Feb 26, 1999	Apr	CAHN

RANITIDINE HYDROCHLORIDE

	TABLET;ORAL						
	RANITIDINE HYDROCHLORIDE						
	STRIDES PHARMA	EQ 150MG BASE	A200536	001	Jun 28, 2011	Jan	CAHN
	ZANTAC 150						
+!	SANOFI US	EQ 150MG BASE	N021698	001	Aug 31, 2004	Mar	CAHN
+		EQ 150MG BASE	N021698	002	Mar 13, 2007	Mar	CAHN
	ZANTAC 75						
	SANOFI US	EQ 75MG BASE	N020520	001	Dec 19, 1995	Mar	CAHN
	TABLET, EFFERVESCENT;ORAL						
	ZANTAC 75						
+	@ SANOFI US	EQ 75MG BASE	N020745	001	Feb 26, 1998	Mar	CAHN

TRIAMCINOLONE ACETONIDE

	SPRAY, METERED;NASAL						
	TRIAMCINOLONE ACETONIDE						
	PERRIGO ISRAEL	0.055MG/SPRAY	A078104	002	Nov 14, 2014	Jan	CAHN

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 04 APRIL 2017

NO APRIL 2017 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of Orphan Designations and Approvals is available at:

<http://www.fda.gov/orphan/designat/list.htm>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO APRIL 2017 ADDITIONS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ABALOPARATIDE - TYMLOS</u>						
N 208743 001					>A> NCE	Apr 28, 2022
<u>ACETAMINOPHEN - OFIRMEV</u>						
N 022450 001					M-196 PED	Jan 27, 2020 Jul 27, 2020
<u>ACETYLCYSTEINE - CETYLEV</u>						
N 207916 001	>A> 9561204	May 08, 2032	U-1373			
<u>ACETYLCYSTEINE - CETYLEV</u>						
N 207916 002	>A> 9561204	May 08, 2032	U-1373			
<u>AFATINIB DIMALEATE - GILOTTRIF</u>						
N 201292 001	9539258	Nov 09, 2026	U-1950			
<u>AFATINIB DIMALEATE - GILOTTRIF</u>						
N 201292 002	9539258	Nov 09, 2026	U-1950			
<u>AFATINIB DIMALEATE - GILOTTRIF</u>						
N 201292 003	9539258	Nov 09, 2026	U-1950			
<u>ALBUTEROL SULFATE; IPRATROPIUM BROMIDE - COMBIVENT RESPIMAT</u>						
N 021747 001	>A> 8733341	Oct 16, 2030	DP			
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 001	8173663 8697125	Dec 02, 2025 Jun 16, 2029	U-1338 DP			
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 002	8173663 8697125	Dec 02, 2025 Jun 16, 2029	U-1338 DP			
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 003	8173663 8697125	Dec 02, 2025 Jun 16, 2029	U-1338 DP			
<u>ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE - KAZANO</u>						
N 203414 001	8288539	Jun 24, 2025	DS			
<u>ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE - KAZANO</u>						
N 203414 002	8288539	Jun 24, 2025	DS			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 005	6329404	Jun 19, 2021	DP U-1334			
<u>AMBRISENTAN - LETAIRIS</u>						
N 022081 001	9549926	Oct 14, 2031	U-1965			
<u>AMBRISENTAN - LETAIRIS</u>						
N 022081 002	9549926	Oct 14, 2031	U-1965			
<u>AMLODIPINE BESYLATE; PERINDOPRIL ARGININE - PRESTALIA</u>						
N 205003 001					NP	Jan 21, 2018
<u>AMLODIPINE BESYLATE; PERINDOPRIL ARGININE - PRESTALIA</u>						
N 205003 002					NP	Jan 21, 2018

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AMLODIPINE BESYLATE; PERINDOPRIL ARGININE - PRESTALIA</u>						
N 205003	003				NP	Jan 21, 2018
<u>ARIPIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533	001	9526726	Mar 19, 2035	DP		
<u>ARIPIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533	002	9526726	Mar 19, 2035	DP		
<u>ARIPIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533	003	9526726	Mar 19, 2035	DP		
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117	001	5763476	Jun 09, 2020	DP U-326	D-166	Jan 13, 2020
		5763476	Jun 09, 2020	DP U-1960	I-597	Jan 13, 2020
		5763476	Jun 09, 2020	DP U-1961		
		5763476	Jun 09, 2020	DP U-1962		
		5763476	Jun 09, 2020	DP U-1963		
		5763476*PED	Dec 09, 2020			
		7741358	Apr 06, 2026	DS DP U-1064		
		7741358	Apr 06, 2026	DS DP U-1960		
		7741358	Apr 06, 2026	DS DP U-1961		
		7741358	Apr 06, 2026	DS DP U-1962		
		7741358	Apr 06, 2026	DS DP U-1963		
		7741358*PED	Oct 06, 2026			
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117	002	5763476	Jun 09, 2020	DP U-326	D-166	Jan 13, 2020
		5763476	Jun 09, 2020	DP U-1960	I-597	Jan 13, 2020
		5763476	Jun 09, 2020	DP U-1961		
		5763476	Jun 09, 2020	DP U-1962		
		5763476	Jun 09, 2020	DP U-1963		
		5763476*PED	Dec 09, 2020			
		7741358	Apr 06, 2026	DS DP U-1064		
		7741358	Apr 06, 2026	DS DP U-1960		
		7741358	Apr 06, 2026	DS DP U-1961		
		7741358	Apr 06, 2026	DS DP U-1962		
		7741358	Apr 06, 2026	DS DP U-1963		
		7741358*PED	Oct 06, 2026			
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117	003	5763476	Jun 09, 2020	DP U-1893	D-166	Jan 13, 2020
		5763476	Jun 09, 2020	DP U-1966	I-597	Jan 13, 2020
		5763476*PED	Dec 09, 2020			
		7741358	Apr 06, 2026	DS DP U-1893		
		7741358	Apr 06, 2026	DS DP U-1966		
		7741358*PED	Oct 06, 2026			
<u>ASPIRIN; OMEPRAZOLE - YOSPRALA</u>						
N 205103	001	9539214	Mar 13, 2033	U-1902		
<u>ASPIRIN; OMEPRAZOLE - YOSPRALA</u>						
N 205103	002	9539214	Mar 13, 2033	U-1902		
<u>AVIBACTAM SODIUM; CEFTAZIDIME - AVYCAZ</u>						
N 206494	001	9284314	Jun 15, 2032	DS		
<u>BEDAQUILINE FUMARATE - SIRTURO</u>						
N 204384	001	7498343	Dec 01, 2026	DS DP U-1321		
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249	001	9533955	Mar 26, 2029	DP U-1949		
		9533955	Mar 26, 2029	DP U-1952		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249 001	9533955	Mar 26, 2029	DP U-1949			
	9533955	Mar 26, 2029	DP U-1952			
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249 002	9533955	Mar 26, 2029	DP U-1949			
	9533955	Mar 26, 2029	DP U-1952			
<u>BENDAMUSTINE HYDROCHLORIDE - BENDEKA</u>						
N 208194 001	9572796	Jan 28, 2031	DP U-1971			
	9572796	Jan 28, 2031	DP U-1972			
	9572797	Jan 28, 2031	U-1971			
	9572797	Jan 28, 2031	U-1972			
	9572887	Mar 15, 2033	U-1971			
	9572887	Mar 15, 2033	U-1972			
	9579384	Mar 15, 2033	U-1971			
	9579384	Mar 15, 2033	U-1972			
	9597397	Mar 15, 2033	U-1971			
	9597397	Mar 15, 2033	U-1972			
	9597398	Mar 15, 2033	U-1971			
	9597399	Mar 15, 2033	U-1971			
	9597399	Mar 15, 2033	U-1972			
<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ONEXTON</u>						
N 050819 002	9561208	Jun 03, 2029	DP U-916			
<u>BIMATOPROST - LATISSE</u>						
N 022369 001	9579270	Jan 31, 2021	U-1975			
<u>BRIGATINIB - ALUNBRIG</u>						
N 208772 001				>A> NCE		Apr 28, 2022
<u>BRIGATINIB - ALUNBRIG</u>						
N 208772 002				>A> NCE		Apr 28, 2022
<u>BROMFENAC SODIUM - PROLENSA</u>						
N 203168 001	9517220	Nov 11, 2033	U-1933			
	9561277	Jan 16, 2024	U-1933			
<u>BROMOCRIPTINE MESYLATE - CYCLOSET</u>						
N 020866 001	9522117	Apr 30, 2032	DP U-976			
	9522117	Apr 30, 2032	DP U-1939			
<u>BUDESONIDE - UCERIS</u>						
N 203634 001	9532954	Jun 09, 2020	DP U-1325			
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N 021929 001	6123924	Sep 26, 2017	DP		NPP	Jan 27, 2020
	6123924*PED	Mar 26, 2018			PED	Jul 27, 2020
	7367333	Nov 11, 2018	DP			
	7367333*PED	May 11, 2019				
	7587988	Apr 10, 2026	DP			
	7587988*PED	Oct 10, 2026				
	>A> 7759328	Jan 29, 2023	DP U-2001			
	>A> 7759328	Jan 29, 2023	DP U-2002			
	>A> 7759328*PED	Jul 29, 2023				
	7967011	Aug 11, 2021	DP			
	7967011*PED	Feb 11, 2022				
	>A> 8143239	Jan 29, 2023	DP U-2001			
	>A> 8143239	Jan 29, 2023	DP U-2002			
	>A> 8143239*PED	Jul 29, 2023				
	8387615	Nov 10, 2024	DP			
	8387615*PED	May 10, 2025				
	8528545	Oct 16, 2028	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N 021929 001	8528545*PED	Apr 16, 2029				
	>A> 8575137	Jan 29, 2023	DP U-2001			
	>A> 8575137	Jan 29, 2023	DP U-2002			
	>A> 8575137*PED	Jul 29, 2023				
	8616196	Apr 07, 2029	DP			
	8616196*PED	Oct 07, 2029				
	8875699	Nov 10, 2024	DP			
	8875699*PED	May 10, 2025				
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N 021929 002	6123924	Sep 26, 2017	DP			
	6123924*PED	Mar 26, 2018				
	7367333	Nov 11, 2018	DP			
	7367333*PED	May 11, 2019				
	7587988	Apr 10, 2026	DP			
	7587988*PED	Oct 10, 2026				
	>A> 7759328	Jan 29, 2023	DP U-2001			
	>A> 7759328	Jan 29, 2023	DP U-2002			
	>A> 7759328*PED	Jul 29, 2023				
	>A> 7897646	Sep 09, 2018		U-2002		
	>A> 7897646*PED	Mar 09, 2019				
	7967011	Aug 11, 2021	DP			
	7967011*PED	Feb 11, 2022				
	>A> 8143239	Jan 29, 2023	DP U-2001			
	>A> 8143239	Jan 29, 2023	DP U-2002			
	>A> 8143239*PED	Jul 29, 2023				
	8387615	Nov 10, 2024	DP			
	8387615*PED	May 10, 2025				
	>A> 8461211	Sep 09, 2018		U-2002		
	>A> 8461211*PED	Mar 09, 2019				
	8528545	Oct 16, 2028	DP			
	8528545*PED	Apr 16, 2029				
	>A> 8575137	Jan 29, 2023	DP U-2001			
	>A> 8575137	Jan 29, 2023	DP U-2002			
	>A> 8575137*PED	Jul 29, 2023				
	8616196	Apr 07, 2029	DP			
	8616196*PED	Oct 07, 2029				
	8875699	Nov 10, 2024	DP			
	8875699*PED	May 10, 2025				
<u>BUPIVACAINE - EXPAREL</u>						
N 022496 001	9585838	Dec 24, 2021	DP			
<u>BUPIVACAINE - EXPAREL</u>						
N 022496 002	9585838	Dec 24, 2021	DP			
<u>BUPRENORPHINE - BUTRANS</u>						
N 021306 001	>A> 9642850	Sep 29, 2017		U-1556		
<u>BUPRENORPHINE - BUTRANS</u>						
N 021306 002	>A> 9642850	Sep 29, 2017		U-1556		
<u>BUPRENORPHINE - BUTRANS</u>						
N 021306 003	>A> 9642850	Sep 29, 2017		U-1556		
<u>BUPRENORPHINE - BUTRANS</u>						
N 021306 004	>A> 9642850	Sep 29, 2017		U-1556		
<u>BUPRENORPHINE - BUTRANS</u>						
N 021306 005	>A> 9642850	Sep 29, 2017		U-1556		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042	001				M-197	Feb 01, 2020
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042	002				M-197	Feb 01, 2020
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353	001				M-197	Feb 01, 2020
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353	002				M-197	Feb 01, 2020
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353	003				M-197	Feb 01, 2020
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353	004				M-197	Feb 01, 2020
<u>CARBAMAZEPINE - CARNEXIV</u>						
N 206030	001	9493582	Feb 27, 2033	DP		
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312	001	9533046	Dec 26, 2028	DP U-219		
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312	002	9533046	Dec 26, 2028	DP U-219		
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312	003	9533046	Dec 26, 2028	DP U-219		
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312	004	9533046	Dec 26, 2028	DP U-219		
<u>CARFILZOMIB - KYPROLIS</u>						
N 202714	001	9493582	Feb 27, 2033	DP		
<u>CARFILZOMIB - KYPROLIS</u>						
N 202714	002	9493582	Feb 27, 2033	DP		
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - GENVOYA</u>						
N 207561	001	>A> 7176220	Aug 27, 2026	DS DP U-257		
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - STRIBILD</u>						
N 203100	001	>A> 7176220	Aug 27, 2026	DS DP U-257	NPP	Jan 27, 2020
<u>COLCHICINE - MITIGARE</u>						
N 204820	001	9555029	Aug 22, 2033	U-1020		
<u>CRISABOROLE - EUCRISA</u>						
N 207695	001	8039451	Jun 11, 2026	DS DP	NCE	Dec 14, 2021
		8168614	Jan 20, 2030	U-1932		
		8501712	Feb 16, 2027	U-1932		
<u>DAPAGLIFLOZIN PROPANEDIOL; SAXAGLIPTIN HYDROCHLORIDE - QTERN</u>						
N 209091	001	6414126	Oct 04, 2020	DS DP U-1976	M-175	Apr 05, 2019
		6414126	Oct 04, 2020	DS DP U-1977	NC	Feb 27, 2020
		6515117	Oct 04, 2020	DS DP U-1976	NCE	Jan 08, 2019
		6515117	Oct 04, 2020	DS DP U-1977		
		6936590	Oct 04, 2020	U-1976		
		6936590	Oct 04, 2020	U-1977		
		7919598	Dec 16, 2029	DS		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DAPAGLIFLOZIN PROPANEDIOL; SAXAGLIPTIN HYDROCHLORIDE - QTERN</u>						
N 209091 001	8221786	Mar 21, 2028	DP			
	8361972	Mar 21, 2028	U-1976			
	8361972	Mar 21, 2028	U-1977			
	8501698	Jun 20, 2027	DP U-1976			
	8501698	Jun 20, 2027	DP U-1977			
	8628799	Jul 13, 2025	DP			
	8716251	Mar 21, 2028	DP			
	9198925	Oct 04, 2020	U-1976			
	9198925	Oct 04, 2020	U-1977			
	RE44186	Jul 31, 2023	DS DP U-1976			
	RE44186	Jul 31, 2023	DS DP U-1977			
<u>DAPTOMYCIN - CUBICIN</u>						
N 021572 002					>A> NPP	Mar 29, 2020
<u>DAPTOMYCIN - CUBICIN RF</u>						
N 021572 003					>A> NPP	Mar 29, 2020
<u>DEFLAZACORT - EMFLAZA</u>						
N 208684 001					NCE	Feb 09, 2022
					>A> ODE	Feb 09, 2024
<u>DEFLAZACORT - EMFLAZA</u>						
N 208684 002					NCE	Feb 09, 2022
					>A> ODE	Feb 09, 2024
<u>DEFLAZACORT - EMFLAZA</u>						
N 208684 003					NCE	Feb 09, 2022
					>A> ODE	Feb 09, 2024
<u>DEFLAZACORT - EMFLAZA</u>						
N 208684 004					NCE	Feb 09, 2022
					>A> ODE	Feb 09, 2024
<u>DEFLAZACORT - EMFLAZA</u>						
N 208685 001					NCE	Feb 09, 2022
					>A> ODE	Feb 09, 2024
<u>DEGARELIX ACETATE - FIRMAGON</u>						
N 022201 001	9579359	Feb 10, 2029	U-1978			
<u>DEGARELIX ACETATE - FIRMAGON</u>						
N 022201 002	9579359	Feb 10, 2029	U-1978			
<u>DEOXYCHOLIC ACID - KYBELLA</u>						
N 206333 001	9522155	Feb 21, 2028	DP U-1940			
<u>DESMOPRESSIN ACETATE - NOCTIVA</u>						
N 201656 001	7405203	May 06, 2023	U-1980		NP	Mar 03, 2020
	7579321	May 06, 2023	U-1980			
	7799761	Sep 26, 2024	DP			
	9539302	Jun 15, 2030	DP			
<u>DESMOPRESSIN ACETATE - NOCTIVA</u>						
N 201656 002	7405203	May 06, 2023	U-1980		NP	Mar 03, 2020
	7579321	May 06, 2023	U-1980			
	7799761	Sep 26, 2024	DP			
	9539302	Jun 15, 2030	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204003	001				PC	Aug 28, 2017
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204003	002				PC	Aug 28, 2017
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204028	001				PC	Aug 28, 2017
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204028	002				PC	Aug 28, 2017
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204082	001				PC	Aug 28, 2017
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204083	001				PC	Aug 28, 2017
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204095	001				PC	Aug 28, 2017
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204095	002				PC	Aug 28, 2017
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204172	001				PC	Aug 28, 2017
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204172	002				PC	Aug 28, 2017
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082	001	>A> 8524733	Mar 27, 2031	DS DP	>A> NCE	Apr 03, 2022
		>A> 9233959	Sep 18, 2033	DP	>A> ODE	Apr 03, 2024
		>A> 9296739	Sep 18, 2033	DP		
		>A> 9550780	Sep 18, 2033	DS DP U-1846		
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082	002	>A> 8524733	Mar 27, 2031	DS DP	>A> NCE	Apr 03, 2022
		>A> 9233959	Sep 18, 2033	DP	>A> ODE	Apr 03, 2024
		>A> 9296739	Sep 18, 2033	DP		
		>A> 9550780	Sep 18, 2033	DS DP U-1846		
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082	003	>A> 8524733	Mar 27, 2031	DS DP	>A> NCE	Apr 03, 2022
		>A> 9233959	Sep 18, 2033	DP	>A> ODE	Apr 03, 2024
		>A> 9296739	Sep 18, 2033	DP		
		>A> 9550780	Sep 18, 2033	DS DP U-1846		
<u>DEXAMETHASONE - OZURDEX</u>						
N 022315	001	>A> 9592242	Oct 20, 2020	U-1989		
		>A> 9592242	Oct 20, 2020	U-1990		
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038	002	>A> 9616049	Jan 04, 2032	DP		
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038	003	>A> 9616049	Jan 04, 2032	DP		
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038	004	>A> 9616049	Jan 04, 2032	DP		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DICLOFENAC POTASSIUM - ZIPSOR</u>						
N 022202 001	9561200	Feb 24, 2029	U-1482			
<u>DICLOFENAC SODIUM - PENNSAID</u>						
N 204623 001	9539335	Oct 17, 2027	U-1614			
<u>DOXEPIH HYDROCHLORIDE - SILENOR</u>						
N 022036 001	9532971	Jun 01, 2029	DP			
	9572814	Jul 20, 2027	U-620			
<u>DOXEPIH HYDROCHLORIDE - SILENOR</u>						
N 022036 002	9532971	Jun 01, 2029	DP			
	9572814	Jul 20, 2027	U-620			
<u>DRONABINOL - SYNDROS</u>						
N 205525 001	>A> 8222292	Aug 06, 2028	DS DP			
	9345771	Aug 06, 2028	DS DP			
<u>EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - ATRIPLA</u>						
N 021937 001	9545414	Jun 13, 2026	DP U-750			
	9545414	Jun 13, 2026	DP U-1170			
<u>EFINACONAZOLE - JUBLIA</u>						
N 203567 001	9566272	Jan 03, 2028	U-1969			
<u>ELUXADOLINE - VIBERZI</u>						
N 206940 001	8772325	Mar 14, 2025	U-1709			
<u>ELUXADOLINE - VIBERZI</u>						
N 206940 002	8772325	Mar 14, 2025	U-1709			
<u>ELVITEGRAVIR - VITEKTA</u>						
N 203093 001	>A> 7176220	Aug 27, 2026	DS DP U-257			
<u>ELVITEGRAVIR - VITEKTA</u>						
N 203093 002	>A> 7176220	Aug 27, 2026	DS DP U-257			
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 002	6642245	Nov 04, 2020	U-248			
	6642245	Nov 04, 2020	U-541			
	6642245	Nov 04, 2020	U-1170			
	6642245*PED	May 04, 2021				
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 003	6642245	Nov 04, 2020	U-248			
	6642245	Nov 04, 2020	U-541			
	6642245	Nov 04, 2020	U-1170			
	6642245*PED	May 04, 2021				
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 004	6642245	Nov 04, 2020	U-248			
	6642245	Nov 04, 2020	U-541			
	6642245	Nov 04, 2020	U-1170			
	6642245*PED	May 04, 2021				
<u>ENZALUTAMIDE - XTANDI</u>						
N 203415 001	>A> 8183274	Aug 24, 2026	U-1281			
	>A> 8183274	Aug 24, 2026	U-1588			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 001	9566244	Oct 23, 2028	DP			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 002	9566244	Oct 23, 2028	DP			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 003	9566244	Oct 23, 2028	DP			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 004	9566244	Oct 23, 2028	DP			
<u>ETELCALCETIDE - PARSABIV</u>						
N 208325 001					NCE	Feb 07, 2022
<u>ETELCALCETIDE - PARSABIV</u>						
N 208325 002					NCE	Feb 07, 2022
<u>ETELCALCETIDE - PARSABIV</u>						
N 208325 003					NCE	Feb 07, 2022
<u>ETHINYL ESTRADIOL; LEVONORGESTREL - FAYOSIM</u>						
A 205943 001					>A> PC	Sep 30, 2017
<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - MIBELAS 24 FE</u>						
A 206287 001					PC	Sep 11, 2017
<u>FENTANYL CITRATE - ONSOLIS</u>						
N 022266 001	9579288	Jul 23, 2027	DP U-767			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N 022266 002	9579288	Jul 23, 2027	DP U-767			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N 022266 003	9579288	Jul 23, 2027	DP U-767			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N 022266 004	9579288	Jul 23, 2027	DP U-767			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N 022266 005	9579288	Jul 23, 2027	DP U-767			
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 001	6446627	Dec 18, 2017	DP		NP	Jan 27, 2020
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8714149	Feb 25, 2032	DP			
	8978966	Jan 13, 2032	DP			
	9216260	Jun 28, 2031	DP			
	9463288	May 19, 2025	DP			
	>A> 9616024	Sep 01, 2024	DP			
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 002	6446627	Dec 18, 2017	DP		NP	Jan 27, 2020
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 002	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8714149	Feb 25, 2032	DP			
	8978966	Jan 13, 2032	DP			
	9216260	Jun 28, 2031	DP			
	9463288	May 19, 2025	DP			
	>A> 9616024	Sep 01, 2024	DP			
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 003	6446627	Dec 18, 2017	DP		NP	Jan 27, 2020
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8714149	Feb 25, 2032	DP			
	8978966	Jan 13, 2032	DP			
	9216260	Jun 28, 2031	DP			
	9463288	May 19, 2025	DP			
	>A> 9616024	Sep 01, 2024	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 001	6446627	Dec 18, 2017	DP		NP	Jan 27, 2020
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8714149	Feb 25, 2032	DP			
	8978966	Jan 13, 2032	DP			
	9066957	Oct 06, 2034	DP U-645			
	9216260	Jun 28, 2031	DP			
	9415008	Oct 06, 2034	DP U-645			
	9463288	May 19, 2025	DP			
	>A> 9616024	Sep 01, 2024	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 002	6446627	Dec 18, 2017	DP		NP	Jan 27, 2020
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8714149	Feb 25, 2032	DP			
	8978966	Jan 13, 2032	DP			
	9066957	Oct 06, 2034	DP U-645			
	9216260	Jun 28, 2031	DP			
	9463288	May 19, 2025	DP			
	>A> 9616024	Sep 01, 2024	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 003	6446627	Dec 18, 2017	DP		NP	Jan 27, 2020
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 003	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8714149	Feb 25, 2032	DP			
	8978966	Jan 13, 2032	DP			
	9066957	Oct 06, 2034	DP U-645			
	9216260	Jun 28, 2031	DP			
	9463288	May 19, 2025	DP			
>A>	9616024	Sep 01, 2024	DP			
<u>GANCICLOVIR - GANCICLOVIR</u>						
N 209347 001	9486530	Sep 02, 2034	DP			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 001	9486451	Sep 12, 2034	U-55			
	9610286	Jul 25, 2033	U-1810			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 002	9486451	Sep 12, 2034	U-55			
	9610286	Jul 25, 2033	U-1810			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 003	9486451	Sep 12, 2034	U-55			
	9610286	Jul 25, 2033	U-1810			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 004	9486451	Sep 12, 2034	U-55			
	9610286	Jul 25, 2033	U-1810			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 005	9486451	Sep 12, 2034	U-55			
	9610286	Jul 25, 2033	U-1810			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 006	9486451	Sep 12, 2034	U-55			
	9610286	Jul 25, 2033	U-1810			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 001	9517236	Oct 30, 2021	DP			
	9545380	Aug 24, 2027	U-1556			
	9572779	Dec 21, 2031	DP			
	9572804	Oct 30, 2021	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 002	9517236	Oct 30, 2021	DP			
	9545380	Aug 24, 2027	U-1556			
	9572779	Dec 21, 2031	DP			
	9572804	Oct 30, 2021	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 003	9517236	Oct 30, 2021	DP			
	9545380	Aug 24, 2027	U-1556			
	9572779	Dec 21, 2031	DP			
	9572804	Oct 30, 2021	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 004	9517236	Oct 30, 2021	DP			
	9545380	Aug 24, 2027	U-1556			
	9572779	Dec 21, 2031	DP			
	9572804	Oct 30, 2021	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 005	9517236	Oct 30, 2021	DP			
	9545380	Aug 24, 2027	U-1556			
	9572779	Dec 21, 2031	DP			
	9572804	Oct 30, 2021	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 006	9517236	Oct 30, 2021	DP			
	9545380	Aug 24, 2027	U-1556			
	9572779	Dec 21, 2031	DP			
	9572804	Oct 30, 2021	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 007	9517236	Oct 30, 2021	DP			
	9545380	Aug 24, 2027	U-1556			
	9572779	Dec 21, 2031	DP			
	9572804	Oct 30, 2021	DP			
<u>HYDROCODONE BITARTRATE - VANTRELA ER</u>						
N 207975 001	8445018	Jul 31, 2029	DP			
	9216176	Sep 13, 2027	DP			
	9572803	Sep 13, 2027	DP			
<u>HYDROCODONE BITARTRATE - VANTRELA ER</u>						
N 207975 002	8445018	Jul 31, 2029	DP			
	9216176	Sep 13, 2027	DP			
	9572803	Sep 13, 2027	DP			
<u>HYDROCODONE BITARTRATE - VANTRELA ER</u>						
N 207975 003	8445018	Jul 31, 2029	DP			
	9216176	Sep 13, 2027	DP			
	9572803	Sep 13, 2027	DP			
<u>HYDROCODONE BITARTRATE - VANTRELA ER</u>						
N 207975 004	8445018	Jul 31, 2029	DP			
	9216176	Sep 13, 2027	DP			
	9572803	Sep 13, 2027	DP			
<u>HYDROCODONE BITARTRATE - VANTRELA ER</u>						
N 207975 005	8445018	Jul 31, 2029	DP			
	9216176	Sep 13, 2027	DP			
	9572803	Sep 13, 2027	DP			
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 001	>A> 8476284	Dec 28, 2026	U-1456		I-741	Jan 18, 2020
	>A> 8476284	Dec 28, 2026	U-1491		ODE	Jan 18, 2024
	>A> 8476284	Dec 28, 2026	U-1947			
	>A> 8497277	Dec 28, 2026	U-1456			
	>A> 8497277	Dec 28, 2026	U-1491			
	>A> 8497277	Dec 28, 2026	U-1650			
	>A> 8497277	Dec 28, 2026	U-1947			
	9540382	Aug 18, 2033	U-1456			
	9540382	Aug 18, 2033	U-1650			
	9540382	Aug 18, 2033	U-1684			
	9540382	Aug 18, 2033	U-1946			
	9540382	Aug 18, 2033	U-1947			
<u>INSULIN GLARGINE RECOMBINANT - LANTUS SOLOSTAR</u>						
N 021081 002	9561331	Aug 28, 2024	DP			
	9604008	Mar 02, 2024	DP			
	9604009	Aug 16, 2024	DP			
	9610409	Mar 02, 2024	DP			
	>A> 9623189	Aug 19, 2024	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN GLARGINE RECOMBINANT - TOUJEO SOLOSTAR</u>						
N 206538 001	9561331	Aug 28, 2024	DP			
	9604008	Mar 02, 2024	DP			
	>A> 9604009	Aug 16, 2024	DP			
	>A> 9610409	Mar 02, 2024	DP			
	>A> 9623189	Aug 19, 2024	DP			
<u>INSULIN GLARGINE; LIXISENATIDE - SOLIQUA 100/33</u>						
N 208673 001	9526764	Oct 09, 2029	DP			
	9561331	Aug 28, 2024	DP			
	9604008	Mar 02, 2024	DP			
	9604009	Aug 16, 2024	DP			
	9610409	Mar 02, 2024	DP			
	>A> 9623189	Aug 19, 2024	DP			
<u>INSULIN GLULISINE RECOMBINANT - APIDRA SOLOSTAR</u>						
N 021629 003	9561331	Aug 28, 2024	DP			
	9604008	Mar 02, 2024	DP			
	9610409	Mar 02, 2024	DP			
	>A> 9623189	Aug 19, 2024	DP			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 001	>A> 9597374	Oct 08, 2031		U-1987		
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 002	>A> 9597374	Oct 08, 2031		U-1987		
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 003	>A> 9597374	Oct 08, 2031		U-1987		
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 001	7973038	Nov 08, 2026		U-1973		
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 002	7973038	Nov 08, 2026		U-1973		
<u>LEDIPASVIR; SOFOSBUVIR - HARVONI</u>						
N 205834 001				>A> NPP		Apr 07, 2020
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 001	5635517	Oct 04, 2019	DS	>A> ODE		Feb 22, 2024
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 002	5635517	Oct 04, 2019	DS	>A> ODE		Feb 22, 2024
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 003	5635517	Oct 04, 2019	DS	>A> ODE		Feb 22, 2024
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 004	5635517	Oct 04, 2019	DS	>A> ODE		Feb 22, 2024
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 005	5635517	Oct 04, 2019	DS	>A> ODE		Feb 22, 2024
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 006	5635517	Oct 04, 2019	DS	>A> ODE		Feb 22, 2024
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021343 001	9254307	Oct 28, 2018	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021379 001	8470359	Oct 15, 2023	DS DP U-621			
	8486455	Oct 28, 2018	DS DP			
	8840916	Nov 13, 2020	DP			
	9539333	Nov 13, 2020	DS DP U-621			
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021488 001	8470359	Oct 15, 2023	DS DP U-621			
	8486455	Oct 28, 2018	DS DP			
	8840916	Nov 13, 2020	DP			
	9539333	Nov 13, 2020	DS DP U-621			
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021731 001	8470359	Oct 15, 2023	DS DP U-621			
	8486455	Oct 28, 2018	DS DP			
	8840916	Nov 13, 2020	DP			
	9539333	Nov 13, 2020	DS DP U-621			
<u>LEVOCETIRIZINE DIHYDROCHLORIDE - XYZAL ALLERGY 24HR</u>						
N 209090 001	8633194	Oct 16, 2027	DP			
<u>LEVONORGESTREL - MIRENA</u>						
N 021225 001 >A>	9615965	Sep 16, 2029	DP U-2003			
<u>LEVONORGESTREL - SKYLA</u>						
N 203159 001 >A>	9615965	Sep 16, 2029	DP U-2003			
<u>LEVONORGESTREL - KYLEENA</u>						
N 208224 001 >A>	9615965	Sep 16, 2029	DP U-2003			
<u>LINACLOTIDE - LINZESS</u>						
N 202811 003	7304036	Aug 30, 2026	DS DP U-1516		NCE	Aug 30, 2017
	7371727	Jan 28, 2024	DS		NS	Jan 25, 2020
	7704947	Jan 28, 2024	DS DP			
	7745409	Jan 28, 2024	DS DP			
	8080526	Jan 28, 2024	DS DP			
	8110553	Jan 28, 2024	U-1516			
	8933030	Feb 17, 2031	DP U-1516			
<u>LINAGLIPTIN - TRADJENTA</u>						
N 201280 001 >A>	8846695	Jun 04, 2030	U-1503	Y		
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 001 >A>	8846695	Jun 04, 2030	U-1503			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 002 >A>	8846695	Jun 04, 2030	U-1503			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 003 >A>	8846695	Jun 04, 2030	U-1503	Y		
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR</u>						
N 208026 001	9555001	Mar 06, 2033	DP U-1967			
	9555001	Mar 06, 2033	DP U-1968			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR</u>						
N 208026 002	9555001	Mar 06, 2033	DP U-1967			
	9555001	Mar 06, 2033	DP U-1968			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 001	7105486	Feb 24, 2023	U-727		I-703	Jan 30, 2018
	7223735	Feb 24, 2023	DP		M-188	Oct 14, 2019

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 001	7655630	Feb 24, 2023	DS DP			
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-727			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-727			
	7678770	Feb 24, 2023	U-727			
	7678771	Feb 24, 2023	DP U-727			
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP U-727			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-727			
	7723305	Feb 24, 2023	DP U-727			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 002	7105486	Feb 24, 2023	U-727		I-703	Jan 30, 2018
	7223735	Feb 24, 2023	DP		M-188	Oct 14, 2019
	7655630	Feb 24, 2023	DS DP			
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-727			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-727			
	7678770	Feb 24, 2023	U-727			
	7678771	Feb 24, 2023	DP U-727			
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP U-727			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-727			
	7723305	Feb 24, 2023	DP U-727			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 003	7105486	Feb 24, 2023	U-727		I-703	Jan 30, 2018
	7223735	Feb 24, 2023	DP		M-188	Oct 14, 2019
	7655630	Feb 24, 2023	DS DP			
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-727			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-727			
	7678770	Feb 24, 2023	U-727			
	7678771	Feb 24, 2023	DP U-727			
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP U-727			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-727			
	7723305	Feb 24, 2023	DP U-727			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 004	7105486	Feb 24, 2023	U-727		I-703	Jan 30, 2018
	7223735	Feb 24, 2023	DP		M-188	Oct 14, 2019
	7655630	Feb 24, 2023	DS DP			
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-727			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-727			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 004	7678770	Feb 24, 2023	U-727			
	7678771	Feb 24, 2023	DP U-727			
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP U-727			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-727			
	7723305	Feb 24, 2023	DP U-727			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 005	7105486	Feb 24, 2023	U-727		I-703	Jan 30, 2018
	7223735	Feb 24, 2023	DP		M-188	Oct 14, 2019
	7655630	Feb 24, 2023	DS DP			
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-727			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-727			
	7678770	Feb 24, 2023	U-727			
	7678771	Feb 24, 2023	DP U-727			
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP U-727			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-727			
	7723305	Feb 24, 2023	DP U-727			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 006	7105486	Feb 24, 2023	U-727		I-703	Jan 30, 2018
	7223735	Feb 24, 2023	DP		M-188	Oct 14, 2019
	7655630	Feb 24, 2023	DS DP			
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-727			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-727			
	7678770	Feb 24, 2023	U-727			
	7678771	Feb 24, 2023	DP U-727			
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP U-727			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-727			
	7723305	Feb 24, 2023	DP U-727			
<u>LISINOPRIL - OBRELIS</u>						
N 208401 001	>A> 9616096	Nov 06, 2035	U-3			
	>A> 9616096	Nov 06, 2035	U-8			
	>A> 9616096	Nov 06, 2035	U-71			
	>A> 9616096	Nov 06, 2035	U-185			
	>A> 9616096	Nov 06, 2035	U-1723			
	>A> 9616096	Nov 06, 2035	U-1864			
	>A> 9616096	Nov 06, 2035	U-1991			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 001	9555027	May 26, 2026	DP U-543		M-195	Jan 27, 2020
					NPP	Jan 27, 2020
					PED	Jul 27, 2020
					PED	Jul 27, 2020
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 002	9555027	May 26, 2026	DP U-543		NPP	Jan 27, 2020
					PED	Jul 27, 2020

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 002	9555027	May 26, 2026	DP U-543		NPP PED	Jan 27, 2020 Jul 27, 2020
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 003	9555027	May 26, 2026	DP U-543		M-195 NPP PED PED	Jan 27, 2020 Jan 27, 2020 Jul 27, 2020 Jul 27, 2020
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 004	9555027	May 26, 2026	DP U-543			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 005	9555027	May 26, 2026	DP U-543		M-195 NPP PED PED	Jan 27, 2020 Jan 27, 2020 Jul 27, 2020 Jul 27, 2020
<u>MARAVIROC - SELZENTRY</u>						
N 022128 001					NPP NS	Nov 04, 2019 Nov 04, 2019
<u>MARAVIROC - SELZENTRY</u>						
N 022128 002					NPP NS	Nov 04, 2019 Nov 04, 2019
<u>MARAVIROC - SELZENTRY</u>						
N 022128 003	6586430	Dec 01, 2019	DS DP U-824		NPP	Nov 04, 2019
	6667314	Aug 06, 2021	DS DP U-824		NS	Nov 04, 2019
	7368460	Nov 25, 2022	U-824			
	7576097	May 25, 2021	DS			
<u>MARAVIROC - SELZENTRY</u>						
N 022128 004	6586430	Dec 01, 2019	DS DP U-824		NPP	Nov 04, 2019
	6667314	Aug 06, 2021	DS DP U-824		NS	Nov 04, 2019
	7368460	Nov 25, 2022	U-824			
	7576097	May 25, 2021	DS			
<u>MARAVIROC - SELZENTRY</u>						
N 208984 001					NP	Nov 04, 2019
<u>MELPHALAN HYDROCHLORIDE - EVOMELA</u>						
N 207155 001	9493582	Feb 27, 2033	DP			
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 001					M-198	Feb 27, 2020
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 002					M-198	Feb 27, 2020
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 003					M-198	Feb 27, 2020
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N 022044 001	>A> 6303661	Apr 24, 2017	U-1996			
	>A> 6890898	Feb 02, 2019	U-1996			
	>A> 7078381	Feb 02, 2019	U-1996			
	>A> 7459428	Feb 02, 2019	U-1996			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N 022044 002	>A> 6303661	Apr 24, 2017	U-1996			
	>A> 6890898	Feb 02, 2019	U-1996			
	>A> 7078381	Feb 02, 2019	U-1996			
	>A> 7459428	Feb 02, 2019	U-1996			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 001	>A> 6303661	Apr 24, 2017	U-1996			
	>A> 6890898	Feb 02, 2019	U-1996			
	>A> 7078381	Feb 02, 2019	U-1996			
	>A> 7459428	Feb 02, 2019	U-1996			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 002	>A> 6303661	Apr 24, 2017	U-1996			
	>A> 6890898	Feb 02, 2019	U-1996			
	>A> 7078381	Feb 02, 2019	U-1996			
	>A> 7459428	Feb 02, 2019	U-1996			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 003	>A> 6303661	Apr 24, 2017	U-1996			
	>A> 6890898	Feb 02, 2019	U-1996			
	>A> 7078381	Feb 02, 2019	U-1996			
	>A> 7459428	Feb 02, 2019	U-1996			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 001	9533102	Jan 24, 2026	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 002	9533102	Jan 24, 2026	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 003	9533102	Jan 24, 2026	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 004	9533102	Jan 24, 2026	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 005	9533102	Jan 24, 2026	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 006	9533102	Jan 24, 2026	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 007	9533102	Jan 24, 2026	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 008	9533102	Jan 24, 2026	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER</u>						
N 207960 001	9545399	Aug 14, 2033	DP U-1827			
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER</u>						
N 207960 002	9545399	Aug 14, 2033	DP U-1827			
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER</u>						
N 207960 003	9545399	Aug 14, 2033	DP U-1827			
<u>MIDOSTAURIN - RYDAPT</u>						
N 207997 001				>A> NCE		Apr 28, 2022

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MORPHINE SULFATE - ARYMO ER</u>						
N 208603 001	9044402	Jul 01, 2033	DP U-1556			
	9549899	Jul 01, 2033	DP U-1556			
<u>MORPHINE SULFATE - ARYMO ER</u>						
N 208603 002	9044402	Jul 01, 2033	DP U-1556			
	9549899	Jul 01, 2033	DP U-1556			
<u>MORPHINE SULFATE - ARYMO ER</u>						
N 208603 003	9044402	Jul 01, 2033	DP U-1556			
	9549899	Jul 01, 2033	DP U-1556			
<u>NALDEMEDINE TOSYLATE - SYMPROIC</u>						
N 208854 001	9108975	Nov 11, 2031	DS DP		NCE	Mar 23, 2022
	>A> RE46365	Jan 11, 2028	DS DP			
	>A> RE46375	Oct 05, 2026	DS DP U-1185			
<u>NALOXONE HYDROCHLORIDE - NARCAN</u>						
N 208411 001	>A> 9211253	Mar 16, 2035	DP			
	9561177	Mar 16, 2035	DP U-1903			
	>A> 9629965	Mar 16, 2035	DP U-1903			
<u>NALOXONE HYDROCHLORIDE - NARCAN</u>						
N 208411 002	9480644	Mar 16, 2035	DP U-1903			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777 001	9555000	Apr 04, 2023	DP U-1556			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777 002	9555000	Apr 04, 2023	DP U-1556			
<u>NIRAPARIB TOSYLATE - ZEJULA</u>						
N 208447 001	>A> 8071623	Mar 22, 2030	DS DP		NCE	Mar 27, 2022
	>A> 8436185	Apr 24, 2029	DS		>A> ODE	Mar 27, 2024
<u>NUSINERSEN SODIUM - SPINRAZA</u>						
N 209531 001	6166197	Dec 26, 2017	DS		ODE	Dec 23, 2023
	6210892	Oct 07, 2018		U-1942		
	7101993	Sep 05, 2023	DS			
	7838657	Jul 11, 2027	DS			
	8110560	Dec 05, 2025		U-1942		
	8110560	Dec 05, 2025		U-1943		
	8110560	Dec 05, 2025		U-1944		
	8361977	May 27, 2030	DS DP			
	8980853	Nov 24, 2030		U-1941		
<u>OLODATEROL HYDROCHLORIDE - STRIVERDI RESPIMAT</u>						
N 203108 001	>A> 8733341	Oct 16, 2030	DP			
<u>OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE - STIOLTO RESPIMAT</u>						
N 206756 001	>A> 8733341	Oct 16, 2030	DP			
<u>LOPATADINE HYDROCHLORIDE - PAZEO</u>						
N 206276 001	9533053	May 19, 2032	DP			
<u>OMACETAXINE MEPESUCCINATE - SYNRIBO</u>						
N 203585 001	>A> 6987103	Oct 26, 2026		U-1300		
<u>OMBITASVIR; PARITAPRE VIR; RITONAVIR - TECHNIVIE</u>						
N 207931 001					I-743	Jul 24, 2018

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OSPHEMIFENE - OSPHENA</u>						
N 203505 001	>A> 6245819	Jul 21, 2020	U-1370			
	>A> 9566252	Jul 21, 2020	U-1370			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 001	9592200	Jul 07, 2023	DP			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 002	9592200	Jul 07, 2023	DP			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 003	9592200	Jul 07, 2023	DP			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 004	9592200	Jul 07, 2023	DP			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 005	9592200	Jul 07, 2023	DP			
<u>OXYCODONE HYDROCHLORIDE - OXAYDO</u>						
N 202080 001	9492443	May 26, 2024	DP			
<u>OXYCODONE HYDROCHLORIDE - OXAYDO</u>						
N 202080 002	9492443	May 26, 2024	DP			
<u>OXYMETAZOLINE HYDROCHLORIDE - RHOFADÉ</u>						
N 208552 001	7812049	May 02, 2028	U-1959		NP	Jan 18, 2020
	8420688	Aug 02, 2024	U-1959			
	8883838	Dec 01, 2031	DP			
<u>PACLITAXEL - ABRAXANE</u>						
N 021660 001	>A> 9393318	Mar 04, 2032	U-1290			
	9511046	Jan 12, 2034	U-1434			
	>A> 9597409	Mar 04, 2032	U-1290			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 001	>A> 7456168	Jan 16, 2023	U-1998			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 002	>A> 7456168	Jan 16, 2023	U-1998			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 003	>A> 7456168	Jan 16, 2023	U-1998			
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N 021372 001	9439854	Jan 30, 2024	DP			
	9439854*PED	Jul 30, 2024				
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N 021372 002	9439854	Jan 30, 2024	DP			
	9439854*PED	Jul 30, 2024				
<u>PERFLUTREN - DEFINITY</u>						
N 021064 001	9545457	Jan 13, 2019	U-665			
<u>PIMAVANSERIN TARTRATE - NUPLAZID</u>						
N 207318 001	9566271	Jan 15, 2024	U-1974			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 001					NCE ODE	Oct 16, 2019 Oct 15, 2021
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 002					NCE ODE	Oct 16, 2019 Oct 15, 2021
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 003					NCE ODE	Oct 16, 2019 Oct 15, 2021
<u>PLECANATIDE - TRULANCE</u>						
N 208745 001	7041786	Mar 25, 2023	DS		NCE	Jan 19, 2022
	7799897	Jun 09, 2022	DS			
	8637451	Mar 28, 2022		U-1964		
	>A> 9610321	Sep 11, 2031		U-1999		
	>A> 9616097	Jul 02, 2032	DP			
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 001	9493470	Dec 12, 2033	DS DP	U-1700		
	9493470	Dec 12, 2033	DS DP	U-1948		
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 002	9493470	Dec 12, 2033	DS DP	U-1700		
	9493470	Dec 12, 2033	DS DP	U-1948		
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 003	8114874	Dec 22, 2026	DS DP			
	9493470	Dec 12, 2033	DS DP	U-1700		
	9493470	Dec 12, 2033	DS DP	U-1948		
<u>PREDNISONE - RAYOS</u>						
N 202020 001	9504699	Aug 03, 2027		U-1362		
<u>PREDNISONE - RAYOS</u>						
N 202020 002	9504699	Aug 03, 2027		U-1362		
<u>RASAGILINE MESYLATE - RASAGILINE MESYLATE</u>						
A 201823 001					PC	Jul 01, 2017
<u>RASAGILINE MESYLATE - RASAGILINE MESYLATE</u>						
A 201823 002					PC	Jul 01, 2017
<u>RASAGILINE MESYLATE - RASAGILINE MESYLATE</u>						
A 201950 001					PC	Jul 01, 2017
<u>RASAGILINE MESYLATE - RASAGILINE MESYLATE</u>						
A 201950 002					PC	Jul 01, 2017
<u>REGADENOSON - LEXISCAN</u>						
N 022161 001					M-194	Jan 17, 2020
<u>REGORAFENIB - STIVARGA</u>						
N 203085 001	>A> 7351834	Jun 28, 2022	DS			
<u>RIBOCICLIB SUCCINATE - KISOALI</u>						
N 209092 001	8324225	Jun 17, 2028	DS DP		NCE	Mar 13, 2022
	8415355	Feb 19, 2031	DS DP			
	8685980	May 25, 2030	DS DP			
	8962630	Dec 09, 2029		U-1981		
	9193732	Nov 09, 2031	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RIBOCICLIB SUCCINATE - KISOALI</u>						
N 209092 001	9416136	Aug 20, 2029	U-1981			
<u>RIFAXIMIN - XIFAXAN</u>						
N 022554 001 >A>	9629828	Jul 24, 2029	U-1994			
<u>RIVAROXABAN - XARELTO</u>						
N 022406 001	9539218	Feb 17, 2034	U-1953			
	9539218	Feb 17, 2034	U-1954			
	9539218	Feb 17, 2034	U-1955			
	9539218	Feb 17, 2034	U-1956			
	9539218	Feb 17, 2034	U-1957			
<u>RIVAROXABAN - XARELTO</u>						
N 022406 002	9539218	Feb 17, 2034	U-1953			
	9539218	Feb 17, 2034	U-1954			
	9539218	Feb 17, 2034	U-1955			
	9539218	Feb 17, 2034	U-1956			
	9539218	Feb 17, 2034	U-1957			
<u>RIVAROXABAN - XARELTO</u>						
N 022406 003	9539218	Feb 17, 2034	U-1953			
	9539218	Feb 17, 2034	U-1954			
	9539218	Feb 17, 2034	U-1955			
	9539218	Feb 17, 2034	U-1957			
<u>ROLAPITANT HYDROCHLORIDE - VARUBI</u>						
N 206500 001	8404702	Apr 04, 2027	U-1741			
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115 001					ODE	Dec 19, 2023
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115 002					ODE	Dec 19, 2023
<u>SACROSIDASE - SUCRAID</u>						
N 020772 001	9469847	Feb 07, 2034	DS DP			
<u>SAFINAMIDE MESYLATE - XADAGO</u>						
N 207145 001 >A>	8076515	Dec 10, 2028	DS DP U-1993		NCE	Mar 21, 2022
	>A> 8278485	Jun 08, 2027	DS U-1993			
	>A> 8283380	Sep 01, 2027	U-1993			
<u>SAFINAMIDE MESYLATE - XADAGO</u>						
N 207145 002 >A>	8076515	Dec 10, 2028	DS DP U-1993		NCE	Mar 21, 2022
	>A> 8278485	Jun 08, 2027	DS U-1993			
	>A> 8283380	Sep 01, 2027	U-1993			
<u>SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA</u>						
N 022350 001					M-198	Feb 27, 2020
<u>SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA</u>						
N 022350 002					M-198	Feb 27, 2020
<u>SIMVASTATIN - SIMVASTATIN</u>						
N 206679 001 >A>	9597289	Feb 23, 2030	DP			
<u>SIMVASTATIN - SIMVASTATIN</u>						
N 206679 002 >A>	9597289	Feb 23, 2030	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 001	>A> 6303661	Apr 24, 2017	U-1996			
	>A> 6890898	Feb 02, 2019	U-1997			
	>A> 7078381	Feb 02, 2019	U-1997			
	7459428	Feb 02, 2019	U-1945			
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 002	>A> 6303661	Apr 24, 2017	U-1996			
	>A> 6890898	Feb 02, 2019	U-1997			
	>A> 7078381	Feb 02, 2019	U-1997			
	7459428	Feb 02, 2019	U-1945			
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 003	>A> 6303661	Apr 24, 2017	U-1996			
	>A> 6890898	Feb 02, 2019	U-1997			
	>A> 7078381	Feb 02, 2019	U-1997			
	7459428	Feb 02, 2019	U-1945			
<u>SODIUM OXYBATE - XYREM</u>						
N 021196 001	9539330	Dec 22, 2019	DP			
<u>SOFOSBUVIR - SOVALDI</u>						
N 204671 001	9549941	Mar 26, 2029	U-1958		>A> NPP	Apr 07, 2020
					>A> ODE	Apr 07, 2024
<u>SUCROFERRIC OXYHYDROXIDE - VELPHORO</u>						
N 205109 001	9561251	Jan 23, 2030	DP U-1468			
<u>TACROLIMUS - ENVARUSUS XR</u>						
N 206406 001	>A> 9549918	May 30, 2028	DP			
<u>TACROLIMUS - ENVARUSUS XR</u>						
N 206406 002	>A> 9549918	May 30, 2028	DP			
<u>TACROLIMUS - ENVARUSUS XR</u>						
N 206406 003	>A> 9549918	May 30, 2028	DP			
<u>TASIMELTEON - HETLIOZ</u>						
N 205677 001	9539234	Jan 25, 2033	U-1934			
	9549913	Jan 25, 2033	U-1486			
<u>TAVABOROLE - KERYDIN</u>						
N 204427 001	9549938	Feb 16, 2026	U-1951			
	9566289	Feb 16, 2026	DP			
	9566290	Feb 16, 2026	U-1970			
	9572823	Feb 16, 2026	U-1970			
<u>TEDUGLUTIDE RECOMBINANT - GATTEX KIT</u>						
N 203441 001	9539310	Nov 01, 2025	U-1320			
	9545434	Nov 01, 2025	U-1320			
	9545435	Nov 01, 2025	U-1320			
	9555079	Nov 01, 2025	U-1320			
	9572867	Nov 01, 2025	U-1320			
	9592273	Nov 01, 2025	U-1320			
	9592274	Nov 01, 2025	U-1320			
<u>TELOTTRISTAT ETIPRATE - XERMELO</u>						
N 208794 001	7553840	Dec 11, 2027	DS		NCE	Feb 28, 2022
	7709493	Dec 11, 2027	DS	U-1979	ODE	Feb 28, 2024
	7968559	Dec 11, 2027	U-1979			
	8193204	Feb 27, 2031	DS			
	8653094	Dec 19, 2028	U-1979			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TELOTTRISTAT ETIPRATE - XERMELO</u>						
N 208794 001	7553840	Dec 11, 2027	DS		NCE	Feb 28, 2022
	7709493	Dec 11, 2027	DS	U-1979	ODE	Feb 28, 2024
	7968559	Dec 11, 2027		U-1979		
	8193204	Feb 27, 2031	DS			
	8653094	Dec 19, 2028		U-1979		
<u>THIOTEPA - TEPADINA</u>						
N 208264 001					ODE	Jan 26, 2024
<u>THIOTEPA - TEPADINA</u>						
N 208264 002					ODE	Jan 26, 2024
<u>TICAGRELOR - BRILINTA</u>						
N 022433 001	6525060	Dec 02, 2019	DS DP U-1171		Y	
	6525060	Dec 02, 2019	DS DP U-1860		Y	
	6525060	Dec 02, 2019	DS DP U-1862		Y	
	6525060	Dec 02, 2019	DS DP U-1863		Y	
	RE46276	Dec 02, 2019	DS DP U-1935			
	RE46276	Dec 02, 2019	DS DP U-1936			
	RE46276	Dec 02, 2019	DS DP U-1937			
	RE46276	Dec 02, 2019	DS DP U-1938			
<u>TICAGRELOR - BRILINTA</u>						
N 022433 002	6525060	Dec 02, 2019	DS DP U-1171		Y	
	6525060	Dec 02, 2019	DS DP U-1860		Y	
	6525060	Dec 02, 2019	DS DP U-1862		Y	
	6525060	Dec 02, 2019	DS DP U-1863		Y	
	RE46276	Dec 02, 2019	DS DP U-1935			
	RE46276	Dec 02, 2019	DS DP U-1936			
	RE46276	Dec 02, 2019	DS DP U-1937			
	RE46276	Dec 02, 2019	DS DP U-1938			
<u>TIOTROPIUM BROMIDE - SPIRIVA</u>						
N 021395 001	6777423	Sep 24, 2021	DS DP			
	6777423*PED	Mar 24, 2022				
	6908928	Sep 24, 2021	DS DP U-566			
	6908928	Sep 24, 2021	DS DP U-762			
	6908928*PED	Mar 24, 2022				
	7070800	Jan 22, 2022	DP U-566			
	7070800*PED	Jul 22, 2022				
	7309707	Sep 24, 2021	DS DP			
	7309707*PED	Mar 24, 2022				
	7642268	Sep 24, 2021	DS DP			
	7642268*PED	Mar 24, 2022				
	7694676	Mar 12, 2027	DP			
	7694676*PED	Sep 12, 2027				
	8022082	Jan 19, 2026	DP U-1186			
	8022082*PED	Jul 19, 2026				
>A>	9010323	Apr 19, 2030	DP			
	RE38912	Oct 11, 2021	DP			
	RE38912*PED	Apr 11, 2022				
	RE39820	Jan 30, 2018	DS DP U-566			
	RE39820*PED	Jul 30, 2018				
<u>TIOTROPIUM BROMIDE - SPIRIVA RESPIMAT</u>						
N 021936 001	5964416	Oct 04, 2016	DP		NPP	Feb 15, 2020
	5964416*PED	Apr 04, 2017			PED	Aug 15, 2020
	6149054	Dec 16, 2016	DP			
	6149054*PED	Jun 16, 2017				
	6176442*PED	Dec 01, 2016				
	6453795	Dec 05, 2016	DP			
	6453795*PED	Jun 05, 2017				
	6726124	Oct 04, 2016	DP			
	6726124*PED	Apr 04, 2017				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TIOTROPIUM BROMIDE - SPIRIVA RESPIMAT</u>						
N 021936 001	6846413	Aug 28, 2018	DP			
	6846413*PED	Feb 28, 2019				
	6977042	Aug 28, 2018	DP			
	6977042*PED	Feb 28, 2019				
	6988496	Feb 23, 2020	DP			
	6988496*PED	Aug 23, 2020				
	7104470	Oct 04, 2016	DP			
	7104470*PED	Apr 04, 2017				
	7246615*PED	Dec 01, 2016				
	7284474	Aug 26, 2024	DP			
	7284474*PED	Feb 26, 2025				
	7396341	Oct 10, 2026	DP			
	7396341*PED	Apr 10, 2027				
	7802568	Feb 26, 2019	DP			
	7802568*PED	Aug 26, 2019				
	7837235	Mar 13, 2028	DP			
	7837235*PED	Sep 13, 2028				
	7896264	May 26, 2025	DP			
	7896264*PED	Nov 26, 2025				
	7988001	Aug 04, 2021	DP			
	7988001*PED	Feb 04, 2022				
	>A> 8733341	Oct 16, 2030	DP			
	>A> 8733341*PED	Apr 16, 2031				
	RE39820	Jan 30, 2018	DS DP	U-1593		
	RE39820*PED	Jul 30, 2018				
<u>TIOTROPIUM BROMIDE - SPIRIVA RESPIMAT</u>						
N 021936 002	>A> 5964416	Oct 04, 2016	DP		NPP	Feb 15, 2020
	>A> 5964416*PED	Apr 04, 2017			PED	Aug 15, 2020
	>A> 6149054	Dec 16, 2016	DP			
	>A> 6149054*PED	Jun 16, 2017				
	>A> 6453795	Dec 05, 2016	DP			
	>A> 6453795*PED	Jun 05, 2017				
	>A> 6726124	Oct 04, 2016	DP			
	>A> 6726124*PED	Apr 04, 2017				
	6846413	Aug 28, 2018	DP			
	6846413*PED	Feb 28, 2019				
	6977042	Aug 28, 2018	DP			
	6977042*PED	Feb 28, 2019				
	6988496	Feb 23, 2020	DP			
	6988496*PED	Aug 23, 2020				
	>A> 7104470	Oct 04, 2016	DP			
	>A> 7104470*PED	Apr 04, 2017				
	7284474	Aug 26, 2024	DP			
	7284474*PED	Feb 26, 2025				
	7396341	Oct 10, 2026	DP			
	7396341*PED	Apr 10, 2027				
	7802568	Feb 26, 2019	DP			
	7802568*PED	Aug 26, 2019				
	7837235	Mar 13, 2028	DP			
	7837235*PED	Sep 13, 2028				
	7896264	May 26, 2025	DP			
	7896264*PED	Nov 26, 2025				
	7988001	Aug 04, 2021	DP			
	7988001*PED	Feb 04, 2022				
	>A> 8733341	Oct 16, 2030	DP			
	>A> 8733341*PED	Apr 16, 2031				
	RE39820	Jan 30, 2018	DS DP			
	RE39820*PED	Jul 30, 2018				
<u>TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURF</u>						
N 207981 001	9527833	Jun 17, 2034	DS DP			
	RE46284	Dec 16, 2026		U-1751		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURF</u>						
N 207981 002	9527833	Jun 17, 2034	DS DP			
	RE46284	Dec 16, 2026			U-1751	
<u>TOFACITINIB CITRATE - XELJANZ XR</u>						
N 208246 001 >A>	RE41783	Dec 08, 2025	DS			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 001	9549940	Nov 16, 2027	DP U-1675			
	9555004	Nov 16, 2027	DP U-1675			
	>A> 9622983	Nov 16, 2027	DP U-1675			
	>A> 9622983	Nov 16, 2027	DP U-1992			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 002	9549940	Nov 16, 2027	DP U-1675			
	9555004	Nov 16, 2027	DP U-1675			
	>A> 9622983	Nov 16, 2027	DP U-1675			
	>A> 9622983	Nov 16, 2027	DP U-1992			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 003	9549940	Nov 16, 2027	DP U-1675			
	9555004	Nov 16, 2027	DP U-1675			
	>A> 9622983	Nov 16, 2027	DP U-1675			
	>A> 9622983	Nov 16, 2027	DP U-1992			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 004	9549940	Nov 16, 2027	DP U-1675			
	9555004	Nov 16, 2027	DP U-1675			
	>A> 9622983	Nov 16, 2027	DP U-1675			
	>A> 9622983	Nov 16, 2027	DP U-1992			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 001	9555005	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 002	9555005	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 003	9555005	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 004	9555005	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 005	9555005	Mar 19, 2033	DP			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 001	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 002	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 003	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 004	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TREPROSTINIL - TYVASO</u>						
N 022387 001	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 001	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 002	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 003	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 004	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 005	6765117	Oct 24, 2017	DS		D-156	Jan 28, 2019
	7417070	Jul 30, 2026	DS		D-157	Jan 28, 2019
	7544713	Jul 14, 2024		U-1475		
	8252839	May 24, 2024	DP			
	8349892	Jan 22, 2031	DP			
	8410169	Feb 13, 2030	DP			
	8497393	Dec 15, 2028	DS			
	8747897	Oct 08, 2029	DP			
	9050311	May 24, 2024	DS DP			
	9278901	May 24, 2024		U-1475		
	9393203	Apr 27, 2026	DP	U-1877		
	9422223	May 24, 2024	DP			
	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
<u>VALBENAZINE TOSYLATE - INGREZZA</u>						
N 209241 001	>A> 8039627	Oct 06, 2029	DS DP			
	>A> 8357697	Nov 08, 2027		U-1995		
<u>ZOLPIDEM TARTRATE - EDLUAR</u>						
N 021997 001	>A> 9265720	Feb 25, 2031		U-674		
	>A> 9597281	Apr 06, 2027		U-674		
<u>ZOLPIDEM TARTRATE - EDLUAR</u>						
N 021997 002	>A> 9265720	Feb 25, 2031		U-674		
	>A> 9597281	Apr 06, 2027		U-674		

Footnote:

1. Patents are published upon receipt by the Orange book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).

2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 37th Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/results_patent.cfm

The current complete list of exclusivity terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/results_exclusivity.cfm